 | Harry Roger BüllerDepartment of Medicine, Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands | From KU Leuven Department of Cardiovascular ... |
KOL简历 Harry Roger Büller (pulmonary embolism, heart, pulmonary heart disease, embolism, pulmonary embolism, disease, pulmonary)
| Year | |
|---|---|
| 2022 | Department of Medicine, Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands |
| 2021 | From KU Leuven Department of Cardiovascular Sciences, Vascular Medicine and Hemostasis, Leuven, Belgium (P.V.); Anthos Therapeutics, Cambridge, MA (B.A.Y., J.S., D.B.); International Trial Expertise Advisory and Services (A.S.) and the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (H.R.B.) - both in Amsterdam; Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City (G.E.R.); and the Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada (J.I.W.). Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands (H.R.B.). |
| 2020 | From the Faculty of Medical Sciences, State University of Groningen, Groningen, the Netherlands (M.O.); Department of Vascular Medicine, Amsterdam University Medical Centre, Amsterdam, the Netherlands (H.R.B., N.V.Es.); Department of Radiology, Haaglanden Medical Centre, The Hague, the Netherlands (D.K.); Department of Radiology, Nederlands Kanker Instituut, Amsterdam, the Netherlands (S.F.O.); Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, U.S.A. (T.M.); Department of Intensive Care Medicine, Erasmus Medical Centre, Rotterdam, the Netherlands (D.G.); 7. National Institute of Public Health, Ministry of Health, Bilthoven, the Netherlands (J.V.D.); Department of Vascular Medicine, Maastricht University, Maastricht, the Netherlands (H.T.C.); Edinburgh Imaging, Queens Medical Research Institute, University of Edinburgh, Edinburgh, U.K.(E.J.R.V.B.) Department of Vascular Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands |
| 2019 | Department of Vascular Medicine, Academic Medical Center, Universiteit van Amsterdam, Amsterdam, The Netherlands. Dept of Vascular Medicine, Amsterdam Cardiovascular Science, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands |
| 2018 | Department of Vascular Medicine, Academic Medical Centre Amsterdam, University of Amsterdam, Amsterdam, Netherlands |
| 2017 | Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, AZ, Amsterdam, The Netherlands. From Academic Medical Center and Slotervaartziekenhuis, Amsterdam, the Netherlands; Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Université de Bretagne Occidentale, Brest, France; Hospital of Padua, Padua, Italy; Clinica Universidad de Navarra, Pamplona, Spain; Virgen del Rocio Hospital, Seville, Spain; Karolinska Institutet, Stockholm, Sweden; Warsaw Medical University, Warsaw, Poland; Centre Hospitalo-Universitaire Estaing, Clermont-Ferrand, France; University of Utah, Salt Lake City, Utah; University Hospital Leuven, Leuven, Belgium; and University G. D'Annunzio, Chieti-Pescara, Italy. |
| 2016 | Center for Experimental and Molecular Medicine, Amsterdam Medical Center, Amsterdam, The Netherlands |
| 2015 | Academic Medical Center University of Amsterdam Department of Vascular Medicine Amsterdam the Netherlands |
| 2014 | From the College of Public Health, University of Oklahoma Health Sciences Center (G.E.R., M.M., A.W.); Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand (P.A.); División Hemostasia, Academia Nacional de Medicina, Buenos Aires, Argentina (A.N.B.); Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands (H.B.); SA Pathology–Department of Hematology, Flinders Medical Center, Adelaide, South Australia, Australia (A.G.); Thrombosis and Thrombophilia Centre, Guy’s & St Thomas’ NHS Foundation Trust, London, United Kingdom (B.J.H.); Boston University School of Medicine, MA (E.M.H.); Thrombosis Research Institute, London, United Kingdom (A.K.); Center for Thrombosis and Hemostasis, Johannes Gutenberg University, Mainz, Germany (S.V.K.); Department of Laboratory Medicine, University of Yamanashi, Tamaho, Yamanashi, Japan (Y.O.); and McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada (J.I.W.). Department of General Practice, Academic Medical Centre, University of Amsterdam, Amsterdam and |
| 2013 | Department of Vascular Medicine, F4-140, Academic Medical Centre, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands Academic Medical Center, Amsterdam (H.R.B.) |
| 2012 | Academic Medical Center, Department of Vascular Medicine, Amsterdam (H.R.B.) Vascular Medicine, AMC, Amsterdam, the Netherlands |
| 2011 | Internal Medicine, Academic Medical Center, Amsterdam, Netherlands, From the Academic Medical Center and Slotervaart Hospital, Amsterdam |
Prominent publications by Harry Roger Büller
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
[ PUBLICATION ]
BACKGROUND: Guidelines addressing the management of venous thromboembolism (VTE) in cancer patients are heterogeneous and their implementation has been suboptimal worldwide.
OBJECTIVES: To establish a common international consensus addressing practical, clinically relevant questions in this setting.
METHODS: An international consensus working group of experts was set up to develop guidelines according to an evidence-based medicine approach, using the GRADE system.
RESULTS: For the ...
| 闻名 Vte Patients | Venous Thromboembolism | Prophylaxis Lmwh | 3 Months | Practice Guidelines |
KOL Index score: 20177
OBJECTIVES: The objective of this study was to compare the predictive performance of bleeding risk-estimation tools in a cohort of patients with atrial fibrillation (AF) undergoing anticoagulation.
BACKGROUND: Three bleeding risk-prediction schemes have been derived for and validated in patients with AF: HEMORR(2)HAGES (Hepatic or Renal Disease, Ethanol Abuse, Malignancy, Older Age, Reduced Platelet Count or Function, Re-Bleeding, Hypertension, Anemia, Genetic Factors, Excessive Fall ...
| 闻名 Atrial Fibrillation | Bled Bleeding | Hemorr2hages Atria | Intracranial Hemorrhage | Topic Risk |
Antithrombotic Therapy for Venous Thromboembolic Disease The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
[ PUBLICATION ]
This chapter about antithrombotic therapy for venous thromboembolic disease is part of the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that individual patients' values may lead to different choices (for a full understanding of the grading see Guyatt et al, CHEST 2004; 126:179S-187S). Among the key ...
| 闻名 Antithrombotic Therapy | Grade 1a | Venous Thromboembolic Disease | Vka Lmwh | Inr Range |
KOL Index score: 16684
PURPOSE: Initial heparinization followed by vitamin K antagonists is the treatment of choice for patients with venous thromboembolism. There is controversy whether known malignancy is a risk factor for recurrences and bleeding complications during this treatment. Furthermore, the incidence of such events in these patients is dependent on the achieved International Normalized Ratio (INR). The aim of this study was to assess the incidence of venous thromboembolic recurrence and major ...
| 闻名 Venous Thromboembolism | Bleeding Complications | Patients Malignancy | Retrospective Analysis | International Normalized |
KOL Index score: 16378
BACKGROUND: Venous thromboembolism occurs commonly in patients with cancer. Direct oral anticoagulants are non-inferior to conventional anticoagulants for the treatment of venous thromboembolism. We hypothesised that edoxaban, a direct oral inhibitor of activated clotting factor Xa, might be more suitable than conventional anticoagulants in the management of cancer-associated venous thromboembolism. The aim of this study was to assess the efficacy and safety of edoxaban compared with ...
| 闻名 Venous Thromboembolism | Patients Cancer | Hazard Ratio | Clinically Relevant Bleeding | Factor Inhibitors |
KOL Index score: 15975
BACKGROUND: Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear.
METHODS: In a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), ...
| 闻名 Warfarin Patients | Hazard Ratio | Venous Thromboembolism | Pulmonary Embolism | Primary Efficacy Outcome |
ADAMTS‐13 and von Willebrand factor predict venous thromboembolism in patients with cancer
[ PUBLICATION ]
ESSENTIALS: Cancer patients are at high risk of venous thromboembolism (VTE). In this study, cases and controls were cancer patients who did or did not develop VTE. von Willebrand factor (VWF) levels were higher if compared with controls and correlated with cancer stage. VWF and ADAMTS-13 are associated with the occurrence of VTE in cancer.
BACKGROUND: Patients with cancer are at high risk of venous thromboembolism (VTE). ADAMTS-13 regulates von Willebrand factor (VWF) activity, which ...
| 闻名 Willebrand Factor | Venous Thromboembolism | Vte Cancer | Vwf Adamts13 | Khorana Score |
KOL Index score: 15571
BACKGROUND: Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for laboratory monitoring.
METHODS: We conducted an open-label, randomized, event-driven, noninferiority study that compared oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with subcutaneous enoxaparin followed by a vitamin K antagonist (either warfarin or ...
| 闻名 Oral Rivaroxaban | Venous Thromboembolism | Vitamin Antagonist | Continued Treatment | Hazard Ratio |
KOL Index score: 15512
BACKGROUND: After hip replacement surgery, prophylaxis following discharge from hospital is recommended to reduce the risk of venous thromboembolism. Our aim was to assess the oral, direct thrombin inhibitor dabigatran etexilate for such prophylaxis.
METHODS: In this double-blind study, we randomised 3494 patients undergoing total hip replacement to treatment for 28-35 days with dabigatran etexilate 220 mg (n=1157) or 150 mg (1174) once daily, starting with a half-dose 1-4 h after ...
| 闻名 Hip Replacement | Dabigatran Enoxaparin | Venous Thromboembolism | Etexilate Versus | Primary Efficacy Outcome |
KOL Index score: 15505
CONTEXT: Previous studies have evaluated the safety of relatively complex combinations of clinical decision rules and diagnostic tests in patients with suspected pulmonary embolism.
OBJECTIVE: To assess the clinical effectiveness of a simplified algorithm using a dichotomized clinical decision rule, D-dimer testing, and computed tomography (CT) in patients with suspected pulmonary embolism.
DESIGN, SETTING, AND PATIENTS: Prospective cohort study of consecutive patients with clinically ...
| 闻名 Pulmonary Embolism | Computed Tomography | Dimer Testing | Patients Suspected | 3 Months |
KOL Index score: 15415
BACKGROUND: Dabigatran etexilate is an oral direct thrombin inhibitor undergoing evaluation for the prevention of venous thromboembolism (VTE) following orthopedic surgery.
METHODS: In a multicenter, parallel-group, double-blind study, 1973 patients undergoing total hip or knee replacement were randomized to 6-10 days of oral dabigatran etexilate (50, 150 mg twice daily, 300 mg once daily, 225 mg twice daily), starting 1-4 h after surgery, or subcutaneous enoxaparin (40 mg once daily) ...
| 闻名 Total Hip | Dabigatran Etexilate | Thromboembolic Events | Knee Replacement | Vte Patients |
KOL Index score: 14849
BACKGROUND: Oral anticoagulants, such as dabigatran etexilate, an oral, direct thrombin inhibitor, that do not require monitoring or dose adjustment offer potential for prophylaxis against venous thromboembolism (VTE) after total knee replacement surgery.
METHODS: In this randomized, double-blind study, 2076 patients undergoing total knee replacement received dabigatran etexilate, 150 mg or 220 mg once-daily, starting with a half-dose 1-4 hours after surgery, or subcutaneous enoxaparin ...
| 闻名 Subcutaneous Enoxaparin | Oral Dabigatran | Total Knee Replacement | Venous Thromboembolism | Prevention Vte |
Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism
[ PUBLICATION ]
BACKGROUND: The standard initial treatment of hemodynamically stable patients with pulmonary embolism is intravenous unfractionated heparin, requiring laboratory monitoring and hospitalization.
METHODS: We conducted a randomized, open-label trial involving 2213 patients with acute symptomatic pulmonary embolism to compare the efficacy and safety of the synthetic antithrombotic agent fondaparinux with those of unfractionated heparin and to document noninferiority in terms of efficacy. ...
| 闻名 Unfractionated Heparin | Pulmonary Embolism | Initial Treatment | Subcutaneous Fondaparinux | Intravenous Injections |
KOL Index score: 14727
OBJECTIVES: To determine the rate of a first recurrent venous thromboembolism (VTE) event after discontinuation of anticoagulant treatment in patients with a first episode of unprovoked VTE, and the cumulative incidence for recurrent VTE up to 10 years.
DESIGN: Systematic review and meta-analysis.
DATA SOURCES: Medline, Embase, and the Cochrane Central Register of Controlled Trials (from inception to 15 March 2019).
STUDY SELECTION: Randomised controlled trials and prospective cohort ...
| 闻名 Anticoagulant Treatment | Recurrent Vte | Unprovoked Venous | 10 Years | 95 Confidence Interval |
Harry Roger Büller：影响统计
运行报告
| Concept | World rank |
|---|---|
| 5395 patients | #1 |
| travel‐related venous thrombosis | #1 |
| uesvt patients | #1 |
| bmi fondaparinux | #1 |
| xageneration | #1 |
| rate recurrent | #1 |
| cancer patients cvcs | #1 |
| extra hospital visits | #1 |
| efficacy heparin therapy | #1 |
| diagnosis deepvein thrombosis | #1 |
| women factor leiden | #1 |
| malignancy achieved inr | #1 |
| pulmonary embolism idraparinux | #1 |
| plateletactivating antibodies risk | #1 |
| prophylaxis idraparinux | #1 |
| laalleles | #1 |
| wells simplified | #1 |
| respondents lmwh | #1 |
| submassive incidence | #1 |
| edoxabantreated | #1 |
| impedance thrombophlebitis | #1 |
| efficiency subgroups | #1 |
| failure cip | #1 |
| dalteparin 6 months | #1 |
| nonhigh cdr | #1 |
| ddimer levels cdr | #1 |
| compression ultrasonography presentation | #1 |
| principal safety | #1 |
| cart lower levels | #1 |
| limited screening 95 | #1 |
| pvoq | #1 |
| fetal loss carriers | #1 |
| venous thrombosis pregnancy | #1 |
| gentamicin patients netilmicin | #1 |
| 0·2 3633 patients | #1 |
| mdct expert radiologist | #1 |
| combination cdrscore | #1 |
| lowmolecularweight heparin treatment | #1 |
| avidin idrabiotaparinux | #1 |
| ldf cus | #1 |
| patients khorana | #1 |
| cdr dimer | #1 |
| tests venography | #1 |
| extended anticoagulation apixaban | #1 |
| constans score | #1 |
| presenting location women | #1 |
| fviii concentration | #1 |
| lowmolecularweight heparin 95 | #1 |
| quantitative ddimer test | #1 |
| residual thrombotic mass | #1 |
| respondents 60 | #1 |
| dvt anticoagulants | #1 |
| apixaban randomized patients | #1 |
| test venography | #1 |
| p0001 saline | #1 |
| rivaroxaban standard therapy | #1 |
| coagulation factors markers | #1 |
| standalone ddimer testing | #1 |
| risk pulmonary embolism | #1 |
| studies doac treatment | #1 |
| 023 relatives | #1 |
| falsenormal | #1 |
| thrombo‐embolic events | #1 |
| wells rule exclusion | #1 |
| hyperhomocysteinemia relatives | #1 |
| pyridines recurrence | #1 |
| carriers pulmonary embolism | #1 |
| d‐dimer level | #1 |
| patients malignancy | #1 |
| crptest | #1 |
| 7268 patients suspected | #1 |
| wound haematoma | #1 |
| intracranial clinical presentation | #1 |
| heparinoid | #1 |
| quantitative ddimer testing | #1 |
| einsteindvt | #1 |
| recurrent dvt dvt | #1 |
| levonorgestrel desogestrelcontaining | #1 |
| elevated levels fviii | #1 |
| fviii hyperhomocysteinemia | #1 |
| matisse clinical trials | #1 |
| patients artificial graft | #1 |
| predefined outcomes vte | #1 |
| rivaroxaban acute dvt | #1 |
| ml1 ctpa | #1 |
| consensus strategy strategy | #1 |
| ipe expert radiologists | #1 |
| hokusaivte trial patients | #1 |
| selective beta‐blocker treatment | #1 |
| compression ultrasound dvt | #1 |
| fetal loss stillbirth | #1 |
| patients antithrombotic prescriptions | #1 |
| vivo coagulation factor | #1 |
| ultrasonography dvt | #1 |
| carriers relative risks | #1 |
| cstatistic major bleeding | #1 |
| ivte | #1 |
| deficiency proteins | #1 |
| 208791 | #1 |
| elderly outpatients combination | #1 |
| dose daily edoxaban | #1 |
| suspected symptomatic | #1 |
| chest perfusion scan | #1 |
| dvt costs | #1 |
| relevant major | #1 |
| heparin acenocoumarol | #1 |
| administration lmwh | #1 |
| recommendations dvt | #1 |
| single dose tb402 | #1 |
| symptomatic recurrent | #1 |
| patients inherited thrombophilia | #1 |
| oral anticoagulants phase | #1 |
| age∗10μg | #1 |
| botticelli dvt dose‐ranging | #1 |
| hokusaivte trial | #1 |
| age multiple comorbidities | #1 |
| clinical uedvt | #1 |
| proximal location ipe | #1 |
| severe presentation patients | #1 |
| netherlands vka | #1 |
| graft patency patency | #1 |
| sgs pretest probability | #1 |
| daily dalteparin treatment | #1 |
| polyethylenglycolhirudin | #1 |
| anticoagulant treatment vte | #1 |
| svt lmwh | #1 |
| 20210a mutation | #1 |
| lmwh venous thrombosis | #1 |
| uedvt terms | #1 |
| extensive screening cancer | #1 |
| recurrent vte statin | #1 |
| ventricular dysfunction edoxaban | #1 |
| withheld | #1 |
| cdrscore combination | #1 |
| patients protein deficiencies | #1 |
| suspected perfusion scan | #1 |
| relevant bleeding | #1 |
| amplify trial apixaban | #1 |
| timeperiod | #1 |
| major bleeding cancer | #1 |
| acute treatment lmwh | #1 |
| plasma concentration fviii | #1 |
| therapeutic doses lmwh | #1 |
| combination ddimer testing | #1 |
| idraparinux vitamin antagonist | #1 |
| treatment experimental thrombosis | #1 |
| patients deep | #1 |
| thiazoles venous | #1 |
| subsequent diagnosis malignancy | #1 |
| patients ivte | #1 |
| individualized duration | #1 |
| 5‐snp scores | #1 |
| risk homozygous women | #1 |
| vte fatal | #1 |
| standardintensity vkas | #1 |
| uedvt recurrent vte | #1 |
| cdrscore | #1 |
| efficacy conventional treatment | #1 |
| p0424 | #1 |
| lowmolecularweight heparin category | #1 |
| poc test patients | #1 |
| riskstroponin | #1 |
| diagnostic management patients | #1 |
| apixaban conventional therapy | #1 |
| hokusaivte study | #1 |
| ufh grade | #1 |
| heparins vitamin antagonists | #1 |
| safety idraparinux | #1 |
| randomized studies efficacy | #1 |
| loss subsequent pregnancy | #1 |
| role exclusion | #1 |
| treatment idraparinux | #1 |
| acenocoumarol therapy acenocoumarol | #1 |
| standard treatment idraparinux | #1 |
| acquired atiii deficiency | #1 |
| deep vein thrombosis | #1 |
| echocardiography normotensive patients | #1 |
| wellsrule | #1 |
| scores riete score | #1 |
| fondaparinux unfractionated | #1 |
| questionnaires thrombosis | #1 |
| avidin vte | #1 |
| patients advanced prostate | #1 |
| chromogenic endotoxin | #1 |
| heparin initial | #1 |
| positive vte | #1 |
| edoxaban warfarin groups | #1 |
| edoxaban east asian | #1 |
| tb402 enoxaparin | #1 |
| rabinov | #1 |
| nadroparin aspirin | #1 |
| local radiologist experts | #1 |
| long haul flights | #1 |
| safety outcome | #1 |
| dalteparin major bleeding | #1 |
| treatment cumulative incidence | #1 |
| embolism suspected | #1 |
| endotoxemia tests | #1 |
| enoxaparin heparin treatment | #1 |
| pulmonary embolism studies | #1 |
| departments pharmacological prophylaxis | #1 |
| puerperium diagnostic suspicion | #1 |
| combination cdrs | #1 |
| systematic search cteph | #1 |
| embolism wells | #1 |
| normotensive patients studies | #1 |
| rnapc2 groups placebo | #1 |
| patients retropubic prostatectomy | #1 |
| levels procoagulant factors | #1 |
| vte study | #1 |
| perfusion scan | #1 |
| fxainhibitors | #1 |
| netherlands lmwh | #1 |
| 5 years lmwh | #1 |
| abelacimab | #1 |
| failure rate efficiency | #1 |
| bleeding clinically | #1 |
| patients uedvt uesvt | #1 |
| early time recurrence | #1 |
| cancer clinical presentation | #1 |
| 0·620·74 | #1 |
| apc resistance tests | #1 |
| patients mismatched scan | #1 |
| lmwh departments | #1 |
| idraparinux placebo | #1 |
| antithrombotic prescriptions adherence | #1 |
| messages justification | #1 |
| pioped study study | #1 |
| s1p1activation | #1 |
| undvt | #1 |
| diagnostic strategies patients | #1 |
| wellscdrscore | #1 |
| probability categories | #1 |
| pulmonary embolism carriers | #1 |
| 547253 | #1 |
| pvo ctscan | #1 |
| patients examiner | #1 |
| milliliter enoxaparin | #1 |
| rnapc2 groups | #1 |
| patients normal tests | #1 |
| relatives normal fviii | #1 |
| uesvt recurrent vte | #1 |
| patients compression ultrasonography | #1 |
| noacs prevention | #1 |
| category fxainhibitors | #1 |
| cancer patients ufh | #1 |
| protein resistance control | #1 |
| treat thrombosis | #1 |
| 2479 relatives | #1 |
| patients reduceddose noacs | #1 |
| mutation relatives | #1 |
| lmwh acute treatment | #1 |
| cstatistic model discrimination | #1 |
| dvt 56 | #1 |
| presentation 1 week | #1 |
| compression ultrasonography | #1 |
| patients advanced malignancy | #1 |
| months standard therapy | #1 |
| evaluable patients apixaban | #1 |
| wellscdr | #1 |
| cdr ddimer test | #1 |
| increasing levels ft4 | #1 |
| symptomatic legs dvt | #1 |
| dvt 69 | #1 |
| vkas lmwh | #1 |
| double heterozygous carriers | #1 |
| patients laalleles | #1 |
| vte arterial | #1 |
| initial treatment dvt | #1 |
| women edoxaban | #1 |
| heparin survival | #1 |
| segmental subsegmental | #1 |
| beta thromboglobulin org | #1 |
| coagulationinhibiting | #1 |
| venous thromboembolism episode | #1 |
| idraparinux patients | #1 |
| patients treatment duration | #1 |
| easier monitoring | #1 |
| avws prevalence | #1 |
| 00515 | #1 |
| vkas efficacy | #1 |
| subcutaneous idraparinux | #1 |
| combined training gps | #1 |
| study ecq | #1 |
| association travel | #1 |
| obese hemophilic patients | #1 |
| activecontrol placebo | #1 |
| low levels ft4 | #1 |
| doses 75 microg | #1 |
| dose response apixaban | #1 |
| time recombinant | #1 |
| excluded pulmonary | #1 |
| year prophylaxis | #1 |
| ddimer test | #1 |
| symptomatic venous | #1 |
| prothrombin individuals | #1 |
| patients idraparinux | #1 |
| models development studies | #1 |
| perelated death classification | #1 |
| factual hemorrhage heparin | #1 |
| proportion 75 years | #1 |
| protein levels mortality | #1 |
| fviii vte | #1 |
| rule cdr | #1 |
| lmwh immobilization | #1 |
| elevated biomarkers hospital | #1 |
| hokusai‐vte trial | #1 |
| acenocoumarol initial treatment | #1 |
| reported incidence vte | #1 |
| patients tests prevalence | #1 |
| reduceddose noacs stroke | #1 |
| current practise | #1 |
| 9 incidence | #1 |
| 3 idraparinux | #1 |
| dimer test | #1 |
| recurrent vte immobilization | #1 |
| ldf diagnosis | #1 |
| frequency venous thromboembolism | #1 |
| cus strategies | #1 |
| doacs cirrhosis patients | #1 |
| laalleles platelets | #1 |
| leg veins patients | #1 |
| tb402 12 kg1 | #1 |
| xainhibitors | #1 |
| strategies abdominal pelvic | #1 |
| extended treatment edoxaban | #1 |
| venography tests | #1 |
| probability ventilation | #1 |
| total vte patients | #1 |
| vte trial | #1 |
| placebo rnapc2 | #1 |
| bleeding risk lmwh | #1 |
| 25mg apixaban | #1 |
| qscan 3 weeks | #1 |
| tsh antitpo | #1 |
| efficacy vte | #1 |
| warfarin cancer patients | #1 |
| tinaquant assay comparison | #1 |
| 5 avidin infusion | #1 |
| proximal extent ipe | #1 |
| clinically suspected cancer | #1 |
| preferred oral anticoagulant | #1 |
| heparins cancer patients | #1 |
| placebo 25mg apixaban | #1 |
| included patients study | #1 |
| prevalence coagulation | #1 |
| patients acute recurrent | #1 |
| simplified wells rule | #1 |
| vte day | #1 |
| pulmonary embolism metaanalysis | #1 |
| strategy abdominal pelvic | #1 |
| thromboembolism relatives | #1 |
| category perelated death | #1 |
| anticoagulants probability | #1 |
| embolism randomized | #1 |
| practiceassistants | #1 |
| double reports | #1 |
| neoplasms heparin | #1 |
| presence venous thrombosis | #1 |
| —brachial | #1 |
| relatives elevated levels | #1 |
| rivaroxaban replacement | #1 |
| sustained antithrombotic effects | #1 |
| dose rnapc2 | #1 |
| subcutaneous nadroparin placebo | #1 |
| fviii venous thromboembolism | #1 |
| oral edoxaban dose | #1 |
| enoxaparin vkas treatment | #1 |
| thrombophilia patients doacs | #1 |
| aged nadroparin | #1 |
| suspected deep | #1 |
| wells clinical | #1 |
| vte addition | #1 |
| leg ultrasonography patients | #1 |
| obese controls difference | #1 |
| 36 papers | #1 |
| matisse trials | #1 |
| pulmonary embolism cdr | #1 |
| normal ddimer result | #1 |
| controlledstudy | #1 |
| false normal | #1 |
| 7268 patients | #1 |
| inr range ttr | #1 |
| 5mg apixaban | #1 |
| screening carriers | #1 |
| original wells | #1 |
| influenza case patients | #1 |
| venous thrombosis hyperglycemia | #1 |
| desogestrelcontaining coagulation factors | #1 |
| presenting location vte | #1 |
| thrombophlebitis tomography | #1 |
| absolute annual incidences | #1 |
| clinical decision rule | #1 |
| heparin vitamin | #1 |
| suspected cdr | #1 |
| postthrombotic symptoms patients | #1 |
| hemorrhage heparin | #1 |
| probabilityscan | #1 |
| isolated deficiencies proteins | #1 |
| scan pulmonary embolism | #1 |
| obstetric complications relatives | #1 |
| subsequent symptomatic cancer | #1 |
| comparison vidas assay | #1 |
| superficial thrombophlebitis incidence | #1 |
| compression ultrasonography detection | #1 |
| patency smokers | #1 |
| excluding pulmonary | #1 |
| axa activity 5 | #1 |
| uesvt mortality | #1 |
| timerequirement | #1 |
| current comprehensions | #1 |
| study centre duration | #1 |
| conventional therapy enoxaparin | #1 |
| uesvt uedvt | #1 |
| protecht shr | #1 |
| safety clinical utility | #1 |
| 12 months edoxaban | #1 |
| oral apixaban treatment | #1 |
| probability normal | #1 |
| idraparinux 25 | #1 |
| elevated fviii | #1 |
| incidence venous | #1 |
| vka netherlands | #1 |
| recurrent thromboembolism enoxaparin | #1 |
| heparin initial treatment | #1 |
| enoxaparin warfarin antiplatelet | #1 |
| iii plg | #1 |
| ifngamma pselectin | #1 |
| 250 patients cancer | #1 |
| prediction models recurrence | #1 |
| simplified geneva score | #1 |
| simplified rule proportion | #1 |
| molecular weight fondaparinux | #1 |
| mutation arg506 | #1 |
| ufh grade 1a | #1 |
| inr studies | #1 |
| ili score | #1 |
| topic thrombophlebitis | #1 |
| successful attenuation | #1 |
| lmwh edoxaban | #1 |
| 12 kg1 enoxaparin | #1 |
| uesvt median | #1 |
| inherited thrombophilia patients | #1 |
| 3 rfviia | #1 |
| enoxaparin vkas | #1 |
| avidin placebo | #1 |
| upper extremity uedvt | #1 |
| patients wells rule | #1 |
| equinox study | #1 |
| exclusion pulmonary | #1 |
| apixaban extended treatment | #1 |
| travel venous thromboembolism | #1 |
| initial treatment patients | #1 |
| compression ultrasonography patients | #1 |
| doacs factor | #1 |
| 97 compression ultrasonography | #1 |
| 15 lmwh | #1 |
| prophylaxis crt | #1 |
| alternative diagnoses patients | #1 |
| outcome recurrent | #1 |
| heparins data | #1 |
| 50 years combination | #1 |
| elevated fviii patients | #1 |
| edoxaban risk factors | #1 |
| quantitative ddimer tests | #1 |
| calfvein thrombi | #1 |
| vte risk coc | #1 |
| realtime bmode ultrasonography | #1 |
| followup overt cancer | #1 |
| oral rivaroxaban treatment | #1 |
| silent dvt | #1 |
| crt cvc | #1 |
| relative risks carriers | #1 |
| extended anticoagulation doacs | #1 |
| submassive elevated ctni | #1 |
| efficacy outcome | #1 |
| previous surveys netherlands | #1 |
| anticoagulant fondaparinux | #1 |
| duration heparin treatment | #1 |
| ddimer test patients | #1 |
| pvo qscan | #1 |
| doacs initial heparin | #1 |
| nadroparin therapeutic dose | #1 |
| ultrasonography leg veins | #1 |
| diagnostic strategy primary | #1 |
| ultrasound strategies patients | #1 |
| org heparin | #1 |
| vka recipients | #1 |
| cdr ddimer levels | #1 |
| intravenous unfractionated | #1 |
| prolactin venous thrombosis | #1 |
| management study | #1 |
| vitamin antagonists time | #1 |
| aptt org 10172 | #1 |
| fetal loss miscarriage | #1 |
| rtap lmwh | #1 |
| clinically suspected dvt | #1 |
| threemonth incidence | #1 |
| 50 rivaroxaban | #1 |
| phase doacs | #1 |
| ccus 4 | #1 |
| cdrs patients | #1 |
| idraparinux months | #1 |
| standardintensity vkas doacs | #1 |
| vitamin antagonist patients | #1 |
| perelated death category | #1 |
| survival lmwh | #1 |
| vte procoagulant activity | #1 |
| cancer patients patients | #1 |
| initial heparin patients | #1 |
| warfarin cstatistic | #1 |
| older patients cdr | #1 |
| women elevated levels | #1 |
| tomography angiography vte | #1 |
| venous thrombus growth | #1 |
| evaluable patients 95 | #1 |
| dvt 3 | #1 |
| beneficial lmwh | #1 |
| treatment venous | #1 |
| abdominal pelvic strategies | #1 |
| progression vte | #1 |
| 69 conclusions | #1 |
| method factor | #1 |
| pulmonary angiography study | #1 |
| infections gentamicin | #1 |
| atherosclerosis hemophilia patients | #1 |
| death vte studies | #1 |
| dimer clinical | #1 |
| normal dimer | #1 |
| studies ttr | #1 |
| animal female heparin | #1 |
| smoking graft patency | #1 |
| local radiologist | #1 |
| 378 patients edoxaban | #1 |
| enoxaparin tb402 | #1 |
| vka share | #1 |
| thrombosis vte | #1 |
| lmwhs 95 | #1 |
| symptomatic pts | #1 |
| venous thromboembolism idraparinux | #1 |
| tests prevalence abi | #1 |
| vte location | #1 |
| lmwh delivery | #1 |
| gastrointestinal cancer edoxaban | #1 |
| travellers thrombosis | #1 |
| idrabiotaparinux idraparinux | #1 |
| noncarriers annual incidence | #1 |
| 95ci tb402 | #1 |
| predefined outcomes | #1 |
| doubleheterozygotes | #1 |
| aptt org | #1 |
| intensity vkas doacs | #1 |
| fibrinolysis levels | #1 |
| rnapc2 inhibition | #1 |
| ddimer test combination | #1 |
| control anticardiolipin antibodies | #1 |
| elevated fviii age | #1 |
| edoxaban dalteparin | #1 |
| dvt impedance plethysmography | #1 |
| rfviia idraparinux | #1 |
| hokusai vte cancer | #1 |
| elevated cardiac troponins | #1 |
| types major bleeding | #1 |
| acute recurrent patients | #1 |
| gogh dvt trial | #1 |
| pulmonary embolism | #1 |
| intravenous injections lmwh | #1 |
| intrinsic coagulation vivo | #1 |
| edoxaban cancer patients | #1 |
| dalteparin vte treatment | #1 |
| protein mortality | #1 |
| aged venous | #1 |
| thromboembolism 3 | #1 |
| heparin org 10172 | #1 |
| vte difference | #1 |
| relatives antithrombin | #1 |
| ddimer result | #1 |
| rivaroxaban lmwh vka | #1 |
| outcome clinically | #1 |
| mortality postthrombotic symptoms | #1 |
| 0·2 edoxabantreated | #1 |
| vte occurred | #1 |
| safety 60 dose | #1 |
| coagulation fibrinolytic proteins | #1 |
| fondaparinux rfviia injection | #1 |
| recurrence bleeding risk | #1 |
| association protein levels | #1 |
| outpatients symptomatic dvt | #1 |
| relatives tafi levels | #1 |
| deepvein thrombosis incidence | #1 |
| major bleeds vka | #1 |
| strategies ultrasonography | #1 |
| selective ddimer thresholds | #1 |
| elevated ctni patients | #1 |
| crp test patients | #1 |
| ankle brachial prevalence | #1 |
| ultrasound compression ultrasound | #1 |
| normal venogram | #1 |
| wells rule primary | #1 |
| chest perfusion scintigraphy | #1 |
| rnapc2 united states | #1 |
| cdr normal | #1 |
| patients enoxaparin vkas | #1 |
| relatives normal levels | #1 |
| ctscan qscan | #1 |
| rule dimer | #1 |
| patients initial heparin | #1 |
| pharmacological methods prophylaxis | #1 |
| matisse dvt | #1 |
| subcutaneous length life | #1 |
| monoclonal antibodies apc | #1 |
| abnormal ipg | #1 |
| ventilation scan chest | #1 |
| clinical presentation category | #1 |
| clinical probability patients | #1 |
| category death | #1 |
| orthopedic surgery netherlands | #1 |
| procoagulant factors levels | #1 |
| anticoagulants chemotherapy | #1 |
| incidental symptomatic vte | #1 |
| baseline pvo | #1 |
| lmwh replacement | #1 |
| fxiaso enoxaparin | #1 |
| d‐dimer test | #1 |
| recurrent thrombosis pts | #1 |
| platelets iqr | #1 |
| unexplained dvt | #1 |
| ventilation lung scanning | #1 |
| heparin vitamin antagonist | #1 |
| guidelines abi | #1 |
| casedescription | #1 |
| asymptomatic extension | #1 |
| absolute thrombotic risk | #1 |
| qscan | #1 |
| 8h flight | #1 |
| clinical probability exclusion | #1 |
| oral administration bsf | #1 |
| fviii women | #1 |
| clinically relevant disease | #1 |
| rivaroxaban dvt treatment | #1 |
| prospective management study | #1 |
| unexplained dvt patients | #1 |
| controlled trials thrombophilia | #1 |
| wells rules | #1 |
| heparins cancer spread | #1 |
| recurrent vte doacs | #1 |
| 3633 patients edoxabantreated | #1 |
| rnapc2 patients | #1 |
| strategies diagnostic management | #1 |
| symptomatic recurrent vte | #1 |
| hellp syndrome mutations | #1 |
| prescriptionbased | #1 |
| ecq ankle brachial | #1 |
| lmprovement | #1 |
| rfviia fondaparinux | #1 |
| reduceddose noacs warfarin | #1 |
| embolism sensitivity | #1 |
| lmwh rtap | #1 |
| nondiagnostic lung scan | #1 |
| relatives mutation | #1 |
| tests pulmonary embolism | #1 |
| treated vka | #1 |
| ldfr symptomatic legs | #1 |
| combination cdr | #1 |
| clinical probability risk | #1 |
| prevention topic guidelines | #1 |
| enoxaparin primary efficacy | #1 |
| pulmonary embolism role | #1 |
| death category | #1 |
| normohomocysteinemic relatives hyperhomocysteinaemia | #1 |
| reocclusion antithrombotic drug | #1 |
| antidote vitamin | #1 |
| scores occult cancer | #1 |
| 750 μg l1 | #1 |
| ddimer test result | #1 |
| einsteinextension | #1 |
| lmwhmediated | #1 |
| elderly patients dvt | #1 |
| advanced malignancy | #1 |
| thrombosis vitamin | #1 |
| embolism radionuclide | #1 |
| anticoagulants double | #1 |
| sspe proximal | #1 |
| idraparinux versus | #1 |
| reduceddose noacs | #1 |
| thrombophilia late loss | #1 |
| presenting vte location | #1 |
| departments orthopedic surgery | #1 |
| preference doacs | #1 |
| venography feasibility | #1 |
| international thrombosis experts | #1 |
| cdr physicians | #1 |
| idraparinux vte | #1 |
| flebography | #1 |
| 500 org | #1 |
| rhir lmwh | #1 |
| revascularisation procedures patients | #1 |
| factor viii homocysteine | #1 |
| standard therapy months | #1 |
| progression svt | #1 |
| simple diagnostic strategy | #1 |
| normal lung scan | #1 |
| standard therapy rivaroxaban | #1 |
| replacement vka | #1 |
| uedvt clinical | #1 |
| 95 elevated ctni | #1 |
| venous thrombosis mutations | #1 |
| ultrasonography diagnostic | #1 |
| 95 3633 patients | #1 |
| venous thrombosis vwf | #1 |
| vka treatment treatment | #1 |
| longhaul flight | #1 |
| carriers thrombophilic defects | #1 |
| feasibility venography | #1 |
| bleeding rates quality | #1 |
| diagnostic strategies strategies | #1 |
| 2 diagnostic management | #1 |
| vte risk day | #1 |
| popliteal veins sensitivity | #1 |
| intestinal microbiota coagulation | #1 |
| pulmonary angiography ultrasonography | #1 |
| idraparinux standard therapy | #1 |
| distal clots | #1 |
| 123362 | #1 |
| quantitative dimer | #1 |
| fxainhibitors vka recipients | #1 |
| death venous thromboembolism | #1 |
| pregnancyrelated complications relatives | #1 |
| normal ddimer concentration | #1 |
| rfviia 3 | #1 |
| guideline adherence justification | #1 |
| non‐invasive diagnostic work‐up | #1 |
| sensitivity 100 percent | #1 |
| members symptomatic carriers | #1 |
| idraparinux recurrent thromboembolism | #1 |
| fviii normal levels | #1 |
| ft4 level patients | #1 |
| cancer patients uedvt | #1 |
| survival fondaparinux | #1 |
| synthetic selective factor | #1 |
| adjusted dose ufh | #1 |
| patients tb402 | #1 |
| presentation major | #1 |
| ctscanreading | #1 |
| pulmonary embolism life | #1 |
| probability cdr | #1 |
| abnormal vaginal bleeding | #1 |
| 6 months avidin | #1 |
| rabinovpaulin | #1 |
| 3633 patients edoxaban | #1 |
| orthopedic thromboprophylaxis | #1 |
| combination nonhigh cdr | #1 |
| venous thrombosis recurrence | #1 |
| acenocoumarol heparin | #1 |
| risk percentage points | #1 |
| tb402 50 | #1 |
| ambulatory computers | #1 |
| cip diagnostic management | #1 |
| patients unexplained dvt | #1 |
| normal levels fviii | #1 |
| pulmonary embolism fondaparinux | #1 |
| analysis hokusai | #1 |
| lmwh plasma levels | #1 |
| annual incidence patients | #1 |
| fviii homocysteine | #1 |
| hokusai‐vte cancer study | #1 |
| pulmonary angiography strategies | #1 |
| amplify trial | #1 |
| specificity pulmonary embolism | #1 |
| weight heparinoid | #1 |
| severity clinical presentation | #1 |
| probability lung scan | #1 |
| heparins inhibition | #1 |
| cancer cdr | #1 |
| 2630 pilots | #1 |
| variable d‐dimer thresholds | #1 |
| uesvt | #1 |
| 95 intracranial | #1 |
| pulmonary embolism basis | #1 |
| anticoagulant treatment patients | #1 |
| einstein dvt patients | #1 |
| cancer edoxaban | #1 |
| rule exclusion | #1 |
| doac recipients | #1 |
| nadroparin patients | #1 |
| calf dvt ultrasound | #1 |
| vitamin anticoagulants | #1 |
| netherlands 5 years | #1 |
| tb402 prevention | #1 |
| age recurrent vte | #1 |
| bleeding risk treatment | #1 |
| 65±9years | #1 |
| idraparinux | #1 |
| org aptt | #1 |
| vitamin antagonists treatment | #1 |
| baseline characteristics duration | #1 |
| clinically suspected uedvt | #1 |
| initial heparin edoxaban | #1 |
| apc resistance factor | #1 |
| united states rnapc2 | #1 |
| wells cdr | #1 |
| thrice daily gentamicin | #1 |
| enoxaparin initial treatment | #1 |
| achieved inr patients | #1 |
| adjunct thrombolysis | #1 |
| acenocoumarol efficacy | #1 |
| smoking patency | #1 |
| single‐detector row | #1 |
| studies 3 months | #1 |
| cvc crt | #1 |
| somittrial | #1 |
| carriers recurrence | #1 |
| scenarioanalysis | #1 |
| proportion pulmonary embolism | #1 |
| early discharge strategies | #1 |
| 393 patients warfarin | #1 |
| khorana | #1 |
| doacs anatomical extent | #1 |
| lmwh users incidence | #1 |
| ivte clinical practice | #1 |
| patients clinical probability | #1 |
| referral basis | #1 |
| 560 pharmacies | #1 |
| decisions duration | #1 |
| vte airline pilots | #1 |
| dvt symptomatic | #1 |
| presentation category | #1 |
| level loss patency | #1 |
| thromboembolism treated | #1 |
| coagulation clinical | #1 |
| recurrence major bleeding | #1 |
| pulmonary embolism tests | #1 |
| venous thromboembolism edoxaban | #1 |
| idraparinux 6 months | #1 |
| prothrombin 20210a mutation | #1 |
| 53 amputations | #1 |
| cancer 145 patients | #1 |
| individuals air travel | #1 |
| anticoagulation period | #1 |
| cancer patients cdr | #1 |
| cancer patients cancer | #1 |
| incidence ctni | #1 |
| failure diagnostic management | #1 |
| factor viii relatives | #1 |
| dimer result | #1 |
| bleeding einstein | #1 |
| thrombosis normal | #2 |
| venographically | #2 |
| bleeding edoxaban | #2 |
| pulmonary embolism asthma | #2 |
| clinical pretest probability | #2 |
| quality warfarin treatment | #2 |
| rule combined | #2 |
| n1423 | #2 |
| anticoagulated patients permanent | #2 |
| exclusion pulmonary embolism | #2 |
| vitamin antagonists quality | #2 |
| amadeus study | #2 |
| risk anticoagulation therapy | #2 |
| 8 wk risk | #2 |
| crd42017056309 | #2 |
| mild risk factor | #2 |
| cancer addition | #2 |
| major bleeding cindexes | #2 |
| embolism deep | #2 |
| patients abi measurement | #2 |
| relation coagulation factors | #2 |
| recurrence thromboembolism | #2 |
| presentation dvt | #2 |
| 95 cancer patients | #2 |
| ultrasonography patients | #2 |
| risk deep | #2 |
| rnapc2 doses | #2 |
| embolism primary | #2 |
| lmwh users | #2 |
| 6 months scores | #2 |
| subcutaneous length | #2 |
| thromboinflammation cardiovascular disease | #2 |
| f5 r506q | #2 |
| enoxaparin warfarin | #2 |
| heparin compounds | #2 |
| computerized impedance | #2 |
| efficiency diagnostic strategies | #2 |
| score dimer | #2 |
| normal ddimer test | #2 |
| concomitant thrombophilic | #2 |
| thrombophilic defects risk | #2 |
| prolactin relation | #2 |
| simplified wells | #2 |
| fibrinolysis pentoxifylline | #2 |
| administration rviia | #2 |
| vte svt | #2 |
| biomarkers casecontrol studies | #2 |
| rivaroxaban 30 bid | #2 |
| clinical probability estimate | #2 |
| ddimer determination | #2 |
| months 25 | #2 |
| patients prior vte | #2 |
| major clinically | #2 |
| rnapc2 | #2 |
| negative ageadjusted ddimer | #2 |
| fibrinolysis influenza | #2 |
| venous | #2 |
| heparin administered | #2 |
| c1173t dimorphism | #2 |
| scan normal | #2 |
| clinical prediction model | #2 |
| secondary strategies | #2 |
| arterial thrombotic disease | #2 |
| resource utilisation treatment | #2 |
| recurrent deep | #2 |
| comparator individuals 95 | #2 |
| women therapeutic doses | #2 |
| medscape | #2 |
| influenza coagulation | #2 |
| fvl carriers carriers | #2 |
| analysis venous | #2 |
| venous thrombophlebitis | #2 |
| adapted ddimer thresholds | #2 |
| incidence recurrent | #2 |
| raskob | #2 |
| tinaquant vidas | #2 |
| patients hemorr2hages | #2 |
| acquired antithrombin | #2 |
| secondary efficiency | #2 |
| primary healthcare secondary | #2 |
| major bleeding recurrent | #2 |
| referred patients secondary | #2 |
| vitamin antagonist rivaroxaban | #2 |
| coagulation factors prolactin | #2 |
| sspe patients patients | #2 |
| 20210a mutations | #2 |
| 3306 patients | #2 |
| heparin effective | #2 |
| mutations cleavage sites | #2 |
| hasbled score hemorr2hages | #2 |
| subsegmental emboli | #2 |
| vte 12 | #2 |
| coumarin sensitivity | #2 |
| beta‐receptor blockade | #2 |
| events severe | #2 |
| outcome symptomatic | #2 |
| hellp syndrome prevalence | #2 |
| heparin nadroparin | #2 |
| pentasaccharide fondaparinux | #2 |
| suspected upper | #2 |
| graft occlusion patients | #2 |
| limits cancer | #2 |
| screening fvl | #2 |
| extended constans score | #2 |
| years 36 | #2 |
| warfarintreated | #2 |
| prothrombin pulmonary embolism | #2 |
| statins recurrent vte | #2 |
| principal safety outcome | #2 |
| blood coagulation inhibition | #2 |
| ddimer assay | #2 |
| recurrent vte risk | #2 |
| ate cancer patients | #2 |
| serum tnf activity | #2 |
| idraparinux vitamin | #2 |
| life treatment duration | #2 |
| lowmolecularweight heparin women | #2 |
| gcpg | #2 |
| sustained antithrombotic | #2 |
| undiagnosed malignancy | #2 |
| thyroid hormone coagulation | #2 |
| vte elevated fviii | #2 |
| central localization | #2 |
| suspected pulmonary embolism | #2 |
| lower clinical utility | #2 |
| primary efficacy outcome | #2 |
| pulmonary embolism efficacy | #2 |
| death vte | #2 |
| safety pravastatin therapy | #2 |
| uedvt cancer patients | #2 |
| patients oral factor | #2 |
| 95 0·2 | #2 |
| bleeding occurred | #2 |
| cancer recurrent vte | #2 |
| mutations propeptide | #2 |
| plasmin activity inhibition | #2 |
| alife study | #2 |
| inflammation neutrophils thrombosis | #2 |
| hyperglycemia diagnosis | #2 |
| uptake noacs | #2 |
| hmb primary outcome | #2 |
| fibrinolytic proteins | #2 |
| enoxaparin difference | #2 |
| low‐molecular‐weight heparin | #2 |
| test cancer | #2 |
| age‐adjusted d‐dimer testing | #2 |
| decision rule | #2 |
| compression doppler | #2 |
| bleeding rate patients | #2 |
| heparin treatment influenza | #2 |
| ufh survival | #2 |
| khorana protecht | #2 |
| euro138 | #2 |
| rivaroxaban thiazoles | #2 |
| plasma d‐dimer concentration | #2 |
| hokusai vte | #2 |
| surgical casts | #2 |
| influenza prothrombotic state | #2 |
| global public awareness | #2 |
| coagulation fibrinolytic | #2 |
| regression pravastatin | #2 |
| efficiency original score | #2 |
| pharmacological strategies | #2 |
| rfviia injection rfviia | #2 |
| thrombophilic disorders | #2 |
| nematode anticoagulant | #2 |
| cha2ds2vasc nri | #2 |
| common alternative diagnoses | #2 |
| antagonists vka | #2 |
| impedance plethysmography patients | #2 |
| duration anticoagulant | #2 |
| endogenous activated protein | #2 |
| bleeding complications treatment | #2 |
| uedvt efficiency | #2 |
| major bleeding intermediate | #2 |
| 17 apixaban | #2 |
| computed venous | #2 |
| sr34006 | #2 |
| angioplasty clopidogrel | #2 |
| exposure flights | #2 |
| fviii increased risk | #2 |
| hospitalbased strategies | #2 |
| incidental vte | #2 |
| travel venous | #2 |
| deficiencies proteins | #2 |
| 95 comparator individuals | #2 |
| duration anticoagulant treatment | #2 |
| hemorr2hages atria scores | #2 |
| cdr wells cdr | #2 |
| apixaban lmwh vka | #2 |
| levothyroxine exposure | #2 |
| intermediate phenotype vte | #2 |
| blood coagulation rnapc2 | #2 |
| incidental venous | #2 |
| treatment deep | #2 |
| wells cdr cdr | #2 |
| n832 | #2 |
| single administration tb402 | #2 |
| lmwh efficacy | #2 |
| vte 1000 personyears | #2 |
| gauge plethysmography | #2 |
| impedance plethysmography diagnosis | #2 |
| recombinant hirudin cgp | #2 |
| 95 dvt | #2 |
| pregnancy venous thrombosis | #2 |
| thromboembolism thrombophilia | #2 |
| interleukin‐10 response | #2 |
| levels coagulation factors | #2 |
| mutation 35 | #2 |
| mdct reference standard | #2 |
| symptomatic outpatients | #2 |
| ventilation scanning | #2 |
| standardised time intervals | #2 |
| uedvt performance | #2 |
| efficiency strategy | #2 |
| pravastatin therapy children | #2 |
| pregnancy coc | #2 |
| treated edoxaban | #2 |
| annual incidences | #2 |
| embolism safely | #2 |
| pulmonary embolism purpose | #2 |
| patients peripheral graft | #2 |
| apixaban enoxaparin warfarin | #2 |
| endotoxininduced activation coagulation | #2 |
| vein compressibility | #2 |
| amuse strategy | #2 |
| cdr variables cdr | #2 |
| diagnostic lung | #2 |
| employees longhaul flight | #2 |
| healthcare settings findings | #2 |
| venous thromboembolism enoxaparin | #2 |
| relevant patient subgroups | #2 |
| intrinsic cascade | #2 |
| absolute incidence | #2 |
| recombinant nematode | #2 |
| vidas assay | #2 |
| patients low probability | #2 |
| oral direct inhibitors | #2 |
| suspected pulmonary | #2 |
| risk khorana | #2 |
| wells cdr patients | #2 |
| crnm bleeds | #2 |
| ufh 6 months | #2 |
| nct00633893 | #2 |
| simplired test | #2 |
| exclude pulmonary | #2 |
| clinically suspected | #2 |
| 8292 patients | #2 |
| major bleeding edoxaban | #2 |
| patients khorana score | #2 |
| ageadjusted ddimer testing | #2 |
| factor iia | #2 |
| current clinical challenges | #2 |
| normohomocysteinemic relatives | #2 |
| model cancer patients | #2 |
| brain metastases doacs | #2 |
| treatment ttr | #2 |
| composite scores area | #2 |
| nonpermanent heart failure | #2 |
| dimer thresholds | #2 |
| rule proportion | #2 |
| primary hospitalbased strategies | #2 |
| received edoxaban | #2 |
| performance constans rule | #2 |
| treated anticoagulants | #2 |
| hokusai vtecancer study | #2 |
| protein rnapc2 | #2 |
| vte orthopedic surgery | #2 |
| plasma concentrations endotoxin | #2 |
| measurement ankle brachial | #2 |
| failure rate strategy | #2 |
| safety acenocoumarol | #3 |
| svt vte | #3 |
| prolactin controls | #3 |
| patients proximalvein thrombosis | #3 |
| baseline values placebo | #3 |
| presenting location | #3 |
| lowmolecularweight humans length | #3 |
| selectine | #3 |
| pulmonary embolism models | #3 |
| probability dimer | #3 |
| 95 wells rule | #3 |
| 02011 | #3 |
| diagnosis deep | #3 |
| patients ultrasonography | #3 |
| bleeding major | #3 |
| ft4 risk | #3 |
| stable acute | #3 |
| patients 6575 years | #3 |
| wells rule dvt | #3 |
| endogenous apc | #3 |
| vte venous thrombosis | #3 |
| ventilation scan | #3 |
| simplified wells specificity | #3 |
| plethysmography impedance | #3 |
| proximalvein thrombosis | #3 |
| patients gastrointestinal cancer | #3 |
| lmwh | #3 |
| female hemorrhage humans | #3 |
| influence heparins | #3 |
| composite stroke | #3 |
| iii deficiency | #3 |
| gestalt 95 | #3 |
| topic heparin heparin | #3 |
| einstein patients | #3 |
| diagnosis pulmonary embolism | #3 |
| pad smokers | #3 |
| heparins cancer | #3 |
| studies cus strategies | #3 |
| discontinuation ufh | #3 |
| monoclonal replacement | #3 |
| impedance predictive | #3 |
| nadroparin placebo | #3 |
| predictable pharmacokinetics | #3 |
| patients venography | #3 |
| healthy donor fmt | #3 |
| travel venous thrombosis | #3 |
| definition perelated death | #3 |
| strategies efficiency | #3 |
| sensitivity compression | #3 |
| axa activity | #3 |
| multiple comorbidities polypharmacy | #3 |
| 100 years year | #3 |
| vte low | #3 |
| thrombophlebitis treatment | #3 |
| combination wells score | #3 |
| thromboembolism background | #3 |
| standard therapy treatment | #3 |
| incidental pulmonary embolism | #3 |
| treatment vte recurrence | #3 |
| lmwh pph | #3 |
| “gestalt | #3 |
| safely | #3 |
| thrombophilic defect | #3 |
| cdr combination | #3 |
| tfindependent | #3 |
| ddimer assays | #3 |
| inhibition blood coagulation | #3 |
| vte 3 | #3 |
| normal ctnt presentation | #3 |
| incidence enoxaparin | #3 |
| fxiaso | #3 |
| oral hormonal cross | #3 |
| thromboembolism low | #3 |
| placebo n4 | #3 |
| 3month incidence | #3 |
| treatment vitamin antagonists | #3 |
| outpatients dvt | #3 |
| heparin edoxaban | #3 |
| capillary blood sample | #3 |
| cancer randomised trials | #3 |
| patients wells | #3 |
| extensive screening | #3 |
| tb‐402 | #3 |
| hasbled | #3 |
| dalteparin difference | #3 |
| single diagnostic | #3 |
| 6575 years | #3 |
| patients venous | #3 |
| factors prothrombin | #3 |
| atria hemorr2hages | #3 |
| mechanisms heparin | #3 |
| einstein studies | #3 |
| venous arterial | #3 |
| normal result | #3 |
| time venous thrombosis | #3 |
| idrabiotaparinux warfarin | #3 |
| outcome venous | #3 |
| crt cancer patients | #3 |
| einstein dvt | #3 |
| cancer patients ate | #3 |
| 3633 patients | #3 |
| alternative diagnoses | #3 |
| venous thrombosis travel | #3 |
| wells rule gestalt | #3 |
| treatment vka | #3 |
| factor viiic | #3 |
| nct00643201 | #3 |
| 3month vte incidence | #3 |
| ddimer threshold | #3 |
| idrabiotaparinux | #3 |
| ipe cancer patients | #3 |
| vte performance | #3 |
| dvt primary | #3 |
| prevalence hemostatic abnormalities | #3 |
| compensated dic | #3 |
| bleeding 3 | #3 |
| efficacy heparin | #3 |
| subcutaneous fondaparinux | #3 |
| thombosis | #3 |
| mutation venous | #3 |
| recombinant hirudin rhir | #3 |
| deep vein | #3 |
| dvt hip | #3 |
| clinical models patients | #3 |
| recurrent thromboembolic | #3 |
| warfarin subgroup | #3 |
| knee factor | #3 |
| coagulation air travel | #3 |
| 20210ga | #3 |
| users incidence | #3 |
| female humans inhibitors | #3 |
| hokusai‐vte | #3 |
| lowmolecularweight heparin placebo | #3 |
| heparin heparin | #3 |
| venous thromboembolism apixaban | #3 |
| revised geneva efficiency | #3 |
| enoxaparin follow | #3 |
| venous thrombosis positive | #3 |
| pulmonary embolism primary | #3 |
| pph lmwh | #3 |
| cancer patients ipe | #3 |
| platelet agents | #3 |
| dvt einstein | #3 |
| safely excluded | #3 |
| low probability models | #3 |
| 12month study period | #3 |
| adult patients vte | #3 |
| ultrasonography strategies | #3 |
| treatment low | #3 |
| patients 6 months | #3 |
| older children vte | #3 |
| favour lmwh | #3 |
| dose reduction edoxaban | #3 |
| dimer blood | #3 |
| ctnt risk stratification | #3 |
| negative predictive proportion | #3 |
| studies hemorrhage | #3 |
| activecontrol | #3 |
| thiophenes venous | #3 |
| death clinical studies | #3 |
| diagnosis pulmonary | #3 |
| outpatient treatment dvt | #3 |
| venous thromboembolism thrombophilia | #3 |
| protein thrombophilia | #3 |
| primary wells rule | #3 |
| cardiac troponine | #3 |
| pulmonary embolism gestalt | #3 |
| dip placebo | #3 |
| prevalence avws | #3 |
| dvt major | #3 |
| rnapc2 fviia | #3 |
| administration rnapc2 | #3 |
| dvt systematic differences | #3 |
| desogestrelcontaining | #3 |
| primary rule | #3 |
| chemotherapy prophylaxis | #3 |
| venous thrombosis cancer | #3 |
| intravenous loading dose | #3 |
| vte denmark | #3 |
| venous thromboembolism | #3 |
| subcutaneous lmwh | #3 |
| safely exclude | #3 |
| vte major burden | #3 |
| failurerate | #3 |
| patients ft4 level | #3 |
| vein thrombosis | #3 |
| treatment lowmolecularweight heparin | #3 |
| products follow | #3 |
| incidence total vte | #3 |
| antithrombin iii concentrate | #3 |
| age annual incidence | #3 |
| approaches primary | #3 |
| detection dvt | #3 |
| embolism‐related | #3 |
| introduction mdct | #3 |
| coagulation influence | #3 |
| hf severity risk | #3 |
| tinaquant assay | #3 |
| patients incidental vte | #3 |
| apc protective | #3 |
| therapy venous | #3 |
| cohort study employees | #3 |
| pulmonary embolism‐related death | #3 |
| gestalt probability | #3 |
| recurrence thrombophlebitis | #3 |
| cancer active cancer | #3 |
| idiopathic venous | #3 |
| cleavage sites apc | #4 |
| primary pulmonary embolism | #4 |
| global disease burden | #4 |
| control anticoagulation | #4 |
| thrombosis symptomatic | #4 |
| thromboembolism arterial | #4 |
| dutch orthopedic | #4 |
| thrombosis deep | #4 |
| vka treatment | #4 |
| 150 microg desogestrel | #4 |
| apixaban efficacy | #4 |
| vte global | #4 |
| serial impedance plethysmography | #4 |
| women normal levels | #4 |
| lmwh female heparin | #4 |
| patients venous thromboembolism | #4 |
| thrombophilia 95 | #4 |
| “reversal | #4 |
| netherlands pulmonary | #4 |
| hemorr2hages | #4 |
| tinaquant | #4 |
| embolism dimer | #4 |
| levels ft4 | #4 |
| measurement abi | #4 |
| death survey | #4 |
| disease vte | #4 |
| hemostatic profile | #4 |
| diagnostic management | #4 |
| treatment unfractionated heparin | #4 |
| leiden carriers | #4 |
| thromboembolism treatment | #4 |
| enoxaparin day | #4 |
| patients alternative diagnosis | #4 |
| warfarin 3 months | #4 |
| 150 microg levonorgestrel | #4 |
| rfviia injection | #4 |
| patient category | #4 |
| women apc resistance | #4 |
| probability prospective | #4 |
| extended treatment | #4 |
| risk occult cancer | #4 |
| life duration | #4 |
| ddimer assay patients | #4 |
| oral rivaroxaban | #4 |
| lmwh cancer patients | #4 |
| sankyo | #4 |
| noacs netherlands | #4 |
| rviia thrombin generation | #4 |
| 0651 | #4 |
| thrombophilic families | #4 |
| clinically relevant bleeding | #4 |
| doac studies | #4 |
| recurrent vte months | #4 |
| patients edoxaban | #4 |
| procoagulant factors | #4 |
| dimer assays | #4 |
| patients clinically | #4 |
| embolism roc | #4 |
| vte highincome countries | #4 |
| gramnegative bacteria humans | #4 |
| embolism tomography | #4 |
| coagulation endotoxin | #4 |
| disease burden vte | #4 |
| abdomen relationship | #4 |
| venous thromboembolism patients | #4 |
| mbe patients | #4 |
| coagulation factors risk | #4 |
| venography patients | #4 |
| 335 patients | #4 |
| advanced cancer 95 | #4 |
| prophylaxis lmwh | #4 |
| thromboembolism study | #4 |
| chads2 p0001 | #4 |
| vitamin antagonists | #4 |
| bleeding anticoagulants | #4 |
| population rivaroxaban | #4 |
| series venograms | #4 |
| impedance plethysmography | #4 |
| refuted | #4 |
| chemotherapy shr | #4 |
| thrombosis air | #4 |
| thrombosis uedvt | #4 |
| proximal patients | #4 |
| preexisting heparin | #4 |
| clot resolution | #4 |
| 35±4 | #4 |
| travel thrombosis | #4 |
| diagnostic prediction models | #4 |
| activation fibrinolytic | #4 |
| patients primary healthcare | #4 |
| amadeus trial | #4 |
| primary failure rate | #4 |
| protecht | #4 |
| safety pravastatin | #4 |
| vte netherlands | #4 |
| thromboembolism occurred | #4 |
| embolism background | #4 |
| global burden vte | #4 |
| venous thrombosis levels | #4 |
| predilution postdilution | #4 |
| patients dimer | #4 |
| pregnancies carriers | #4 |
| chinese korean ethnicity | #4 |
| vte total | #4 |
| risk vkas | #4 |
| chromogenic compounds | #4 |
| cancer vwf | #4 |
| vitamin antagonist treatment | #4 |
| vte treatment patients | #4 |
| thromboembolism systematic | #4 |
| noacs cancer patients | #4 |
| postthrombotic symptoms | #4 |
| vte global burden | #4 |
| serial impedance | #4 |
| lowmolecular weight heparins | #4 |
| hyperhomocysteinemic relatives | #4 |
| fibrin generation test | #4 |
| 6 months prophylaxis | #4 |
| symptomatic deep | #4 |
| diagnostic management strategies | #4 |
| patients fondaparinux | #4 |
| daily netilmicin | #4 |
| chemotherapy vte prophylaxis | #4 |
| thromboembolism vitamin | #4 |
| received warfarin | #4 |
| patients submassive | #4 |
| patients nonpermanent | #4 |
| rule pulmonary | #4 |
| 3587 | #4 |
| criteria dose reduction | #4 |
| lowmolecularweight heparin | #4 |
| diagnosis uedvt | #4 |
| negative point | #4 |
| rivaroxaban 20 | #4 |
| arterial thrombotic | #4 |
| total vte | #4 |
| estrogen therapy patients | #4 |
| edoxaban patients | #4 |
| thrombosis ischemic stroke | #4 |
| episode venous | #4 |
| questionnaires venous | #4 |
| lmwhs standard heparin | #4 |
| 10172 | #4 |
| patients crcl 60 | #4 |
| clot lysis patients | #4 |
| ageadjusted cutoff patients | #4 |
| patient education treatment | #4 |
| enoxaparin female humans | #4 |
| contraindications treatment | #4 |
| dose noacs | #4 |
| idiopathic venous thrombosis | #4 |
| thromboembolism factor | #4 |
| vitamin antagonists patients | #4 |
| nct00571649 | #4 |
| ultrasonography venous | #4 |
| point dimer | #4 |
| secondary venous thrombosis | #5 |
| ventricular dysfunction echocardiography | #5 |
| clinical probability | #5 |
| incidence prognostic significance | #5 |
| preschool contraceptives | #5 |
| fh patients cvd | #5 |
| vte 6 | #5 |
| cdr patients | #5 |
| deepvein thrombosis | #5 |
| 2 rules | #5 |
| predilution | #5 |
| sensitivity negative predictive | #5 |
| fviia rnapc2 | #5 |
| diagnosis questionnaire | #5 |
| diagnostic strategies | #5 |
| thromboembolism idraparinux | #5 |
| isolated calfvein thrombosis | #5 |
| heparin compared | #5 |
| hokusai | #5 |
| molecularweight heparin | #5 |
| thrombosis primary | #5 |
| pad smoking | #5 |
| embolism reproducibility | #5 |
| compression ultrasound | #5 |
| exclusion venous thromboembolism | #5 |
| asymptomatic carriers mutation | #5 |
| daiichi sankyo | #5 |
| upper extremity thrombosis | #5 |
| netilmicin patients | #5 |
| lmwh incidence | #5 |
| dvt prevalence | #5 |
| outpatients hospital | #5 |
| vte factor | #5 |
| vte patients cancer | #5 |
| day rivaroxaban | #5 |
| low molecularweight humans | #5 |
| suspected uedvt | #5 |
| thromboembolism studies | #5 |
| treatment acute dvt | #5 |
| pregnancy pph | #5 |
| factor leiden 95 | #5 |
| thromboembolism | #5 |
| outcome major | #5 |
| panwards | #5 |
| normal ctpa | #5 |
| coronary angioplasty angioplasty | #5 |
| thrombosis upper | #5 |
| bleeding cancer | #5 |
| specificity thrombophlebitis | #5 |
| lmwh recommended | #5 |
| risk prediction scores | #5 |
| thrombosis leg | #5 |
| women warfarin | #5 |
| patients wells score | #5 |
| southern latin america | #5 |
| medea study | #5 |
| clinical probability assessment | #5 |
| iii plasminogen | #5 |
| low‐molecular‐weight | #5 |
| fviii families | #5 |
| inhibition plasminogen activation | #5 |
| patients subtherapeutic | #5 |
| severe pph women | #5 |
| endotoxin testing | #5 |
| gestalt | #5 |
| thromboembolism thrombosis | #5 |
| hirudin treatment | #5 |
| pulmonary embolism patients | #5 |
| patients recurrent dvt | #5 |
| 8292 | #5 |
| clinical presentation clinical | #5 |
| dimer combination | #5 |
| antithrombotic drug treatment | #5 |
| adjusted dimer | #5 |
| ft4 level | #5 |
| efficiency patients | #5 |
| repeated ultrasonography | #5 |
| phlebography plethysmography | #5 |
| secondary dvt | #5 |
| thrombophlebitis ultrasonography | #5 |
| patients superficial thrombophlebitis | #5 |
| elevated plasma level | #5 |
| consensus strategy | #5 |
| 8491 | #5 |
| recurrent dvt patients | #5 |
| venous thromboembolism studies | #5 |
| patients pulmonary embolism | #5 |
| transfusion blood loss | #5 |
| treatment fondaparinux | #5 |
| coc pregnancy | #5 |
| rivaroxaban enoxaparin vka | #5 |
| cgp 39393 | #5 |
| patients parenteral anticoagulants | #5 |
| endotoxin chimpanzees | #5 |
| cancer strategy | #5 |
| burden vte | #5 |
| vka patients | #5 |
| endogenous activated | #5 |
| previous venous thromboembolism | #5 |
| warfarin venous thromboembolism | #6 |
| assay fibrin | #6 |
| symptoms intermittent claudication | #6 |
| oral edoxaban | #6 |
| vte anticoagulant treatment | #6 |
| severe dic | #6 |
| fixeddose regimen | #6 |
| pembqol questionnaire | #6 |
| risk increasing levels | #6 |
| compression stockings patients | #6 |
| ultrasonography normal | #6 |
| rate major bleeding | #6 |
| simplired dimer | #6 |
| conventional therapy treatment | #6 |
| treatment ufh | #6 |
| thrombophilic defects | #6 |
| venograms | #6 |
| myocardial infarction ctni | #6 |
| patients anticoagulation clinic | #6 |
| severe antithrombin | #6 |
| wells rule | #6 |
| symptomatic legs | #6 |
| endotoxin assays | #6 |
| synthetic pentasaccharides | #6 |
| 049 95 | #6 |
| vte cancer | #6 |
| patients uedvt | #6 |
| amplify | #6 |
| efficiency proportion | #6 |
| 12month cumulative incidence | #6 |
| lmwh cancer | #6 |
| 10±4 | #6 |
| combined utility | #6 |
| grade 1a ufh | #6 |
| patients lowmolecularweight heparin | #6 |
| arterial cardiovascular | #6 |
| dvt trial | #6 |
| proportion cancer patients | #6 |
| thromboembolism bleeding | #6 |
| duration rivaroxaban | #6 |
| treatment svt | #6 |
| subcutaneous low | #6 |
| neoplasms pulmonary embolism | #6 |
| treatment pulmonary embolism | #6 |
| selective beta | #6 |
| embolism pulmonary | #6 |
| pulmonary embolism presence | #6 |
| antagonists treatment | #6 |
| cancer primary patients | #6 |
| stressinduced hyperglycaemia | #6 |
| risk khorana score | #6 |
| blood coagulation mechanism | #6 |
| repeatedly normal | #6 |
| svt extension | #6 |
| lmwh users users | #6 |
| edoxaban efficacy | #6 |
| d‐dimer testing | #6 |
| women hyperhomocysteinemia | #6 |
| low absolute risk | #6 |
| patients tests | #6 |
| oral anticoagulants dabigatran | #6 |
| vte controls | #6 |
| apixaban treatment dose | #6 |
| prevalence vte | #6 |
| fviia inhibition | #6 |
| patients diagnostic | #6 |
| effects ufh | #6 |
| 393 patients | #6 |
| anticoagulants hemorrhage | #6 |
| patients iohexol | #6 |
| incidence recurrence | #6 |
| factor leiden carriers | #6 |
| outcome occurred | #6 |
| dabigatran etexilate dabigatran | #6 |
| daily gentamicin | #6 |
| effects levonorgestrel | #6 |
| subjects vte | #6 |
| patients proximal | #6 |
| anticoagulant treatment | #6 |
| patients pulmonary angiography | #6 |
| elisapositive | #6 |
| thrombosis guidelines | #6 |
| embolism ventricular | #6 |
| diagnostic workup | #6 |
| probability pulmonary | #6 |
| subcutaneous nadroparin | #6 |
| vka | #6 |
| patients suspected | #6 |
| recurrent pulmonary | #6 |
| isolated deficiencies | #6 |
| leiden | #6 |
| patients factor mutation | #6 |
| standardized morbidity ratio | #6 |
| dimer cut | #6 |
| initial heparin treatment | #6 |
| perioperative blood loss | #6 |
| treatment intermittent claudication | #6 |
| clinically relevant subgroups | #6 |
| c1173 | #6 |
| anticoagulants female | #6 |
| ft4 patients | #6 |
| endotoxininduced activation | #6 |
| dalteparin dose | #6 |
| 39393 | #6 |
| enoxaparin incidence | #6 |
| levonorgestrel desogestrel | #6 |
| funding bayer | #6 |
| diagnostic suspicion | #7 |
| factor female humans | #7 |
| stockings control | #7 |
| heparin org | #7 |
| pulmonary embolism sensitivity | #7 |
| proportion older patients | #7 |
| anticoagulant parameters | #7 |
| rivaroxaban 10 | #7 |
| inhibitor apixaban | #7 |
| mpc1609 | #7 |
| mutations factor viii | #7 |
| relation levels | #7 |
| dvt ipg | #7 |
| relation prolactin levels | #7 |
| ufh treatment | #7 |
| tnf injection | #7 |
| vka therapy | #7 |
| primary dvt | #7 |
| patients standard heparin | #7 |
| specific antidotes | #7 |
| protein protein deficiencies | #7 |
| noncompressibility | #7 |
| general practitioners guideline | #7 |
| spiral sensitivity | #7 |
| major bleeding rate | #7 |
| rates edoxaban | #7 |
| combination ipg | #7 |
| doppler skin | #7 |
| embolism prospective | #7 |
| deepvein thrombosis patients | #7 |
| administration bsf | #7 |
| thrombophlebitis adolescent | #7 |
| blood coagulation humans | #7 |
| neoplasms pulmonary | #7 |
| 220 dabigatran | #7 |
| carriers venous thromboembolism | #7 |
| arterial cardiovascular disease | #7 |
| day initial treatment | #7 |
| antithrombin protein | #7 |
| 597939 | #7 |
| vte cancer diagnosis | #7 |
| carriers defects | #7 |
| etexilate oral | #7 |
| unselected women | #7 |
| placebo rivaroxaban | #7 |
| statin treatment risk | #7 |
| leg ultrasonography | #7 |
| ottawa score | #7 |
| negative predictive npv | #7 |
| coagulation humans | #7 |
| recurrent dvt | #7 |
| 680 | #7 |
| diagnosis venous thrombosis | #7 |
| plasma levels ifngamma | #7 |
| perelated death | #7 |
| thromboembolism vte | #7 |
| tb402 | #7 |
| treatment doac | #7 |
| negative ddimer test | #7 |
| prothrombin risk | #7 |
| primary efficacy | #7 |
| presence cteph | #7 |
| vitamin antagonists vka | #7 |
| phenprocoumon polymorphism | #7 |
| thromboembolism total | #7 |
| major bleeding vkas | #7 |
| levels factor viii | #7 |
| nondiagnostic lung scans | #7 |
| lung scan | #7 |
| thromboembolism adult | #7 |
| thrombophilia pregnancy loss | #7 |
| aspirin combined | #7 |
| silent pulmonary embolism | #7 |
| venous thrombosis treatment | #7 |
| major bleeding | #7 |
| incidence recurrent vte | #7 |
| low clinical probability | #8 |
| ufh initial treatment | #8 |
| patients extended anticoagulation | #8 |
| inr determination | #8 |
| vte score | #8 |
| wells scores | #8 |
| current approach | #8 |
| thrombosis prophylaxis | #8 |
| severe preeclampsia patients | #8 |
| administration low | #8 |
| patients symptomatic vte | #8 |
| v617f jak2 | #8 |
| acute symptomatic vte | #8 |
| persistent risk factors | #8 |
| dimer tests | #8 |
| heparin vitamin antagonists | #8 |
| fxi aso | #8 |
| initial heparin | #8 |
| pvoct | #8 |
| oac adherence | #8 |
| risk employees | #8 |
| deficiency antithrombin | #8 |
| prevention vte | #8 |
| recurrent vte bleeding | #8 |
| anticoagulants antineoplastic | #8 |
| objectively confirmed | #8 |
| structured algorithm | #8 |
| 0·2 | #8 |
| symptomatic deepvein thrombosis | #8 |
| arg506 factor | #8 |
| vitamin antagonists vkas | #8 |
| proximal deepvein thrombosis | #8 |
| products humans | #8 |
| dimer concentration | #8 |
| chemotherapy low risk | #8 |
| 150 enoxaparin | #8 |
| compression surveys | #8 |
| homocysteine markers | #8 |
| leiden prothrombin | #8 |
| discontinuation anticoagulant treatment | #8 |
| analysis apixaban | #8 |
| carriers fvl | #8 |
| testing rule | #8 |
| warfarin hazard ratio | #8 |
| cancer pulmonary embolism | #8 |
| international organisations | #8 |
| increased fibrinolytic | #8 |
| tests pulmonary | #8 |
| unprovoked vte patients | #8 |
| inr values patients | #8 |
| prospective management | #8 |
| funding daiichi | #8 |
| 1599 patients | #8 |
| point ultrasonography | #8 |
| duration treatment | #8 |
| p0001 hasbled score | #8 |
| comorbidity polypharmacy | #8 |
| treatment venous thrombosis | #8 |
| 97 95 | #8 |
| vka lmwh | #8 |
| overt cancer | #8 |
| nafronyl | #8 |
| probability lung | #8 |
| levonorgestrelcontaining | #8 |
| thrombosis adolescent | #8 |
| ageadjusted ddimer cutoff | #8 |
| apixaban enoxaparin | #8 |
| occult cancer patients | #8 |
| normal computed | #8 |
| consecutive outpatients | #8 |
| optimal intensity | #8 |
| anticoagulation unprovoked vte | #8 |
| aged phlebography | #8 |
| bnp ctnt | #8 |
| proximal deep | #8 |
| oral glucocorticoids risk | #8 |
| years cumulative incidence | #8 |
| oral apixaban | #8 |
| physicians stockings | #8 |
| inherited thrombophilic | #8 |
| patients excluded | #8 |
| agnelli | #8 |
| venous thrombosis hyperhomocysteinaemia | #8 |
| contrast venography | #8 |
| euro55 | #8 |
| lmwh grade 1a | #8 |
| risks dvt | #8 |
| xii deficient | #8 |
| enoxaparin vka | #8 |
| recurrent vte mb | #8 |
| vascular endothelial barrier | #8 |
| nondiagnostic scan | #8 |
| lmwh mortality | #9 |
| discontinuing anticoagulation | #9 |
| thromboembolism cancer | #9 |
| cancer factor | #9 |
| heparin therapy patients | #9 |
| vte rcts | #9 |
| independent committee | #9 |
| oral contraceptive pregnancy | #9 |
| iii concentrate | #9 |
| postdilution | #9 |
| homocysteine women | #9 |
| combination stroke | #9 |
| male oligosaccharides | #9 |
| weight heparin | #9 |
| crcl 60 | #9 |
| therapeutic dose patients | #9 |
| compression stockings prevention | #9 |
| factors thrombophlebitis | #9 |
| carriers factor leiden | #9 |
| embolism venous | #9 |
| oral antithrombins | #9 |
| incidence postthrombotic syndrome | #9 |
| cofact | #9 |
| enoxaparin factor | #9 |
| thrombosis thromboinflammation | #9 |
| cancer episode | #9 |
| büller | #9 |
| diagnosis mdct | #9 |
| tafi levels | #9 |
| treatment prophylaxis | #9 |
| hemorr2hages atria | #9 |
| longterm treatment vte | #9 |
| diagnostic prediction model | #9 |
| bled bleeding | #9 |
| incidental pulmonary | #9 |
| anticoagulant pathways | #9 |
| ultrasonogram | #9 |
| comorbidities polypharmacy | #9 |
| nonpermanent | #9 |
| lipoproteina women | #9 |
| generation pill | #9 |
| method enoxaparin | #9 |
| concomitant cancer | #9 |
| patients active cancer | #9 |
| treatment edoxaban | #9 |
| placebo plasma levels | #9 |
| thrombosis venous thromboembolism | #9 |
| fxa inhibitor | #9 |
| edoxaban major bleeding | #9 |
| fondaparinux cancer patients | #9 |
| vte relatives | #9 |
| daiichisankyo | #9 |
| serotonin platelet | #9 |
| cancer cell extravasation | #9 |
| months efficacy | #9 |
| characteristics severity | #9 |
| prothrombin 20210a | #9 |
| thrombosis compared | #9 |
| apixaban oral factor | #9 |
| strategies dimer | #9 |
| abnormal vaginal | #9 |
| acute medical illnesses | #9 |
| normal ddimer | #9 |
| patients fxa inhibitors | #9 |
| major bleeding treatment | #9 |
| atiii concentrates | #9 |
| intimamedia thickness imt | #10 |
| factor prevention | #10 |
| anticoagulants | #10 |
| induced coagulation | #10 |
| lmwh studies | #10 |
| venous thrombosis | #10 |
| incidence 1000 personyears | #10 |
| rabbits administration | #10 |
| probability pulmonary embolism | #10 |
| pregnancy carriers | #10 |
| hypocoagulable state | #10 |
| treatment vitamin | #10 |
| single loss | #10 |
| wells | #10 |
| thr incidence | #10 |
| aged antithrombin | #10 |
| thrombosis background | #10 |
| leg veins | #10 |
| schedule heparin | #10 |
| simplified geneva | #10 |
| retrospective study efficacy | #10 |
| gramnegative septicemia | #10 |
| embolism patients | #10 |
| year years | #10 |
| dvt lower extremity | #10 |
| patients venous thrombosis | #10 |
| crp test | #10 |
| vte efficacy | #10 |
| injection avidin | #10 |
| snp scores | #10 |
| inr cases | #10 |
| thrombophlebitis adult | #10 |
| protein dic | #10 |
| treatment aprotinin | #10 |
| 1215 patients | #10 |
| 598 patients | #10 |
| venous thromboembolic event | #10 |
| magellan trial | #10 |
| cvd fh patients | #10 |
| severity clinical | #10 |
| 100 years discontinuation | #10 |
| 4470 | #10 |
| normohomocysteinemic | #10 |
| cancer patients vte | #10 |
| vnv | #10 |
| treatment uedvt | #10 |
| fondaparinux risk | #10 |
| oral thrombin inhibitor | #10 |
| factor levels patients | #10 |
| bled scores | #10 |
| patients endotoxemia | #10 |
| cus diagnosis | #10 |
| asymptomatic pulmonary embolism | #10 |
| embolism clinical | #10 |
| cancer patients lmwh | #10 |
| inherited thrombophilic factors | #10 |
| nadroparine | #10 |
| incidence major bleeding | #10 |
| subcutaneous metaanalysis | #10 |
| deficiencies antithrombin | #10 |
| oral administration dabigatran | #10 |
| magellan study | #10 |
| rates recurrent vte | #10 |
| ageadjusted cutoff | #10 |
| ddimer concentration | #10 |
| extremity deep | #10 |
| major bleeding crnmb | #10 |
| animal heparin | #10 |
| fii mutation | #10 |
| heparin nomogram | #10 |
| rfviia blood loss | #10 |
| lmwh pregnancies | #11 |
| endotoxin assay | #11 |
| dvt | #11 |
| factor venous | #11 |
| hospital lmwh | #11 |
| pulmonary angiography venography | #11 |
| cancer patients dvt | #11 |
| d‐dimer levels | #11 |
| edoxaban | #11 |
| embolism recurrence | #11 |
| thromboembolism major | #11 |
| heparinoid org | #11 |
| 30 microg ethinylestradiol | #11 |
| screening cancer | #11 |
| gps training | #11 |
| lmwh pregnancy | #11 |
| air travel | #11 |
| weight humans | #11 |
| patients cancer vte | #11 |
| knee clinical trials | #11 |
| adult anticoagulants | #11 |
| incidence major | #11 |
| 750 μg | #11 |
| variation inr | #11 |
| 880 patients | #11 |
| ldfr | #11 |
| org 10172 | #11 |
| embolism prevalence | #11 |
| ufh studies | #11 |
| clinical pretest | #11 |
| pregnancyrelated complications | #11 |
| fondaparinux hemorrhage | #11 |
| vte vwf | #11 |
| previous venous | #11 |
| pyridines thiazoles | #11 |
| oral dabigatran | #11 |
| intensity anticoagulation | #11 |
| gentamicin treatment patients | #11 |
| combination dimer | #11 |
| recombinant human tnf | #11 |
| crnmb 95 | #11 |
| pcc dabigatran | #11 |
| levels prolactin | #11 |
| inhibitors hemorrhage | #11 |
| patients cvcs | #11 |
| carriers factor | #11 |
| mutations prevalence | #11 |
| dabigatran enoxaparin | #11 |
| haemophilia vwd | #11 |
| reference testing | #11 |
| sulfates dermatan | #11 |
| patients anticoagulant treatment | #11 |
| endotoxin pentoxifylline | #11 |
| patients probability | #11 |
| pulmonary embolism incidence | #11 |
| medical conferences | #11 |
| cancer patients evidence | #11 |
| proximal vein | #12 |
| anticoagulation unprovoked | #12 |
| livebirth rate | #12 |
| peghirudin | #12 |
| hemodynamically stable | #12 |
| thrombosis dvt | #12 |
| months primary | #12 |
| perelated | #12 |
| warfarin treated | #12 |
| vka noacs | #12 |
| risk venous | #12 |
| bnp cardiac troponin | #12 |
| proximal veins | #12 |
| warfarin therapy inr | #12 |
| hirulog1 | #12 |
| factor leiden prothrombin | #12 |
| deficient women | #12 |
| bayer schering pharma | #12 |
| ageadjusted ddimer | #12 |
| thrombin generation fibrinolysis | #12 |
| outpatient management patients | #12 |
| stopping anticoagulation | #12 |
| 72 children | #12 |
| dvt treatment | #12 |
| humanized arthroplasty | #12 |
| patients lmwhs | #12 |
| event recurrence | #12 |
| observation risk | #12 |
| pioped study | #12 |
| women factor | #12 |
| concomitant disorders | #12 |
| treatment crt | #12 |
| topic venous | #12 |
| prevention venous thrombosis | #12 |
| outcomes venous thromboembolism | #12 |
| patients incidental | #12 |
| 9295 | #12 |
| patients lupus anticoagulant | #12 |
| thrombophilic | #12 |
| anticoagulant factor | #12 |
| 9702 | #12 |
| fondaparinux unfractionated heparin | #12 |
| subsegmental pulmonary emboli | #12 |
| female heparin humans | #12 |
| control metaanalysis | #12 |
| venous thromboembolism incidence | #12 |
| noacs vka | #12 |
| nephro | #12 |
| recurrent vte anticoagulation | #12 |
| paulin | #12 |
| crd42013003526 | #12 |
| warfarin recurrent vte | #12 |
| recurrent vte | #12 |
| geneva score | #12 |
| vte recurrence risk | #12 |
| annual incidence vte | #12 |
| doseadjustment | #12 |
| safety efficiency | #12 |
| heparin low | #13 |
| factor viii apc | #13 |
| vte | #13 |
| patients thrombophilia | #13 |
| daily subcutaneous | #13 |
| groups inr | #13 |
| indication anticoagulation | #13 |
| arixtra | #13 |
| vte female humans | #13 |
| bayer healthcare | #13 |
| uedvt | #13 |
| spiral computed tomography | #13 |
| time prothrombin | #13 |
| 95 carriers | #13 |
| strain gauge plethysmography | #13 |
| superficial thrombophlebitis | #13 |
| randomized cross | #13 |
| ufh dalteparin | #13 |
| hematologic pregnancy trimester | #13 |
| inhibition tnf | #13 |
| thrombosis young | #13 |
| major hip | #13 |
| occult cancer | #13 |
| rivaroxaban thiophenes | #13 |
| clinical decision rules | #13 |
| 86 percent | #13 |
| patients anticoagulant | #13 |
| levels factor | #13 |
| antithrombin iii activity | #13 |
| dimer testing | #13 |
| conventional anticoagulants | #13 |
| inferiority efficacy | #13 |
| vte major | #13 |
| dabigatran vte | #13 |
| thrombosis acute | #13 |
| marder score | #13 |
| arterial thromboembolism ate | #13 |
| concomitant antiplatelet therapy | #13 |
| safety oral | #13 |
| deepvein thrombosis dvt | #13 |
| selective testing | #13 |
| pselectin patients | #13 |
| category studies | #13 |
| dimer threshold | #13 |
| treatment venous thromboembolism | #13 |
| plethysmograms | #13 |
| association venous thrombosis | #13 |
| prevention venous thromboembolism | #13 |
| dvt lower | #13 |
| continuous intravenous heparin | #13 |
| obesity haemophilia patients | #13 |
| dabigatran 220 | #13 |
| nct00986154 | #13 |
| plethysmography | #13 |
| factor leiden mutation | #13 |
| recombinant hirudin rhirudin | #13 |
| vte groups | #13 |
| bleeding events edoxaban | #13 |
| vte recurrence 95 | #13 |
| safety doacs | #13 |
| vte 64 | #13 |
| atiii deficiency | #14 |
| ultrasound strategies | #14 |
| 12 kg1 | #14 |
| placebo rfviia | #14 |
| costs dvt | #14 |
| experimental endotoxaemia | #14 |
| edoxaban warfarin | #14 |
| patients outpatients | #14 |
| obstetric complications women | #14 |
| awareness pad | #14 |
| treated lmwh | #14 |
| loss women | #14 |
| pregnancy venous | #14 |
| bolus intravenous injection | #14 |
| cadherins endothelium | #14 |
| aged anticoagulants | #14 |
| crnm | #14 |
| thrombophilia patients | #14 |
| recurrent venous | #14 |
| aspirin women | #14 |
| standard heparin | #14 |
| lmwh vka | #14 |
| patients acute vte | #14 |
| 17 placebo | #14 |
| acute deep | #14 |
| unprovoked vte vte | #14 |
| gastrointestinal bleeding patients | #14 |
| plasminogen apoa | #14 |
| effects hyperthyroidism | #14 |
| safety edoxaban | #14 |
| female fibrin | #14 |
| conventionaltherapy | #14 |
| thrombosis | #14 |
| patients vka therapy | #14 |
| patients dvt | #14 |
| thromboembolism age | #14 |
| fvl carriers | #14 |
| factor viii levels | #14 |
| recurrent venous thromboembolism | #14 |
| low molecular | #14 |
| edoxaban oral factor | #14 |
| riete score | #14 |
| aged plethysmography | #14 |
| anticoagulant rivaroxaban | #14 |
| vte statin | #14 |
| limited screening | #14 |
| doseranging study | #14 |
| incidence severe pph | #14 |
| dvt lower extremities | #14 |
| vte months | #14 |
| cancer patients anticoagulation | #14 |
| treatment duration patients | #14 |
| symptomatic pulmonary | #14 |
| higher ddimer levels | #14 |
| revised geneva | #14 |
| subcutaneous regimen | #15 |
| arg562 | #15 |
| thrombinography | #15 |
| hyperthyroidism atrial fibrillation | #15 |
| thyroid hormone excess | #15 |
| recombinant factor viia | #15 |
| edoxaban treatment | #15 |
| inr range | #15 |
| factor leiden | #15 |
| activation contact | #15 |
| lmwh ufh | #15 |
| subcutaneous enoxaparin | #15 |
| cteph incidence | #15 |
| prior venous thromboembolism | #15 |
| thrombosis diagnosis | #15 |
| established vte | #15 |
| control subjects prevalence | #15 |
| antagonist vka | #15 |
| oral direct factor | #15 |
| vitaminkantagonists | #15 |
| symptomatic events | #15 |
| generation oral | #15 |
| 500 pg | #15 |
| thrombus growth | #15 |
| inr patient | #15 |
| abdominal pelvic | #15 |
| clinically relevant endpoints | #15 |
| doacs aspirin | #15 |
| probability assessment | #15 |
| diagnosis venous | #15 |
| coc vte | #15 |
| anticoagulants patients | #15 |
| coagulation | #15 |
| patients vitamin antagonists | #15 |
| fondaparinux efficacy | #15 |
| experimental thrombosis | #15 |
| pregnancy outcome pregnancy | #15 |
| khorana score | #15 |
| cardiovascular diseases thrombosis | #15 |
| prophylaxis venous thromboembolism | #15 |
| lomoparan | #15 |
| primary safety outcome | #15 |
| arg506 | #15 |
| treatment 12 months | #15 |
| patients ctpa | #15 |
| enoxaparin vte | #15 |
| studies pulmonary | #15 |
| thrombosis haemostasis | #16 |
| patients acenocoumarol | #16 |
| bleeding aged | #16 |
| test clinical | #16 |
| deep venous thrombosis | #16 |
| thrombosis association | #16 |
| women unexplained | #16 |
| subsequent pregnancy loss | #16 |
| venous thrombosis warfarin | #16 |
| avws patients | #16 |
| thrombosis adult | #16 |
| warfarin acenocoumarol | #16 |
| combination clinical | #16 |
| impaired fibrinolysis | #16 |
| major bleeding anticoagulation | #16 |
| arterial vascular events | #16 |
| occult cancer detection | #16 |
| recurrent symptomatic | #16 |
| factors major | #16 |
| major bleeding events | #16 |
| risk clinically | #16 |
| ddimer levels patients | #16 |
| thromboembolism time | #16 |
| abdomino | #16 |
| analysis rivaroxaban | #16 |
| cancer cancer patients | #16 |
| cancer screening patients | #16 |
| 6 months placebo | #16 |
| thrombosis low | #16 |
| 100 95 | #16 |
| vterelated death | #16 |
| vte khorana score | #16 |
| viia activity | #16 |
| dvt lmwh | #16 |
| factor inhibitor | #16 |
| netilmicin gentamicin | #16 |
| positivity threshold | #16 |
| postthrombotic syndrome children | #16 |
| female humans vte | #17 |
| patients impedance | #17 |
| endotoxemia bacteremia | #17 |
| vkorc1 gene | #17 |
| ctscans | #17 |
| thrombosis clinical | #17 |
| factor monoclonal | #17 |
| recurrent vte events | #17 |
| rivaroxaban oral factor | #17 |
| lower specificity | #17 |
| fibrinolysis treatment | #17 |
| fragment f1 | #17 |
| hematoma heparin | #17 |
| management crt | #17 |
| 12 months patients | #17 |
| permanent patients | #17 |
| diagnosis svt | #17 |
| anticoagulants drug | #17 |
| factors venous | #17 |
| lmwhs patients | #17 |
| excessive blood loss | #17 |
| prohemostatic | #17 |
| topic hemorrhage humans | #17 |
| women mutation | #17 |
| gentamicin netilmicin | #17 |
| 2688 | #17 |
| dvt prevention | #17 |
| anticoagulant therapy patients | #17 |
| thromboembolism patients | #17 |
| 516 patients | #17 |
| anticoagulants clinical | #17 |
| dimer assay | #17 |
| patients overt hypothyroidism | #17 |
| pharmo record linkage | #17 |
| mutation women | #17 |
| scan classification | #17 |
| compared enoxaparin | #17 |
| vte edoxaban | #17 |
| incidence pts | #17 |
| prothrombin g20210a | #18 |
| venous thromboembolism rivaroxaban | #18 |
| hivinfected patients cart | #18 |
| weight adjusted | #18 |
| simplired | #18 |
| apc thrombin generation | #18 |
| proximal vein thrombosis | #18 |
| poc test | #18 |
| lmwh doacs | #18 |
| outcome events | #18 |
| edoxaban vte | #18 |
| thrombosis pulmonary | #18 |
| relevant nonmajor | #18 |
| flight hours | #18 |
| warfarin hazard | #18 |
| 023 | #18 |
| treatment vkas | #18 |
| thrombosis total | #18 |
| vka edoxaban | #18 |
| cancer vte | #18 |
| antithrombotic treatment patients | #18 |
| intravenous heparin therapy | #18 |
| commercial airline pilots | #18 |
| sanofi aventis | #18 |
| vka vte | #18 |
| diagnostic strategy | #18 |
| patients strategy | #18 |
| stable anticoagulation | #18 |
| aptt heparin | #18 |
| combined form | #18 |
| thromboembolism venous | #18 |
| annual incidence | #18 |
| women pregnancy loss | #18 |
| 4 clinical | #18 |
| favor lmwh | #18 |
| ddimer tests | #19 |
| vwf vte | #19 |
| 56 95 | #19 |
| doubleblinding | #19 |
| patients major bleeding | #19 |
| vitamin antagonist | #19 |
| lmwh patients | #19 |
| retropubic prostatectomy | #19 |
| recurrent venous thrombosis | #19 |
| fondaparinux enoxaparin | #19 |
| coagulation studies | #19 |
| oral dabigatran enoxaparin | #19 |
| patients prevalence | #19 |
| increased fibrinolytic activity | #19 |
| active search | #19 |
| thromboembolism administration | #19 |
| local angiogenesis | #19 |
| venous thromboembolism relatives | #19 |
| versions version | #19 |
| endogenous fibrinolysis | #19 |
| acute recurrent | #19 |
| increased risk relatives | #19 |
| ipdma | #19 |
| edoxaban dose | #19 |
| antibodynegative | #19 |
| adjusted dose | #19 |
| patients sspe | #19 |
| treatment heparin | #19 |
| systemic activation coagulation | #19 |
| symptomatic dvt | #19 |
| fibrinolytic response | #19 |
| low platelets | #19 |
| subcutaneous dalteparin | #19 |
| ufh lmwh | #19 |
| studies factor | #19 |
| 35 women | #19 |
| extended oral | #19 |
| patients derivation | #19 |
| objective testing | #19 |
| dvt rivaroxaban | #19 |
| prognostic echocardiography | #19 |
| abnormal ultrasound | #19 |
| recurrence vte | #19 |
| venography sensitivity | #19 |
| patients elevated biomarkers | #19 |
| blindly | #20 |
| incidences death | #20 |
| abi risk factors | #20 |
| ctnt bnp | #20 |
| calf veins | #20 |
| proteins thrombin | #20 |
| abi measurement | #20 |
| intravenous injections | #20 |
| subsegmental | #20 |
| diagnostic workup patients | #20 |
| shr 95 | #20 |
| thrombosis ultrasonography | #20 |
| standardtherapy hazard ratio | #20 |
| symptomatic venous thrombosis | #20 |
| statin vte | #20 |
| recurrence bleeding | #20 |
| anticoagulation clinic | #20 |
| excluded patients | #20 |
| risk thrombophilia | #20 |
| established atherosclerosis | #20 |
| single criterion | #20 |
| compared ufh | #20 |
| guidance ssc | #20 |
| cancer severity | #20 |
| dabigatran 150 | #20 |
| antagonists vkas | #20 |
| pregnancyrelated vte | #20 |
| nadroparin | #20 |
| antitpo | #20 |
| prothrombin mutation | #20 |
| carriers prothrombin | #20 |
| warfarin edoxaban | #20 |
| versions questionnaire | #20 |
| synthetic cross | #20 |
| patients ddimer testing | #20 |
| thrombophilia vte | #20 |
| control situation | #20 |
| distance treatment | #20 |
| therapy rivaroxaban | #20 |
| impedance plethysmography ipg | #20 |
| residual venous | #20 |
| treatment vte | #20 |
| new agent | #20 |
| malignancy time | #20 |
| life venous thrombosis | #20 |
| absolute risk | #20 |
| injections subcutaneous | #20 |
| portola | #20 |
| discriminatory performance | #21 |
| fibrinolysis inflammation | #21 |
| concomitant anti | #21 |
| treatment acenocoumarol | #21 |
| occult malignancy | #21 |
| vte patients | #21 |
| venogram | #21 |
| doacs lmwhs | #21 |
| hemostatic abnormalities | #21 |
| ddimer concentrations | #21 |
| thromb | #21 |
| thrombosis anticoagulants | #21 |
| distance quality | #21 |
| internists cardiologists | #21 |
| deep venous | #21 |
| major bleeding patients | #21 |
| patients 3 months | #21 |
| outcome incidence | #21 |
| current standard treatment | #21 |
| d‐dimer | #21 |
| disease ischemic | #21 |
| carriers noncarriers | #21 |
| prothrombin 20210 | #21 |
| risk cohort study | #21 |
| treatment apixaban | #21 |
| hemodynamically stable patients | #21 |
| vascular endotoxins | #22 |
| bleeding treatment | #22 |
| cttr | #22 |
| patients recurrent symptoms | #22 |
| recurrent thromboembolism | #22 |
| thrombophilia screening | #22 |
| venous thromboembolic | #22 |
| patients severe hf | #22 |
| anticoagulants heparin | #22 |
| patients immobilization | #22 |
| riskbenefit ratio | #22 |
| dichotomously | #22 |
| dose subcutaneous | #22 |
| dimer age | #22 |
| cmax ctrough | #22 |
| safety treatment | #22 |
| patientyears | #22 |
| anticoagulants humans | #22 |
| public awareness | #22 |
| alternative anticoagulation | #22 |
| hormonal cross | #22 |
| treatment dvt | #22 |
| time inr | #22 |
| lpa plasminogen | #22 |
| host defense response | #22 |
| acute vte | #22 |
| ttr inr | #22 |
| doppler venous thrombosis | #22 |
| daily enoxaparin | #22 |
| bidirectional relation | #23 |
| elevated ctni | #23 |
| hasbled score | #23 |
| standardduration | #23 |
| kakkar | #23 |
| thromboembolism anticoagulants | #23 |
| venous arterial thrombosis | #23 |
| lower extremity amputation | #23 |
| odis | #23 |
| cancer patients risk | #23 |
| gentamicin patients | #23 |
| patients coagulation disorders | #23 |
| 011 | #23 |
| direct factor inhibitors | #23 |
| 2 investigators | #23 |
| rivaroxaban dosing | #23 |
| vte studies | #23 |
| prevalence venous thromboembolism | #23 |
| fondaparinux | #23 |
| percentage increase | #23 |
| development dic | #23 |
| time platelet | #23 |
| clotbound thrombin | #23 |
| normal angiogram | #23 |
| recurrence venous | #23 |
| life pulmonary embolism | #23 |
| ambulatory cancer patients | #23 |
| n1157 | #23 |
| enoxaparin 40 | #23 |
| 5392 | #23 |
| desogestrel levonorgestrel | #24 |
| recurrent thromboembolism patients | #24 |
| rates venous thromboembolism | #24 |
| patients acute treatment | #24 |
| therapy heparin | #24 |
| viiic | #24 |
| food drugs | #24 |
| parameters fibrinolysis | #24 |
| followup incidence | #24 |
| years episode | #24 |
| fondaparinux placebo | #24 |
| ddimer testing | #24 |
| subtherapeutic | #24 |
| levels fviii | #24 |
| lowmolecularweight humans | #24 |
| bleeding complication | #24 |
| ufh patients | #24 |
| month incidence | #24 |
| patients severe bleeding | #24 |
| thrombosis carriers | #24 |
| prevalence deficiencies | #24 |
| specific antidote | #24 |
| safety fondaparinux | #24 |
| patients abnormal perfusion | #24 |
| 049 | #24 |
| independent external validation | #24 |
| a21gly | #24 |
| recurrent pulmonary embolism | #24 |
| overt hyperthyroidism | #24 |
| presence dvt | #24 |
| predefined criteria | #24 |
| f1 2 levels | #25 |
| thromboembolism acute | #25 |
| cha2ds2vasc chads2 | #25 |
| influence smoking | #25 |
| treatment symptomatic | #25 |
| expert radiologists | #25 |
| specificity efficiency | #25 |
| willebrand factor adamts13 | #25 |
| lmwh treatment | #25 |
| suggestions improvement | #25 |
| factors anticoagulants | #25 |
| studies lmwh | #25 |
| middeldorp | #25 |
| vte clinical | #25 |
| anatomical extent | #25 |
| fatima | #25 |
| patients gastrointestinal bleeding | #25 |
| xii activity | #25 |
| perfusion lung scan | #25 |
| fibrinogen degradation | #25 |
| amadeus | #25 |
| sepsis intravascular coagulation | #25 |
| rethoracotomy | #26 |
| specificity negative predictive | #26 |
| ecq | #26 |
| viia complex | #26 |
| failure rate | #26 |
| patients essential thrombocythaemia | #26 |
| patients symptomatic dvt | #26 |
| rate recurrent vte | #26 |
| dalteparin ufh | #26 |
| venous thromboemboli | #26 |
| events year | #26 |
| parameters risk | #26 |
| thromboprophylaxis hospitalized patients | #26 |
| patients cdr | #26 |
| edoxaban vka | #26 |
| doacs vitamin antagonists | #26 |
| asymptomatic carriers | #26 |
| hormonal manipulation | #26 |
| unprovoked vte | #26 |
| edoxaban versus | #26 |
| miscarriage stillbirth | #26 |
| treatment lmwh | #26 |
| homozygous carriers | #26 |
| 9715 | #26 |
| major bleeding bleeding | #26 |
| extremity venous | #27 |
| cancer spread | #27 |
| lmwh prophylaxis | #27 |
| current guidance | #27 |
| female heterozygote | #27 |
| treating physician | #27 |
| noncarriers 95 | #27 |
| patients 50 | #27 |
| airline pilots | #27 |
| thrombocytopenia antibodies | #27 |
| vte thr | #27 |
| 0·63 | #27 |
| nonmajor | #27 |
| anticoagulants factor | #27 |
| enoxaparin female | #27 |
| thrombosis venous | #27 |
| thrombophlebitis | #27 |
| vte doacs | #27 |
| combined training | #27 |
| patients elevated levels | #27 |
| low molecularweight heparin | #27 |
| training gps | #27 |
| perfusion lung | #27 |
| patients major hemorrhage | #27 |
| npv patients | #27 |
| day 35 | #27 |
| unprovoked venous | #27 |
| anticoagulants blood | #27 |
| lowmolecularweight heparin patients | #27 |
| venous thromboembolism carriers | #27 |
| months studies | #27 |
| specific reversal agent | #28 |
| vte 6 months | #28 |
| 4650 | #28 |
| rfviia placebo | #28 |
| factors recurrent | #28 |
| presentation followup | #28 |
| apc plasma | #28 |
| pph severe pph | #28 |
| tests diagnostic | #28 |
| objective tests | #28 |
| monitoring therapy | #28 |
| cancer venous thromboembolism | #28 |
| hirudin therapy | #28 |
| anticoagulation women | #28 |
| vitamin aged | #28 |
| anticoagulants compared | #28 |
| pembqol | #28 |
| patients unprovoked | #28 |
| 2½ | #28 |
| embolism retrospective | #28 |
| therapeutic doses | #28 |
| receiving rivaroxaban | #28 |
| unexplained | #28 |
| acutely medical patients | #28 |
| coagulation tissue factor | #28 |
| 1000 individuals | #29 |
| g20210a mutation | #29 |
| bleeding increased | #29 |
| prediction scores | #29 |
| 8240 | #29 |
| patients standard therapy | #29 |
| aminoglycoside therapy | #29 |
| thrombosis treatment | #29 |
| pulmonary embolism death | #29 |
| plateletactivating antibodies | #29 |
| heparin versus | #29 |
| aspirin placebo | #29 |
| recurrence svt | #29 |
| patients avws | #29 |
| pbac score | #29 |
| blind trials | #29 |
| years year | #29 |
| pulmonary embolism recurrence | #29 |
| dutch famine | #29 |
| current management strategies | #29 |
| direct oral anticoagulants | #29 |
| dabigatran pcc | #29 |
| pulmonary angiography | #29 |
| aged morpholines | #29 |
| authors incidence | #29 |
| resistance activated protein | #29 |
| oral glucocorticoids | #29 |
| sex‐specific differences | #29 |
| thrombo | #29 |
| spread cancer | #29 |
| acenocoumarol patients | #29 |
| septicemia | #29 |
| diagnosis dvt | #29 |
| cindexes | #29 |
| major bleeding rivaroxaban | #29 |
| dvt pulmonary embolism | #29 |
| thrombosis 95 | #29 |
| residual thrombosis | #30 |
| cancer venous | #30 |
| 1000 personyears incidence | #30 |
| markers coagulation activation | #30 |
| doac vka | #30 |
| 95 risk | #30 |
| subcutaneous heparin | #30 |
| support techniques | #30 |
| rule patients | #30 |
| direct oral factor | #30 |
| patients vte | #30 |
| costs diagnosis | #30 |
| f1 2 | #30 |
| administration pentoxifylline | #30 |
| ufh vte | #30 |
| thromboembolism warfarin | #30 |
| vte coc | #30 |
| prevention venous | #30 |
| xii factor | #30 |
| new anticoagulants | #30 |
| embolism risk | #30 |
| ufh fondaparinux | #31 |
| recurrent vte patients | #31 |
| incidence cteph | #31 |
| vte ufh | #31 |
| experimental endotoxemia | #31 |
| patients deepvein thrombosis | #31 |
| term risk | #31 |
| events 95 | #31 |
| recurrent episode | #31 |
| women recurrent miscarriage | #31 |
| bled | #31 |
| iii activity | #31 |
| prevalence probability | #31 |
| rfviia novoseven | #31 |
| thromboprophylaxis risk | #31 |
| activation blood coagulation | #31 |
| incidence pph | #31 |
| recurrent patients | #31 |
| inhibitor edoxaban | #31 |
| 2 antiplasmin | #31 |
| extended prophylaxis | #31 |
| apixaban placebo | #31 |
| thromboembolism adolescent | #31 |
| imaging sensitivity specificity | #31 |
| pharmacological prophylaxis | #31 |
| placebo observation | #31 |
| analysis reviewers | #31 |
| rhir | #31 |
| standardtherapy | #31 |
| antithrombotic therapies | #31 |
| ventilation scintigraphy | #31 |
| dimer cutoff | #31 |
| 0206 | #31 |
| dvt pulmonary | #31 |
| 8755 | #31 |
| low clinical | #32 |
| parenteral anticoagulation | #32 |
| factor female | #32 |
| varicosis | #32 |
| resistance activated | #32 |
| leiden mutation | #32 |
| netherlands predictive | #32 |
| negative septicemia | #32 |
| ufh | #32 |
| generation patients | #32 |
| parenteral anticoagulants | #32 |
| suspected patients | #32 |
| normal genotype | #32 |
| age adjusted | #32 |
| treatment anticoagulants | #32 |
| year 95 | #32 |
| negative dimer | #32 |
| warfarin vte | #32 |
| khorana score patients | #32 |
| international society thrombosis | #32 |
| factors thrombolytic | #32 |
| low probability | #33 |
| rhirudin | #33 |
| active implementation | #33 |
| pulmonary angiogram | #33 |
| activation factors | #33 |
| apixaban treatment | #33 |
| factor viii patients | #33 |
| cancer patients diagnosis | #33 |
| thromboembolism young | #33 |
| data meta | #33 |
| subcutaneous male | #33 |
| unitage | #33 |
| heparin lmwh | #33 |
| nephrotoxicity gentamicin | #33 |
| chapter patients | #33 |
| mega study | #33 |
| warfarin risks | #33 |
| additional tests | #33 |
| anticoagulant protein | #33 |
| prophylaxis vte | #33 |
| lmwh unfractionated heparin | #34 |
| subsegmental pulmonary embolism | #34 |
| plasmin alpha | #34 |
| anticoagulant | #34 |
| 9241 | #34 |
| reocclusion patients | #34 |
| hemorrhage heparin humans | #34 |
| compare efficacy | #34 |
| phytonadione | #34 |
| apcsr | #34 |
| vte thrombophilia | #34 |
| deficiency protein | #34 |
| thrombosis lower | #34 |
| vte compared | #34 |
| bilateral venography | #34 |
| control trials | #34 |
| grade 1a | #34 |
| 10 95 | #34 |
| 590 | #34 |
| pregnancy loss women | #34 |
| 3 months treatment | #34 |
| warfarin adult | #34 |
| pph blood loss | #35 |
| risk members | #35 |
| anticoagulants benzimidazoles | #35 |
| activation coagulation | #35 |
| weekly subcutaneous | #35 |
| patients efficiency | #35 |
| neoplasms venous | #35 |
| statin association | #35 |
| enoxaparin prevention | #35 |
| prevention model | #35 |
| radiologists diagnosis | #35 |
| rviia | #35 |
| embolism | #35 |
| lung scanning | #35 |
| surgery hip | #35 |
| 36 95 | #35 |
| venous thromboembolism dabigatran | #36 |
| thrombophilia venous | #36 |
| inherited risk factors | #36 |
| novoseven | #36 |
| fibrinolytic activation | #36 |
| peripheral endovascular | #36 |
| riskbenefit | #36 |
| acute symptomatic | #36 |
| viii levels | #36 |
| treatment acute vte | #36 |
| 4139 | #36 |
| dose reduction patients | #36 |
| 287 patients | #36 |
| iii antithrombin | #36 |
| levels coagulation | #36 |
| factors travel | #36 |
| regular monitoring | #36 |
| catheterrelated infection | #36 |
| studies echocardiography | #36 |
| 1698 | #36 |
| hellp patients | #36 |
| fibrinogen depletion | #36 |
| venous thromboembolic disease | #36 |
| venography | #37 |
| prophylactic heparin | #37 |
| warfarin 95 | #37 |
| rivaroxaban thromboprophylaxis | #37 |
| magellan | #37 |
| vte increased | #37 |
| perelated mortality | #37 |
| tat complexes | #37 |
| risk venous thrombosis | #37 |
| ctpa patients | #37 |
| suspected venous | #37 |
| factors thrombophilia | #37 |
| screening occult | #37 |
| risk factors pts | #37 |
| anticoagulants prevention | #37 |
| genotype 95 | #37 |
| thrombosis humans | #37 |
| outcome composite | #37 |
| excluding | #37 |
| pad studies | #37 |
| anticoagulant action | #37 |
| ototoxicity nephrotoxicity | #37 |
| bagsvaerd | #37 |
| recombinant hirudin | #37 |
| cumulative incidence vte | #37 |
| lwmh | #37 |
| vte cancer patients | #38 |
| 3306 | #38 |
| anticoagulants female humans | #38 |
| patients ddimer levels | #38 |
| age recurrence | #38 |
| 10 total | #38 |
| sensitivity biomarkers | #38 |
| 2835 | #38 |
| recurrence day | #38 |
| rivaroxaban placebo | #38 |
| doac lmwh | #38 |
| restenosis reocclusion | #38 |
| nonmajor bleeding | #38 |
| vte bleeding | #38 |
| congenital deficiencies | #38 |
| fetal loss women | #38 |
| coagulation protein | #38 |
| catheterrelated thrombosis | #38 |
| submassive pulmonary | #38 |
| heparins lmwhs | #39 |
| specificity patients | #39 |
| continued treatment | #39 |
| 277 patients | #39 |
| subcutaneous intention | #39 |
| enoxaparin placebo | #39 |
| children familial hypercholesterolemia | #39 |
| low molecular weight | #39 |
| septic syndrome | #39 |
| submassive | #39 |
| compression stocking | #39 |
| incidence patients | #39 |
| diagnostic prediction | #39 |
| time compression | #39 |
| doacs | #39 |
| fibrin fibrinogen | #39 |
| incidence cancer | #39 |
| embolus | #39 |
| systemic inflammatory responses | #39 |
| superficial vein thrombosis | #39 |
| anticoagulation therapy patients | #40 |
| ambulatory cancer | #40 |
| patients normal | #40 |
| anticoagulant therapy | #40 |
| fviiic | #40 |
| clotting activation | #40 |
| day 6 months | #40 |
| standardized definition | #40 |
| tfmp | #40 |
| dalteparin treatment | #40 |
| activatable fibrinolysis | #40 |
| bleeding | #40 |
| common femoral vein | #40 |
| arterial vascular | #40 |
| therapeutic dosages | #40 |
| international clinical | #40 |
| endotoxininduced | #40 |
| episode venous thromboembolism | #40 |
| thrombinantithrombin complexes | #40 |
| pemb | #40 |
| grade 1a patients | #40 |
| calf vein thrombosis | #41 |
| lowmolecularweight heparins | #41 |
| submassive pulmonary embolism | #41 |
| pentasaccharides | #41 |
| 95 genotype | #41 |
| endotoxin induced | #41 |
| 7268 | #41 |
| cancer lmwh | #41 |
| anticoagulated patients | #41 |
| triage tests | #41 |
| risk recurrent vte | #41 |
| dabigatran etexilate | #41 |
| placebo 6 months | #41 |
| lung scintigraphy | #41 |
| heparin therapy | #41 |
| 8101 | #42 |
| major contributor | #42 |
| anticoagulation risk | #42 |
| netilmicin | #42 |
| stroke thrombosis | #42 |
| neoplasms thrombosis | #42 |
| patients prospective | #42 |
| cell extravasation | #42 |
| thrombosis administration | #42 |
| patients vasopressors | #42 |
| standardization committee | #42 |
| prophylaxis venous | #42 |
| type graft | #42 |
| patients silent | #42 |
| 543 patients | #43 |
| patients vte risk | #43 |
| monthly incidence | #43 |
| fetal loss | #43 |
| post‐thrombotic syndrome | #43 |
| warfarin anticoagulants | #43 |
| cancer adjusted | #43 |
| initial treatment | #43 |
| draft document | #43 |
| heparin risk | #43 |
| venous thromboembolism vte | #43 |
| vkas patients | #43 |
| probability patients | #43 |
| venous thrombosis thrombophilia | #43 |
| ischemic events | #43 |
| rtap | #43 |
| efficiency models | #44 |
| 10–14 | #44 |
| experimental venous thrombosis | #44 |
| factors thromboembolism | #44 |
| nonvka oral anticoagulants | #44 |
| expert physicians | #44 |
| edoxaban therapy | #44 |
| patients tinzaparin | #44 |
| uedvt patients | #44 |
| 20 30 | #44 |
| indications patients | #44 |
| protein sepsis | #44 |
| recurrent vte 95 | #44 |
| enoxaparin risk | #44 |
| rate venous | #44 |
| 95 pulmonary embolism | #44 |
| role coagulation | #44 |
| restoration euthyroidism | #44 |
| mild hyperhomocysteinaemia | #44 |
| years algorithm | #45 |
| revascularisation procedures | #45 |
| patients bnp | #45 |
| dose adjusted | #45 |
| 95 warfarin | #45 |
| venous thrombotic | #45 |
| oral direct | #45 |
| coumarin therapy | #45 |
| fondaparinux patients | #45 |
| dose lmwh | #45 |
| treated warfarin | #45 |
| coagulation activation | #45 |
| wells score | #45 |
| dvt patients | #45 |
| prothrombin fragment f1 | #46 |
| daily rivaroxaban | #46 |
| ruling | #46 |
| extended duration | #46 |
| stroke risk assessment | #46 |
| percent confidence | #46 |
| standard therapy | #46 |
| day levels | #46 |
| abtpo | #46 |
| healthcare settings | #46 |
| patients unprovoked vte | #46 |
| ssc isth | #46 |
| major bleeding placebo | #46 |
| treatment model | #46 |
| hospital outpatients | #46 |
| management venous | #46 |
| bleeding rivaroxaban | #46 |
| pioped | #46 |
| ambulatory anticoagulants | #47 |
| mutation pregnancy | #47 |
| male methimazole | #47 |
| iiia receptors | #47 |
| plasma ddimer levels | #47 |
| roccurve | #47 |
| mechanical prophylaxis | #47 |
| central venous lines | #47 |
| bristol myers squibb | #47 |
| boehringer ingelheim | #47 |
| outcome vitamin | #47 |
| episode vte | #47 |
| new oral anticoagulant | #47 |
| patients pulmonary | #48 |
| elevated plasma levels | #48 |
| subcommittee | #48 |
| small studies | #48 |
| travel risk | #48 |
| diagnosis physicians | #48 |
| rivaroxaban compared | #48 |
| thrombotic burden | #48 |
| intermediate risk risk | #48 |
| risk recurrent | #48 |
| daiichi | #48 |
| thromboprophylactic | #48 |
| factors rivaroxaban | #48 |
| recurrence venous thromboembolism | #48 |
| fondaparinux heparin | #48 |
| patients acute dvt | #48 |
| factor viii deficiency | #49 |
| women aspirin | #49 |
| vte diagnosis | #49 |
| calf vein | #49 |
| lowmolecularweight heparin lmwh | #49 |
| rivaroxaban prevention | #49 |
| enoxaparin | #49 |
| levels protein | #49 |
| incidence venous thromboembolism | #50 |
| nonselective betablockers | #50 |
| transient risk factor | #50 |
| etexilate | #50 |
| thromboembolism aged | #50 |
| cardiac surgery mortality | #50 |
| intensity treatment | #50 |
| acute respiratory insufficiency | #50 |
| vitamink antagonists | #50 |
| dvt diagnosis | #50 |
| atria patients | #50 |
| outpatient therapy | #50 |
| treatment threshold | #50 |
| buller | #50 |
| prospective diagnostic | #50 |
| protein deficiencies | #51 |
| patients 11 | #51 |
| acenocoumarol | #51 |
| tomography pulmonary | #51 |
| 95 apixaban | #51 |
| discrimination model | #51 |
| global disease | #51 |
| normal perfusion | #51 |
| effects coagulation | #51 |
| strategies treatment | #51 |
| previous survey | #51 |
| factor vte | #51 |
| lung scans | #52 |
| hematologic malignancies patients | #52 |
| svt patients | #52 |
| free thyroxine ft4 | #52 |
| patients comorbid conditions | #52 |
| 3 month | #52 |
| vte major bleeding | #52 |
| 1·12 | #52 |
| apixaban vte | #52 |
| unnecessarily | #52 |
| risk venous thromboembolism | #52 |
| inhibitors heparin | #52 |
| pdvt | #52 |
| doacs vka | #52 |
| lmwh fondaparinux | #52 |
| absolute risks | #53 |
| patients initially | #53 |
| cross study | #53 |
| suspected venous thromboembolism | #53 |
| 1522 | #53 |
| 479 patients | #53 |
| 40 daily | #53 |
| warfarintreated patients | #53 |
| versus enoxaparin | #53 |
| preference patients | #53 |
| thromboembolism prevention | #53 |
| thrombophilic factors | #53 |
| hemostatic balance | #53 |
| reported incidence | #53 |
| postthrombotic syndrome | #53 |
| antithrombotic drug | #54 |
| 034 | #54 |
| major bleeds | #54 |
| vte mortality | #54 |
| thromboembolism death | #54 |
| male pulmonary embolism | #54 |
| 378 patients | #54 |
| chads2 cha2ds2vasc | #54 |
| familial thrombophilia | #54 |
| prethrombotic | #54 |
| endocrine disorders | #54 |
| pai1 levels patients | #54 |
| patients incidence | #54 |
| acquired risk factors | #54 |
| bled score | #54 |
| patients obese | #54 |
| 2537 | #54 |
| unfractionated heparin | #55 |
| methods randomized | #55 |
| anticoagulants arthroplasty replacement | #55 |
| insurances | #55 |
| compared lmwh | #55 |
| proximal extent | #55 |
| long term risk | #55 |
| unfractionated heparin ufh | #55 |
| biological pan | #55 |
| legs patients | #55 |
| treatment thresholds | #55 |
| nondeficient | #55 |
| rivaroxaban | #55 |
| dosereduction | #55 |
| tromboembólica | #56 |
| venous outflow obstruction | #56 |
| weight heparins | #56 |
| reduced capacity | #56 |
| risk major bleeding | #56 |
| 20210a | #56 |
| enoxaparin patients | #56 |
| vasopressors | #56 |
| vitamin warfarin | #56 |
| deficiency prevalence | #56 |
| inr values | #56 |
| seventh accp conference | #56 |
| enoxaparin rivaroxaban | #56 |
| physicians guidelines | #56 |
| level mortality | #56 |
| major bleeding apixaban | #56 |
| preeclampsia hellp syndrome | #56 |
| time event | #56 |
| vte death | #56 |
| calf dvt | #57 |
| inhibitors female humans | #57 |
| risk factors vte | #57 |
| ctscan | #57 |
| clinical models | #57 |
| subsegmental pulmonary | #57 |
| levels survival | #57 |
| antithrombin iii heparin | #57 |
| unfractionated heparin patients | #58 |
| spiral computed | #58 |
| fibrinolysis humans | #58 |
| thrombin activatable | #58 |
| ruled | #58 |
| pharmo | #58 |
| doacs patients | #58 |
| lowmolecular weight heparin | #58 |
| inhibitors female | #58 |
| malignancy mortality | #58 |
| safety warfarin | #59 |
| risk vte | #59 |
| mutation prothrombin | #59 |
| thrombosis aged | #59 |
| factor generation | #59 |
| direct oral | #59 |
| acute venous thromboembolism | #59 |
| warfarin treatment | #59 |
| clot lysis time | #59 |
| heterozygous factor | #59 |
| risk periods | #59 |
| risk factors sensitivity | #59 |
| incidence symptomatic | #59 |
| bias trial | #59 |
| aventis | #59 |
| hemorrhage humans | #60 |
| anticoagulants treatment | #60 |
| target inr | #60 |
| women difference | #60 |
| prevalence pulmonary | #60 |
| constans | #60 |
| atrial fibrillation metaanalysis | #60 |
| fixeddose | #60 |
| pulmonary embolism 95 | #60 |
| pediatric venous thromboembolism | #60 |
| acute pulmonary embolism | #60 |
| awareness risk factors | #60 |
| 079 95 | #60 |
| perfusion ventilation | #61 |
| tests prevalence | #61 |
| amuse | #61 |
| long‐term treatment | #61 |
| benzimidazoles dabigatran | #61 |
| hypocoagulable | #61 |
| 3633 | #61 |
| association protein | #61 |
| cdr score | #61 |
| dvt 95 | #61 |
| rosendaal | #61 |
| month surgery | #61 |
| free thyroxine | #61 |
| ttr patients | #62 |
| general practitioners patients | #62 |
| 250 patients | #62 |
| protein fibrinogen | #62 |
| informatizado | #62 |
| 273 patients | #62 |
| procoagulant state | #62 |
| activated partial | #62 |
| patients administration | #62 |
| combined contraceptives oral | #62 |
| post thrombotic | #62 |
| human endotoxemia | #62 |
| factor leiden risk | #63 |
| treatment network | #63 |
| smoking smoking cessation | #63 |
| management anticoagulation | #63 |
| vte thromboprophylaxis | #63 |
| revised geneva score | #63 |
| physicians predictive | #63 |
| women mutations | #63 |
| venous thromboembolisms | #63 |
| cvrs | #63 |
| quantitative test | #63 |
| 33 women | #63 |
| common odds ratio | #63 |
| rivaroxaban lmwh | #63 |
| symptoms dvt | #63 |
| injection endotoxin | #63 |
| selfadjustment | #64 |
| cancer noncancer patients | #64 |
| thrombophilic risk | #64 |
| patients aortic valve | #64 |
| superficial vein | #64 |
| blinded trial | #64 |
| decision rules | #64 |
| acute pulmonary | #64 |
| heparin fondaparinux | #64 |
| postthrombotic | #64 |
| factor inhibitors | #64 |
| vkas treatment | #64 |
| bleeding events patients | #64 |
| dvts | #64 |
| prior vte | #64 |
| oral thrombin | #64 |
| prevalence abnormalities | #65 |
| fvl vte | #65 |
| treatment pad | #65 |
| prothrombin g20210a mutation | #65 |
| ultrasonograms | #65 |
| accuracy diagnostic tests | #65 |
| stroke thromboembolism | #65 |
| rapid triage | #66 |
| statin therapy risk | #66 |
| dvt sensitivity | #66 |
| elfa | #66 |
| death classification | #66 |
| 0 points | #66 |
| axa | #66 |
| newer anticoagulants | #66 |
| 95 bleeding | #66 |
| female heparin | #66 |
| risk factor thrombosis | #66 |
| 1127 | #67 |
| patients factor | #67 |
| apixaban | #67 |
| atrial fibrillation stroke | #67 |
| rate major | #67 |
| patients tertiles | #67 |
| standard therapy patients | #67 |
| 3594 | #68 |
| 1894 | #68 |
| fibrinolytic | #68 |
| coagulation fibrinolysis | #68 |
| 20210g | #68 |
| patients bnp levels | #68 |
| academic medical centre | #68 |
| patients benefits | #68 |
| perioperative blood | #68 |
| 05 95 | #68 |
| ranging study | #68 |
| heparin ufh | #69 |
| recurrent thrombosis patients | #69 |
| postphlebitic | #69 |
| thrombosis blood | #69 |
| justify | #69 |
| enfermedad tromboembólica | #69 |
| plasma interleukin | #69 |
| certoparin | #69 |
| suspected | #69 |
| ionis | #69 |
| thrombosis recurrence | #70 |
| elevated cardiac | #70 |
| 8190 | #70 |
| patients protein | #70 |
| aged predictive | #70 |
| gramnegative sepsis | #70 |
| test patients | #70 |
| fixed dose | #70 |
| cutoff levels | #70 |
| withhold | #70 |
| α2ap | #70 |
| vwfrco | #70 |
| ischemic events patients | #70 |
| mantelhaenszel | #70 |
| major bleeding complications | #70 |
| rivaroxaban treatment | #70 |
| levels vwf | #71 |
| clopidogrel placebo | #71 |
| unfractionated | #71 |
| vte vka | #71 |
| diagnostic sensitivity specificity | #71 |
| tests prospective | #71 |
| plasminogen plg | #71 |
| thromboprophylaxis | #71 |
| asymptomatic atherosclerosis | #71 |
| topic costs | #71 |
| activation prothrombin | #72 |
| trifurcation | #72 |
| complications hematologic | #72 |
| ddimer values | #72 |
| pooled rate | #72 |
| hf studies | #72 |
| overt hypothyroidism | #72 |
| new anticoagulant | #72 |
| patients lmwh | #72 |
| versus vitamin | #72 |
| antithrombin iii iii | #72 |
| elevated factor | #72 |
| viia factor | #72 |
| ddimer measurement | #73 |
| soluble fibrin | #73 |
| noacs | #73 |
| ingelheim | #73 |
| tomography spiral | #73 |
| reversal agent | #73 |
| 12 months 95 | #73 |
| analysis diagnostic | #73 |
| prolongations | #73 |
| longterm risk | #74 |
| dvt study | #74 |
| prethrombotic state | #74 |
| 2124 | #74 |
| soluble thrombomodulin | #74 |
| experimental metastasis | #74 |
| female hemorrhage | #74 |
| 1732 | #74 |
| study selection | #74 |
| carriers | #74 |
| suspected dvt | #74 |
| 2550 | #74 |
| 5395 | #74 |
| proteins patients | #74 |
| incidence bleeding events | #75 |
| postoperative dvt | #75 |
| 2904 | #75 |
| carotid femoral arteries | #75 |
| 1334 | #75 |
| 8492 | #75 |
| selective factor | #75 |
| retrospective follow | #75 |
| thrombolytic therapy patients | #75 |
| angiography ctpa | #76 |
| oral combined contraceptives | #76 |
| duration thromboprophylaxis | #76 |
| extended anticoagulation | #76 |
| early time | #76 |
| combined contraceptives | #76 |
| tests primary | #76 |
| factor xii deficiency | #76 |
| risk thrombosis | #76 |
| boehringer | #77 |
| patients secondary | #77 |
| p023 | #77 |
| social aspects | #77 |
| individual patient | #77 |
| thrombosis pregnancy | #77 |
| 20 daily | #78 |
| arterial wall thickness | #78 |
| women thrombophilia | #78 |
| ipg | #78 |
| elevated dimer | #78 |
| female fibrinolysis | #78 |
| unprovoked | #78 |
| arterial thromboembolism | #78 |
| vte fvl | #79 |
| topic heparin | #79 |
| suspected acute | #79 |
| vkas | #79 |
| humans pulmonary | #79 |
| limulus test | #79 |
| time therapeutic | #79 |
| factor adult | #79 |
| 2486 | #79 |
| efficacy agents | #79 |
| bleeding mortality | #80 |
| daily bid | #80 |
| subhazard ratio | #80 |
| thromboembolism incidence | #80 |
| patient data | #80 |
| suspected cancer | #80 |
| heterozygous deficiency | #80 |
| alife | #80 |
| validation models | #80 |
| 95 05 | #80 |
| sspe patients | #80 |
| vte rate | #80 |
| test evaluation | #81 |
| topic risk | #81 |
| walking distance | #81 |
| systemic inflammatory | #81 |
| vascular events | #81 |
| knee arthroplasty patients | #81 |
| weitz | #81 |
| lmwh vte | #81 |
| prothrombin complex concentrate | #81 |
| outpatient basis | #81 |
| mammography patients | #82 |
| placebo women | #82 |
| thrombosis incidence | #82 |
| common practice | #82 |
| prospective validation | #82 |
| heparin prevention | #82 |
| 50 micrograms | #82 |
| posthoc analysis | #82 |
| clinical sign | #82 |
| thrombolytic drugs | #82 |
| 3month followup | #82 |
| timeperiods | #82 |
| crnmb | #82 |
| thrombosis thrombophilia | #82 |
| symptomatic carriers | #82 |
| 287 | #83 |
| elective coronary | #83 |
| patients thrombi | #83 |
| dimer patients | #83 |
| 2213 | #83 |
| bleeding women | #83 |
| inhibitor dabigatran | #83 |
| bistro | #83 |
| normotensive patients | #84 |
| duration therapy | #84 |
| diagnostic outcome | #84 |
| screening humans | #84 |
| inherited thrombophilia | #84 |
| healthcare setting | #84 |
| inhibitor rivaroxaban | #84 |
| heparin treatment | #84 |
| prophylactic dose | #84 |
| thrombosis svt | #85 |
| asymptomatic dvt | #85 |
| peripheral vascular diseases | #85 |
| venous thrombosis patients | #85 |
| anticoagulants antiphospholipid | #85 |
| antithrombin iii protein | #85 |
| normal levels | #85 |
| endotoxins | #85 |
| major bleeding warfarin | #86 |
| elevated ddimer levels | #86 |
| 75 microg | #86 |
| dabigatran vka | #86 |
| 4576 | #86 |
| venovenous hemofiltration | #86 |
| 10⁶ | #86 |
| rhapc | #86 |
| clinical impact | #87 |
| ≤50 | #87 |
| patients 28 | #87 |
| contact activation | #87 |
| vidas | #87 |
| 95 100 | #87 |
| obstetric patients | #87 |
| acute venous | #87 |
| post‐hoc analysis | #87 |
| avws | #87 |
| lmwhs | #88 |
| 4 points | #88 |
| washout period | #88 |
| activation factor | #88 |
| cdr | #88 |
| aged multicenter | #88 |
| venographic | #88 |
| 3319 | #88 |
| treatment statins | #88 |
| internist | #88 |
| treatment incidence | #88 |
| unexplained recurrent | #89 |
| adequate treatment | #89 |
| tests test | #89 |
| matisse | #89 |
| ddimer | #89 |
| anticoagulants dabigatran | #89 |
| cytokine release | #89 |
| costs patient | #89 |
| rates major bleeding | #89 |
| ventilation lung | #89 |
| beta blockers | #89 |
| reversal strategies | #89 |
| stroke bleeding | #89 |
| smoking incidence | #89 |
| severe hf | #89 |
| vte venous thromboembolism | #89 |
| safety noacs | #89 |
| popliteal vein | #90 |
| primary thromboprophylaxis | #90 |
| pediatric venous | #90 |
| vka dabigatran | #90 |
| venous thrombosis risk | #90 |
| outweighs | #90 |
| 2293 | #90 |
| new patients | #90 |
| fibrinolytic factors | #90 |
| thrombophilic risk factors | #90 |
| cdrs | #91 |
| inconvenience | #91 |
| thromboembolism pregnancy | #91 |
| 20210 | #91 |
| thrombosis women | #91 |
| 60 95 | #91 |
| pyridines pyridones | #91 |
| perfusion ratio | #91 |
| agents hemorrhage | #91 |
| anticoagulants doacs | #91 |
| prophylaxis incidence | #92 |
| combined clinical | #92 |
| single intravenous | #92 |
| thrombotic disease | #92 |
| rivaroxaban edoxaban | #93 |
| incidence knee | #93 |
| direct thrombin inhibitors | #93 |
| compression patients | #93 |
| 95 years | #93 |
| anticoagulation reversal | #93 |
| scenario analyses | #93 |
| 1027 | #94 |
| heparins | #94 |
| vte surgery | #94 |
| children vte | #94 |
| test result | #94 |
| 125 patients | #94 |
| hf severity | #94 |
| patients symptomatic | #94 |
| atherogenic lipid | #94 |
| viia rfviia | #95 |
| european consensus statement | #95 |
| direct oral anticoagulant | #95 |
| 2 levels | #95 |
| xii deficiency | #96 |
| randomised crossover study | #96 |
| risk symptomatic | #96 |
| fondaparinux treatment | #96 |
| symptomatic vte | #96 |
| efficacy rivaroxaban | #96 |
| 6 12 months | #96 |
| ddimer level | #96 |
| abnormal perfusion | #97 |
| haemophilia patients | #97 |
| doacs risk | #97 |
| studies evaluated | #97 |
| symptomatic pulmonary embolism | #97 |
| tpa release | #97 |
| invasive testing | #97 |
| fibrin generation | #97 |
| difference rates | #97 |
| pyrazoles pyridones | #97 |
| 16slice | #98 |
| essential thrombocythaemia | #98 |
| supervised exercise therapy | #98 |
| 2875 | #98 |
| simplify | #98 |
| activated protein apc | #98 |
| pregnancy postpartum period | #98 |
| hypercoagulable | #98 |
| major bleed | #98 |
| risk arterial | #99 |
| probast | #99 |
| unselected | #99 |
| acute dvt | #99 |
| lmwh warfarin | #99 |
| hirudin | #99 |
| 2·0 | #99 |
| perfusion scintigraphy | #99 |
| gbd 2010 | #100 |
| 1116 | #100 |
| patient groups | #100 |
| previews | #100 |
| doubleblind trial | #100 |
| 3 trials | #100 |
| warfarin patients | #100 |
| fatty foods | #100 |
| increasing levels | #100 |
| prevention recurrent | #100 |
| morpholines | #101 |
| factor viia | #101 |
| factor vii factor | #101 |
| aptts | #101 |
| low pretest probability | #102 |
| pts patients | #102 |
| enoxaparin fondaparinux | #102 |
| 265 patients | #102 |
| alternative diagnosis | #102 |
| venous thromboembolism women | #102 |
| 40 microg | #102 |
| doppler method | #103 |
| adjudicated | #103 |
| arthroscopic anterior | #103 |
| therapeutic consequences | #103 |
| pregnancy puerperium | #103 |
| cteph patients | #103 |
| 338 | #103 |
| endogenous thrombin | #103 |
| antithrombin iii | #104 |
| diagnostic imaging humans | #104 |
| oral factor | #104 |
| recurrence women | #104 |
| separate analyses | #104 |
| fibrin degradation products | #104 |
| absolute increase | #104 |
| heparin pregnancy | #104 |
| term treatment | #104 |
| assay variation | #104 |
| partial restoration | #104 |
| apparent increase | #104 |
| conventional therapy patients | #105 |
| embryo loss | #105 |
| 7 children | #105 |
| 1089 | #105 |
| thromboprophylaxis patients | #106 |
| hospitalized patients hf | #106 |
| essentials | #106 |
| fibrinolytic systems | #106 |
| elevated levels | #106 |
| 314 | #106 |
| blind double | #106 |
| 2479 | #106 |
| thrombophilia | #106 |
| study total | #106 |
| thrombosis age | #106 |
| chest ray | #106 |
| survival cancer patients | #107 |
| ddimer levels | #107 |
| simplified version | #107 |
| thromboembolic | #107 |
| topic recurrence | #107 |
| definition classification | #107 |
| vte risk | #107 |
| specific subgroups | #108 |
| human volunteers | #108 |
| patients cancer | #108 |
| noncancer patients | #108 |
| post thrombotic syndrome | #108 |
| cardiovascular death stroke | #108 |
| grade 1c | #108 |
| factor mutation | #109 |
| 500μg | #109 |
| thrombin antithrombin | #109 |
| routine coagulation | #109 |
| evaluation studies | #109 |
| embolism treatment | #109 |
| synthetic pentasaccharide | #109 |
| anticoagulants cohort | #109 |
| 1235 | #109 |
| viia | #109 |
| 039 | #109 |
| primary safety | #110 |
| cancer activity | #110 |
| antiplasmin | #110 |
| subsequent pregnancy | #110 |
| embolism quality | #110 |
| inferiority trial | #110 |
| vka doac | #110 |
| thrombosis treated | #110 |
| siset | #111 |
| anticoagulants biomarkers | #111 |
| comparison control | #111 |
| negative predictive 100 | #111 |
| treatment risk factors | #111 |
| humans intermittent | #111 |
| obstetric complications | #111 |
| predefined | #111 |
| epidemiology risk factors | #112 |
| publication anticoagulants | #112 |
| efficacy prevention | #112 |
| emergency situations | #112 |
| topic guidelines | #112 |
| thromboembolic diseases | #112 |
| rivaroxaban enoxaparin | #112 |
| patients ventricular dysfunction | #112 |
| recurrence treatment | #112 |
| chromogenic | #112 |
| risk rivaroxaban | #112 |
| patients 70 | #112 |
| heterozygous carriers | #113 |
| nonionic contrast | #113 |
| metabolic response | #113 |
| inappropriate treatment | #113 |
| patients nephrotoxicity | #113 |
| lmwh risk | #113 |
| study centre | #114 |
| postphlebitic syndrome | #114 |
| cancerassociated vte | #114 |
| patients intermediate | #114 |
| total knee replacement | #114 |
| 0·0 | #114 |
| dialysers | #114 |
| hyperhomocysteinaemia | #115 |
| global public | #115 |
| patients recurrent | #115 |
| 393 | #115 |
| fibrinogen vwf | #115 |
| positive predictive values | #115 |
| life treatment | #116 |
| agents heparin | #116 |
| vte data | #116 |
| women severe preeclampsia | #116 |
| anticoagulants arthroplasty | #116 |
| effects tnf | #116 |
| major bleeding 95 | #116 |
| computed tomography patients | #116 |
| topic dabigatran | #116 |
| heparin warfarin | #116 |
| reference standard | #116 |
| fibrinolytic parameters | #117 |
| protein inhibitor pci | #117 |
| vte complications | #117 |
| protein resistance | #117 |
| women caesarean | #117 |
| arthroscopies | #117 |
| 2460 | #117 |
| vte children | #117 |
| 2744 | #118 |
| patients extensive | #118 |
| proximal dvt | #118 |
| 4118 | #118 |
| arterial thrombosis patients | #118 |
| autopsyconfirmed | #118 |
| incidence pulmonary embolism | #119 |
| humans leg | #119 |
| patients doac | #119 |
| compared warfarin | #119 |
| compression stockings | #119 |
| thrombosis study | #120 |
| healthy humans | #120 |
| acquired deficiency | #120 |
| previous vte | #120 |
| months follow | #120 |
| mortality diseases | #120 |
| lactoferrin leukocyte | #120 |
| rivaroxaban patients | #120 |
| risk thromboembolism | #120 |
| dabigatran factor | #120 |
| patients prostatic cancer | #121 |
| thrombocytopenia thrombosis | #121 |
| oral hormonal | #122 |
| fatal pulmonary embolism | #122 |
| studies venous | #122 |
| patients 6 | #122 |
| anti factor | #122 |
| 100 patients | #123 |
| factor xia | #123 |
| acute infection | #123 |
| minor bleeding | #123 |
| heparin | #123 |
| venous thromboembolism pregnancy | #123 |
| heparin hirudin | #123 |
| early dynamics | #123 |
| placebo standard | #123 |
| thrombophilia pregnancy | #124 |
| ft4 levels | #124 |
| statin risk | #124 |
| atherogenic lipid profile | #124 |
| treatment data | #124 |
| vte lmwh | #124 |
| association level | #124 |
| incidence thrombosis | #125 |
| elevated liver enzymes | #125 |
| thromboembolism recurrence | #125 |
| puerperal disorders | #125 |
| treatment indication | #125 |
| diseases mortality | #125 |
| skin perfusion | #125 |
| fibrinolysis inhibitor | #125 |
| nonsignificantly | #125 |
| peripheral arterial disease | #125 |
| intravenous heparin | #125 |
| bayer | #125 |
| doacs treatment | #126 |
| upper extremity | #126 |
| distal dvt | #126 |
| occurrence vte | #127 |
| patients permanent | #127 |
| thromboprophylaxis lmwh | #127 |
| marder | #127 |
| performance scores | #127 |
| patients ventilation | #127 |
| unacceptably | #127 |
| resistance apc | #128 |
| venous thromboembolism risk | #128 |
| development vte | #128 |
| treatment months | #128 |
| 50 age | #128 |
| patients conventional therapy | #128 |
| direct factor | #128 |
| prevention | #128 |
| mortality cancer patients | #129 |
| elevated biomarkers | #129 |
| 060 | #129 |
| ctrough | #129 |
| 1041 | #129 |
| riete registry | #129 |
| 220 | #130 |
| internists | #130 |
| anticoagulants antithrombins | #130 |
| day 10 | #130 |
| 194 patients | #130 |
| hospital discharge records | #130 |
| patients episode | #130 |
| plaster cast | #130 |
| obviating | #131 |
| 05 patients | #131 |
| long‐term clinical outcomes | #131 |
| tests specificity | #131 |
| pooled incidence | #131 |
| linear interpolation | #131 |
| hoc analysis | #132 |
| postpartum period women | #132 |
| rivaroxaban versus | #132 |
| hypocoagulability | #132 |
| fxa inhibitors | #133 |
| started | #133 |
| cha2ds2vasc | #133 |
| 80 anticoagulants | #133 |
| avidin | #133 |
| direct inhibitors | #133 |
| enoxaparin treatment | #133 |
| rco vwf | #134 |
| risk pad | #134 |
| embolism acute | #134 |
| pulmonary angiography patients | #134 |
| selectin levels | #134 |
| instituted | #134 |
| bnp concentration | #135 |
| activator plasminogen | #135 |
| prevalence dvt | #135 |
| anticoagulant prophylaxis | #135 |
| followup patients | #136 |
| apixaban edoxaban | #136 |
| east asian patients | #136 |
| thrombotic syndrome | #136 |
| months anticoagulation | #136 |
| severe pph | #136 |
| 0056 | #136 |
| clinical prediction | #136 |
| sequential application | #137 |
| 2283 | #137 |
| 99 patients | #137 |
| acquired thrombophilia | #137 |
| phase 3 trials | #137 |
| diagnostic work | #137 |
| point‐of‐care | #137 |
| factor prothrombin | #137 |
| studies mortality | #138 |
| complete inhibition | #138 |
| bleeding warfarin | #138 |
| enhanced factor | #138 |
| national guidelines | #138 |
| antidote | #138 |
| intravascular coagulation dic | #138 |
| factor viii factor | #139 |
| direct inhibitor | #139 |
| patients comparison | #139 |
| reproducibility risk | #139 |
| oral anticoagulant treatment | #139 |
| risk fatal | #139 |
| 3 weeks | #139 |
| 95 major bleeding | #139 |
| 2465 | #139 |
| distal deep | #140 |
| dvt incidence | #140 |
| 20 iu | #140 |
| ottawa | #140 |
| 0114 | #140 |
| 12 95 | #140 |
| 80 cohort | #140 |
| vwf rco | #140 |
| human activated | #140 |
| antidotes | #141 |
| thromboembolic disorders | #141 |
| pharmacy records | #141 |
| thrombin potential | #142 |
| carriership | #142 |
| ischaemic events | #143 |
| geneva | #143 |
| escherichia humans | #143 |
| warfarin administration | #143 |
| treatment pulmonary | #143 |
| points 95 | #143 |
| active malignancy | #143 |
| jugular veins | #143 |
| topic practice patterns | #144 |
| management vte | #144 |
| compared treatment | #144 |
| postoperative venous | #144 |
| fatal pulmonary | #144 |
| pregnancy female humans | #144 |
| doac treatment | #144 |
| thrombosis model | #145 |
| serial testing | #145 |
| hyperthyroxinemia | #145 |
| referred patients | #145 |
| dose rivaroxaban | #145 |
| patient populations | #145 |
| filters venous | #145 |
| months treatment | #146 |
| derived microvesicles | #146 |
| protein factor | #146 |
| death cancer patients | #146 |
| tissue factor pathway | #147 |
| personal fees | #147 |
| rebuttal | #148 |
| long‐acting | #148 |
| antithrombotic drugs | #148 |
| intention treat | #148 |
| partial thromboplastin | #148 |
| 2076 | #148 |
| acute medical illness | #148 |
| embolism diagnosis | #148 |
| 10 years patients | #148 |
| thrombocyte | #149 |
| 0·45 | #149 |
| procoagulant | #149 |
| individual patient data | #149 |
| risk subgroups | #149 |
| diagnostic score | #149 |
| vte hospitalization | #149 |
| relevant publications | #149 |
| dimer level | #150 |
| humans injections | #151 |
| enoxaparin unfractionated heparin | #151 |
| coagulation dic | #151 |
| additional imaging | #151 |
| patients primary outcome | #152 |
| patient eligibility | #152 |
| continuous venovenous | #152 |
| longterm treatment | #152 |
| bleeding patients | #152 |
| thrombosis prevention | #153 |
| extracorporeal circuit | #153 |
| point systems | #153 |
| cardiopulmonary bypass surgery | #153 |
| hypercoagulable state | #153 |
| bleeding scores | #154 |
| direct thrombin | #154 |
| active cancer | #154 |
| angioplasty patients | #154 |
| dimer levels | #154 |
| thrombosis factor | #154 |
| activity mortality | #154 |
| warfarin apixaban | #155 |
| states venous | #155 |
| thromboembolic event | #155 |
| drug factor | #155 |
| curve sensitivity | #155 |
| tomography patients | #155 |
| fiia | #155 |
| stockings | #156 |
| 09 | #156 |
| vte treatment | #156 |
| coagulant activity | #156 |
| daily oral | #156 |
| recurrent symptoms | #156 |
| patients gastrointestinal | #156 |
| enoxaparin dose | #156 |
| fvl | #156 |
| hemodynamically | #157 |
| cross‐sectional survey | #157 |
| prophylaxis patients | #157 |
| increased thrombin | #157 |
| duration anticoagulation | #158 |
| months chemotherapy | #158 |
| 2126 | #158 |
| underlying malignancy | #158 |
| dfl | #158 |
| 97 | #158 |
| adjusted relative risk | #159 |
| increased risk thrombosis | #159 |
| children fh | #160 |
| schering | #160 |
| 145 patients | #160 |
| thrombotic disorders | #160 |
| guidelines prevention | #160 |
| antithrombotic efficacy | #160 |
| 120 minutes | #160 |
| plasma dimer | #160 |
| antagonists patients | #161 |
| prophylactics | #161 |
| pvo | #161 |
| women time | #162 |
| lysine analogues | #162 |
| patients imaging | #162 |
| incidence vte | #162 |
| 2206 | #162 |
| rates vte | #163 |
| increased plasma levels | #163 |
| lmwh therapy | #163 |
| venous thrombus | #163 |
| factors bleeding | #163 |
| strain gauge | #163 |
| imaging test | #163 |
| 198 patients | #163 |
| coagulation blood | #163 |
| observer variability | #164 |
| age comorbidity | #164 |
| justified | #164 |
| inborn humans | #164 |
| 028 | #164 |
| relatives patients | #165 |
| patients enoxaparin | #165 |
| mutation factor | #165 |
| subhazard | #165 |
| viii factor | #166 |
| pravastatin therapy | #166 |
| microvascular thrombosis | #166 |
| stockings compression | #166 |
| management venous thromboembolism | #166 |
| strategies patients | #166 |
| phlebography | #166 |
| 3658 | #167 |
| thrombin venous | #167 |
| ankle brachial abi | #167 |
| recurrent thrombosis | #167 |
| cvcs | #168 |
| recurrent acute | #168 |
| double heterozygosity | #168 |
| treatment 3 months | #168 |
| cstatistics | #168 |
| syndrome pts | #168 |
| warfarin | #168 |
| current clinical practice | #168 |
| patients infections | #169 |
| risk profile | #169 |
| postthrombotic syndrome pts | #169 |
| preexistent | #169 |
| therapeutic range | #169 |
| fold increased | #169 |
| 3 12 | #169 |
| thrombosis cancer | #170 |
| heavy menstrual bleeding | #170 |
| cart patients | #170 |
| interobserver agreement | #170 |
| postoperative blood loss | #170 |
| adamts‐13 | #171 |
| 57 years | #171 |
| aged algorithms | #171 |
| recombinant factor | #171 |
| venous thrombotic events | #171 |
| clinical trials patients | #172 |
| patients blood transfusion | #172 |
| pulmonology | #172 |
| lmw heparin | #172 |
| antifibrinolytic | #172 |
| risk factors patients | #172 |
| vaginal bleeding | #172 |
| pulmonary | #173 |
| inr | #173 |
| bleeds | #173 |
| hospitalized medical patients | #173 |
| bleeding tendency | #174 |
| clinically bleeding | #174 |
| arterial occlusions | #174 |
| laboratory monitoring | #174 |
| patients initial | #174 |
| reocclusion | #175 |
| data control | #175 |
| fragment 1 | #175 |
| vte common | #175 |
| arterial venous | #175 |
| mitsubishi | #177 |
| picotamide | #177 |
| prothrombin | #177 |
| hyperthyroidism hypothyroidism | #178 |
| short‐ | #178 |
| intention analysis | #178 |
| 122 | #178 |
| aspirin ticlopidine | #178 |
| oral female humans | #179 |
| concomitance | #179 |
| vte event | #179 |
| noninferior | #179 |
| baseline day | #179 |
| isth | #180 |
| referral bias | #180 |
| ventilation perfusion | #180 |
| thromboplastin time | #180 |
| patients deficiency | #180 |
| additional risk factors | #180 |
| aged partial | #181 |
| antithrombin | #182 |
| testing patients | #182 |
| acute episode | #182 |
| painkillers | #182 |
| biological variation | #183 |
| hyperhomocysteinemic | #183 |
| patients major | #183 |
| 2–4 | #183 |
| coagulation factors | #184 |
| pregnancy vte | #184 |
| risk bleeding | #184 |
| subsequent diagnosis | #184 |
| treat analysis | #184 |
| 4150 | #184 |
| prognosis pulmonary | #184 |
| incidental | #184 |
| antithrombin iii atiii | #184 |
| n110 | #184 |
| thromboinflammation | #184 |
| vte age | #185 |
| deficient patients | #185 |
| hemostatic effects | #186 |
| patients intensive units | #186 |
| studies heparin | #186 |
| anticoagulated | #186 |
| symptomatic | #186 |
| brain natriuretic | #186 |
| live birth rate | #186 |
| patients thromboprophylaxis | #186 |
| cutoff level | #187 |
| safety apixaban | #187 |
| antifibrinolytic agents | #187 |
| patients haemophilia | #187 |
| risk composite | #187 |
| ratio inr | #188 |
| humans international | #188 |
| doacs vkas | #188 |
| 926 | #188 |
| absolute rate | #188 |
| prevalence cancer | #188 |
| spontaneous rupture | #188 |
| blood loss patients | #189 |
| 64slice | #189 |
| willebrand factor antigen | #189 |
| heparin administration | #189 |
| clinical validity | #189 |
| riete | #189 |
| viia female | #189 |
| fibrinolysis | #189 |
| patients netherlands | #189 |
| ischemic event | #190 |
| thrombosis patients | #190 |
| current views | #190 |
| ccus | #190 |
| anticoagulant drugs | #190 |
| gogh | #191 |
| venous outflow | #191 |
| 07 | #191 |
| score patients | #191 |
| attending physicians | #191 |
| acute thrombosis | #191 |
| 1495 | #192 |
| stroke systemic | #192 |
| 058 | #192 |
| endothelial cell activation | #193 |
| coagulation assays | #193 |
| anticoagulation | #194 |
| prothrombin activation | #194 |
| heparin patients | #194 |
| 070 | #194 |
| blood coagulation | #194 |
| antagonist treatment | #195 |
| 65 months | #195 |
| risk major | #195 |
| recurrent ischemic events | #195 |
| target range | #195 |
| antixa levels | #195 |
| complications cardiovascular | #196 |
| abnormal test | #196 |
| 29 95 | #196 |
| coagulation status | #196 |
| vii rfviia | #198 |
| sew2871 | #198 |
| difference treatment | #198 |
| ate | #198 |
| treatment groups patients | #198 |
| vwf adamts13 | #198 |
| cachectin | #199 |
| coagulation monitoring | #199 |
| patient diagnosis | #199 |
| patients 12 months | #200 |
| screening patients | #200 |
| incidence cardiovascular events | #200 |
| obese controls | #200 |
| thrombin factor | #201 |
| patients abnormal | #201 |
| vte incidence | #201 |
| thromboembolic disease | #201 |
| validation sets | #201 |
| arterial thrombosis | #202 |
| johnson | #202 |
| 17 95 | #202 |
| peritoneovenous | #202 |
| worldwide survey | #203 |
| induced activation | #203 |
| symptomatic pad | #203 |
| invitees | #203 |
| heparin dose | #203 |
| levonorgestrel | #204 |
| antithrombotic agents | #204 |
| extended thromboprophylaxis | #205 |
| stroke systemic embolism | #205 |
| thrombophilia risk | #205 |
| 0 95 | #205 |
| period time | #205 |
| low incidence | #205 |
| fgt | #206 |
| varese | #206 |
| venous ultrasonography | #206 |
| data synthesis | #206 |
| patients anticoagulant therapy | #206 |
| algorithms anticoagulants | #207 |
| objectively | #207 |
| cardiologist | #207 |
| desogestrel | #207 |
| platelet activation patients | #207 |
| methods consecutive | #207 |
| systematic review studies | #207 |
| 06 | #207 |
| imt patients | #207 |
| death female humans | #207 |
| fviii | #207 |
| bleeding compared | #208 |
| patients hypothyroidism | #208 |
| thrombocythaemia | #208 |
| deficiency risk | #209 |
| free protein | #209 |
| tgt | #210 |
| women frequency | #210 |
| antixa activity | #210 |
| hirudins | #210 |
| stocking | #211 |
| ioxaglate | #211 |
| toxaemia | #211 |
| systemic embolism patients | #211 |
| anticoagulation management | #212 |
| atrial fibrillation study | #212 |
| heparitin sulfate | #213 |
| plasminogen activator activity | #213 |
| topic practice | #214 |
| dabigatran dose | #214 |
| correct interpretation | #214 |
| standard duration | #215 |
| current developments | #215 |
| factors vte | #215 |
| thrombin inhibition | #215 |
| studies rivaroxaban | #215 |
| warfarin stroke | #216 |
| community hospital | #216 |
| duplex venous | #216 |
| deamino | #216 |
| betatg | #216 |
| diagnostic algorithm | #217 |
| undergoing total | #217 |
| mildest | #217 |
| obviates | #217 |
| studies difference | #217 |
| npv 100 | #218 |
| g20210a | #218 |
| cstatistic | #218 |
| plasminogen activator inhibitor | #218 |
| conclusive evidence | #218 |
| deamino arginine | #219 |
| 077 95 | #219 |
| cancer | #219 |
| patients cart | #219 |
| vii factor | #220 |
| viii female | #220 |
| techniques female | #220 |
| data extraction | #220 |
| hip replacement surgery | #220 |
| hmvec | #221 |
| heparin humans | #221 |
| healthy human subjects | #221 |
| preventive measures | #221 |
| postoperative vte | #221 |
| vte events | #222 |
| proximally | #222 |
| apc resistance | #222 |
| substantial proportion | #223 |
| engl | #223 |
| pulmonologists | #223 |
| 1 january | #223 |
| 1541 | #223 |
| subsequent cancer | #224 |
| thromboendarterectomy | #224 |
| protein pathway | #224 |
| topic factor | #224 |
| kruskalwallis | #225 |
| balloon coronary anticoagulants | #225 |
| thrombosis warfarin | #225 |
| org | #225 |
| neoplasms prospective | #225 |
| inr monitoring | #226 |
| 16 95 | #226 |
| extremity amputation | #226 |
| 0·67 | #226 |
| vascular events patients | #226 |
| acute medical | #227 |
| tests diagnosis | #227 |
| haemostasis | #227 |
| 35 ± | #227 |
| ipe | #228 |
| mild hyperhomocysteinemia | #228 |
| cgp | #229 |
| residual thrombus | #229 |
| scant | #229 |
| dalteparin | #229 |
| 037 | #230 |
| advocated | #230 |
| major orthopaedic surgery | #231 |
| severe preeclampsia | #231 |
| thiazoles | #231 |
| 6 studies | #231 |
| patients discontinuation | #231 |
| resource utilisation | #231 |
| equinox | #231 |
| ft4 | #231 |
| habitual abortion | #231 |
| urosepsis | #231 |
| aspirin dipyridamole | #232 |
| patients warfarin | #232 |
| surgical embolectomy | #233 |
| recurrence risk factors | #233 |
| humans netherlands | #233 |
| anticoagulant effects | #233 |
| endogenous thrombin potential | #233 |
| dimer | #233 |
| cancer prevalence | #233 |
| effective alternative | #234 |
| graduated compression | #235 |
| doac | #235 |
| prothrombotic state | #235 |
| venous thromboembolic events | #236 |
| brain natriuretic peptide | #236 |
| humans meta | #236 |
| oral anticoagulants | #237 |
| myocardial infarction 95 | #237 |
| treatment continuation | #237 |
| 6500 | #238 |
| patients vkas | #238 |
| predictive tests | #238 |
| 009 | #238 |
| rational approach | #239 |
| factor viii fviii | #239 |
| factor tnf | #239 |
| anticoagulants aspirin | #239 |
| crossover study | #239 |
| patients initial treatment | #240 |
| arterial venous thrombosis | #240 |
| hip knee arthroplasty | #241 |
| 045 | #241 |
| aspirin heparin | #241 |
| bleeding incidence | #242 |
| time therapeutic range | #242 |
| pivotal trials | #243 |
| patients intermittent claudication | #243 |
| prothrombin fragment | #243 |
| iohexol | #244 |
| vte risk factors | #245 |
| n89 | #245 |
| children neonates | #246 |
| thrombogenesis | #246 |
| casecontrol | #246 |
| vte cases | #246 |
| antithrombotic | #247 |
| lipoproteina levels | #247 |
| 23 95 | #247 |
| warfarin aged | #247 |
| treatment compared | #248 |
| patients solid tumours | #248 |
| committees | #248 |
| anti activity | #248 |
| coronary anticoagulants | #248 |
| bleeding rates | #249 |
| multiple comorbidities | #249 |
| score risk | #249 |
| diagnostic models | #249 |
| fv leiden | #250 |
| protein risk | #250 |
| ioxaglic | #250 |
| ischemic strokes | #250 |
| patients contraindications | #251 |
| finalized | #251 |
| microthrombosis | #251 |
| 8595 | #251 |
| somit | #252 |
| simplification | #252 |
| vkas doacs | #252 |
| thrombin thrombosis | #253 |
| incidence | #253 |
| treatment duration | #254 |
| agents anticoagulants | #254 |
| palga | #255 |
| fibrinolytic activity | #255 |
| haul | #256 |
| medea | #256 |
| activation humans | #256 |
| continuous intravenous | #257 |
| cost‐effectiveness | #257 |
| bleeding risk | #257 |
| clinical utility | #257 |
| activity assay | #257 |
| q24h | #257 |
| patient subgroups | #258 |
| fibrin degradation | #258 |
| ctpa | #258 |
| unpublished data | #259 |
| 30 50 | #259 |
| sspe | #260 |
| dvt risk | #260 |
| thrombus size | #261 |
| toxicosis | #261 |
| noncarriers | #261 |
| heparin dosing | #261 |
| patients hospitalization | #262 |
| risk pulmonary | #263 |
| optimal duration | #263 |
| blind study | #264 |
| graft type | #265 |
| 400 patients | #266 |
| einstein | #267 |
| pbac | #267 |
| statins risk | #268 |
| endotoxaemia | #268 |
| malignancy patients | #269 |
| lysis time | #269 |
| relation time | #269 |
| versus aspirin | #269 |
| randomised cross | #269 |
| propeptide | #269 |
| discontinuing | #270 |
| exclusion | #270 |
| protein patients | #270 |
| single test | #270 |
| protein apc | #271 |
| hormonal replacement therapy | #271 |
| platelet serotonin | #271 |
| 3·0 | #271 |
| orthopaedic patients | #271 |
| thrombosis inflammation | #271 |
| groups levels | #272 |
| bleeding patient | #272 |
| vte recurrence | #272 |
| clopidogrel ticlopidine | #272 |
| patients combination | #272 |
| ankle brachial | #273 |
| efficacy analysis | #273 |
| risk levels | #274 |
| prevalence pad | #274 |
| cleavage sites | #274 |
| months 12 | #274 |
| parenteral nutrition patients | #275 |
| international normalized | #275 |
| performance score | #275 |
| fourth quartile | #276 |
| antithrombotic agent | #276 |
| smoking hypertension | #277 |
| time aptt | #277 |
| dose reduction | #278 |
| imaging sensitivity | #278 |
| normalized ratio | #278 |
| aptt | #279 |
| rco | #279 |
| blood test | #279 |
| hospitalized medical | #280 |
| obviate | #280 |
| propositi | #280 |
| exclusion criteria | #280 |
| intracranial hemorrhage patients | #280 |
| partial thromboplastin time | #280 |
| patients presence | #281 |
| thromboplastin | #282 |
| diagnostic test | #282 |
| puerperal | #283 |
| diagnostic sensitivity | #283 |
| neutrophil degranulation | #283 |
| thyroid diseases | #283 |
| presentation patients | #283 |
| outpatient treatment | #284 |
| favor | #284 |
| test characteristics | #284 |
| noninferiority margin | #284 |
| departments | #284 |
| animals anticoagulants | #284 |
| major orthopaedic | #285 |
| gentamicin treatment | #286 |
| 2630 | #286 |
| patients apixaban | #286 |
| plasma bnp | #286 |
| levels measured | #287 |
| patients pancreatic cancer | #287 |
| subdistribution | #287 |
| clinically | #287 |
| disseminated intravascular | #287 |
| md patients | #288 |
| oral combined | #288 |
| 227 | #288 |
| premature atherosclerosis | #288 |
| vte rates | #289 |
| cvt patients | #289 |
| substantiation | #289 |
| vte women | #289 |
| clot lysis | #289 |
| thrombin time | #290 |
| 0·50 | #290 |
| n59 | #290 |
| extracted data | #291 |
| oral contraceptives | #291 |
| carriers mutation | #291 |
| current clinical | #291 |
| 016 | #291 |
| willebrand disease vwd | #292 |
| 1603 | #292 |
| activator inhibitor | #292 |
| 2 studies | #292 |
| 1000 personyears | #293 |
| patients dabigatran | #293 |
| adverse outcome patients | #293 |
| pentasaccharide | #293 |
| plasmin activity | #293 |
| tissuetype plasminogen activator | #294 |
| patients rivaroxaban | #294 |
| cardiac troponin ctnt | #294 |
| lower extremities | #294 |
| 1025 | #295 |
| scenario analysis | #295 |
| extremity dvt | #295 |
| classified | #296 |
| peripheral vascular | #296 |
| coagulation factor viii | #296 |
| routine monitoring | #297 |
| observer agreement | #297 |
| recurrent miscarriage | #298 |
| episode patients | #298 |
| thrombocytes | #298 |
| specificity npv | #298 |
| patients inr | #299 |
| inferiority | #300 |
| 041 | #301 |
| heparitin | #301 |
| 155 patients | #302 |
| toxemia | #302 |
| aged neoplasms | #302 |
| thromboglobulin | #302 |
| subclinical thyroid dysfunction | #302 |
| absolute difference | #304 |
| 1214 | #304 |
| rivaroxaban dabigatran | #305 |
| prophylactic administration | #306 |
| medline embase | #306 |
| chimpanzees | #307 |
| noninvasive testing | #308 |
| complex concentrate | #309 |
| thrombotic | #310 |
| surgery day | #310 |
| vte pregnancy | #310 |
| hematologic pregnancy | #310 |
| percentage points | #311 |
| clinical presentation | #311 |
| patients 100 | #311 |
| 105 patients | #311 |
| antithrombins blood | #311 |
| leg male | #312 |
| 598 | #312 |
| negative reactions | #313 |
| hereditary thrombophilia | #313 |
| vte 95 | #313 |
| obesity risk factor | #313 |
| diagnosis | #314 |
| postpartum haemorrhage | #315 |
| funding | #315 |
| cardiologists | #315 |
| puerperium | #315 |
| heparin aspirin | #315 |
| apixaban versus | #316 |
| therapeutic dose | #316 |
| patients followup | #317 |
| adjudicators | #317 |
| deciding | #318 |
| 0·92 | #318 |
| decision model | #319 |
| failure rates | #319 |
| safety outcomes | #319 |
| catheter thrombosis | #320 |
| patients pregnancy | #320 |
| combined administration | #320 |
| bnp levels | #320 |
| influenza infections | #320 |
| 1731 | #320 |
| ventricular dysfunction patients | #321 |
| difference risk | #322 |
| additional data | #322 |
| intermediate phenotype | #322 |
| patients noacs | #322 |
| peripheral arterial | #324 |
| inrs | #324 |
| glaxosmithkline | #324 |
| mortality odds ratio | #325 |
| convincing evidence | #325 |
| blood coagulation factor | #326 |
| 122 patients | #326 |
| pulmonary embolus | #326 |
| mechanical heart valves | #326 |
| surgery trauma | #327 |
| clinical | #327 |
| association vte | #329 |
| incidence bleeding | #331 |
| thrombotic event | #331 |
| vitamin administration | #331 |
| pregnancy outcome women | #331 |
| new oral | #332 |
| analysis trials | #333 |
| n69 | #333 |
| embase databases | #333 |
| 95 percent | #333 |
| minor effects | #334 |
| 95 confidence limits | #334 |
| complicate | #334 |
| incidences | #334 |
| patients healthy volunteers | #335 |
| rationale design | #335 |
| fibrillation benzimidazoles | #335 |
| central venous catheter | #336 |
| septicaemia | #336 |
| pulmonary perfusion | #336 |
| total hip replacement | #337 |
| plethysmographic | #337 |
| recurrent | #337 |
| 065 | #337 |
| 2 points | #337 |
| 035 | #337 |
| outpatient management | #338 |
| coagulation abnormalities | #338 |
| aged netherlands | #338 |
| fatal bleeding | #338 |
| prospective clinical study | #339 |
| noacs warfarin | #339 |
| placebo trials | #339 |
| antithrombotic effects | #340 |
| patients 12 | #340 |
| 024 | #340 |
| activatable | #341 |
| coagulation markers | #341 |
| 217 | #341 |
| knee arthroscopy | #342 |
| noac patients | #342 |
| pretest | #344 |
| patients covid19 infection | #344 |
| antithrombotic strategies | #345 |
| rfviia | #345 |
| splanchnic vein thrombosis | #345 |
| vte prevention | #345 |
| embolisms | #346 |
| diagnosis vte | #346 |
| activated protein resistance | #347 |
| 073 | #347 |
| patients thrombosis | #347 |
| cochrane central | #348 |
| 044 | #348 |
| chads2 | #349 |
| 2575 | #349 |
| bsf | #349 |
| tafia | #350 |
| trousseau | #350 |
| brain predictive | #350 |
| randomized studies | #350 |
| versus warfarin | #351 |
| factor viii | #351 |
| 013 | #351 |
| factor activation | #352 |
| anticoagulants noacs | #352 |
| dermatan sulphate | #352 |
| selection bias | #352 |
| 1590 | #353 |
| oral anticoagulant therapy | #353 |
| vein | #353 |
| 5075 | #353 |
| relative efficacy | #353 |
| international normalized ratio | #354 |
| aged pulmonary | #354 |
| patients gp | #355 |
| studies diagnostic accuracy | #355 |
| protein deficiency | #356 |
| tests prospective studies | #357 |
| intestinal microbiome | #357 |
| categorised | #357 |
| post hoc | #357 |
| 127 patients | #358 |
| sucra | #360 |
| pilots | #360 |
| intermittent claudication | #361 |
| treatment risk | #362 |
| consensus agreement | #362 |
| anticoagulation patients | #364 |
| conventional therapy | #365 |
| humans risk | #365 |
| bleeding rate | #366 |
| topic female | #366 |
| prediction models | #367 |
| time recurrence | #368 |
| patients 3 | #368 |
| infrainguinal | #368 |
| thrombin inhibitor | #369 |
| patients acl reconstruction | #370 |
| 6week | #370 |
| influenza infection | #370 |
| endotoxin infusion | #371 |
| venous stasis | #371 |
| 055 | #372 |
| 803 | #372 |
| recombinant activated | #373 |
| aprotinin blood | #373 |
| clinical suspicion | #373 |
| knee surgery | #373 |
| patients svt | #373 |
| patients scores | #374 |
| human cytomegalovirus infection | #374 |
| helical computed tomography | #374 |
| subcutaneous | #375 |
| hmb | #375 |
| lyg | #377 |
| subclinical hyperthyroidism | #378 |
| contraceptives oral | #380 |
| stroke venous | #380 |
| tafi | #381 |
| ethinyloestradiol | #381 |
| antitnf | #382 |
| prefilter | #383 |
| reassessed | #384 |
| thromboembolic complications | #384 |
| multivariate regression analysis | #384 |
| standardized questionnaire | #384 |
| 0·8 | #384 |
| alpha2m | #385 |
| systemic activation | #385 |
| bleeding events | #386 |
| surrogate outcome | #386 |
| conference proceedings | #386 |
| sensitivity npv | #387 |
| cumulative incidences | #387 |
| antithrombins | #387 |
| major orthopedic | #388 |
| delegates | #388 |
| systemic embolism | #389 |
| referred | #389 |
| 880 | #389 |
| safety rivaroxaban | #389 |
| apixaban warfarin | #390 |
| vitt | #390 |
| tinzaparin | #390 |
| postop | #391 |
| abi | #391 |
| increased bleeding | #391 |
| drug prescription | #391 |
| comparison patients | #391 |
| biosis | #391 |
| time presentation | #392 |
| patients chest | #392 |
| topic female humans | #392 |
| factors thrombosis | #393 |
| kappa values | #393 |
| injections intravenous | #394 |
| clinical score | #394 |
| background patients | #394 |
| pulmonary emboli | #394 |
| 007 | #395 |
| popliteal | #396 |
| bleeding event | #396 |
| 95 12 | #396 |
| hirudins humans | #397 |
| 665 | #397 |
| factors factor | #397 |
| embolic events | #397 |
| replacement surgery | #397 |
| risk score patients | #399 |
| echography | #400 |
| risk factors asthma | #400 |
| patients risk | #400 |
| heparin induced | #400 |
| hemostatic parameters | #401 |
| fibrinolytic agents | #402 |
| dabigatran | #403 |
| increased risk vte | #403 |
| controversy | #403 |
| massive pulmonary embolism | #405 |
| thrombolytic agents | #406 |
| 2215 | #406 |
| 075 | #406 |
| treatment patient | #406 |
| oral anticoagulant | #408 |
| factor levels | #408 |
| biologic effects | #410 |
| patients assigned | #411 |
| safety combination | #411 |
| noacs patients | #411 |
| fviii levels | #411 |
| 20 microg | #412 |
| major risk factor | #412 |
| transfusion patients | #412 |
| euthyroidism | #414 |
| maastricht | #414 |
| coagulation patients | #414 |
| xii | #415 |
| aged odds | #415 |
| hypocortisolism | #415 |
| deserve | #416 |
| dose heparin | #416 |
| pai1 levels | #416 |
| intravascular coagulation | #416 |
| comparable | #417 |
| data risk | #417 |
| 95 10 | #417 |
| carotid femoral | #418 |
| 95 | #418 |
| pretest probability | #418 |
| 269 | #419 |
| risk factors thrombosis | #419 |
| dermatan | #419 |
| ototoxicity | #420 |
| xia | #420 |
| fibrillation risk | #421 |
| 2850 | #422 |
| fibrillation clinical | #422 |
| tests radiography | #422 |
| 1989 | #422 |
| fibrinolysin | #423 |
| subanalysis | #424 |
| fviia | #424 |
| prevalence patients | #425 |
| randomised double | #426 |
| adjunct | #426 |
| cancer cohort | #426 |
| fii | #426 |
| activated factor | #427 |
| consecutive | #427 |
| plg | #428 |
| excessive bleeding | #428 |
| daily practice | #428 |
| conferences | #428 |
| daily clinical practice | #429 |
| idiopathic myelofibrosis | #429 |
| patients testing | #429 |
| undergoing elective | #429 |
| prolactin levels | #429 |
| 1904 | #430 |
| heparinoids | #431 |
| rule | #431 |
| bleeding complications | #431 |
| 04 | #432 |
| outpatients | #433 |
| incidence length | #433 |
| patients systematic review | #434 |
| ncb | #434 |
| firstdegree relatives patients | #436 |
| blood cultures | #436 |
| 059 | #437 |
| bolus injection | #437 |
| women compared | #439 |
| composite point | #439 |
| prostatic cancer | #439 |
| proven | #439 |
| dose adjustment | #439 |
| highrisk populations | #441 |
| concomitant medications | #441 |
| rate vte | #442 |
| 074 | #442 |
| standard therapies | #444 |
| –control study | #444 |
| prespecified | #445 |
| febrile patients | #446 |
| patients atrial fibrillation | #446 |
| female fibrinolytic | #447 |
| utrecht | #449 |
| 58 | #449 |
| hellp | #449 |
| patients parenteral nutrition | #449 |
| 3 12 months | #450 |
| prevalence distribution | #450 |
| stigmatisation | #451 |
| category | #451 |
| pipecolic | #452 |
| noninvasive tests | #453 |
| fatal disease | #453 |
| aspirin risk | #453 |
| thrombin generation | #453 |
| factor xii | #454 |
| portal blood | #454 |
| 30 40 | #454 |
| placebo day | #454 |
| 12week | #455 |
| microthrombi | #455 |
| 026 | #455 |
| fviii vwf | #456 |
| dichotomized | #456 |
| squibb | #457 |
| dicumarol | #457 |
| onwards | #457 |
| anti levels | #458 |
| iii complexes | #458 |
| hazard ratio 95 | #458 |
| plasma lipoprotein | #460 |
| svt | #460 |
| recommend | #460 |
| gastrointestinal cancer | #461 |
| factor fxa | #461 |
| hip arthroplasty replacement | #462 |
| expert consensus document | #462 |
| curve biomarkers | #462 |
| guidelines patients | #463 |
| haemolysis | #463 |
| studies ultrasonography | #464 |
| gp iib | #464 |
| patients values | #464 |
| month follow | #465 |
| diabetes stroke | #466 |
| cancerassociated thrombosis | #466 |
| accuracy detection | #467 |
| thrombin formation | #467 |
| prophylaxis | #468 |
| patients nsaids | #468 |
| intimamedia thickness | #468 |
| eligible studies | #469 |
| teaching hospitals | #469 |
| bmi≥30 | #469 |
| test probability | #470 |
| 077 | #470 |
| inr patients | #470 |
| roc analysis | #470 |
| hemihepatectomy | #470 |
| placebo recipients | #471 |
| hypercoagulability | #472 |
| prophylactic anticoagulation | #472 |
| case control study | #472 |
| cardiovascular risk assessment | #473 |
| thrombophilia testing | #474 |
| heterozygote humans | #475 |
| intermittent pneumatic | #475 |
| 15 95 | #475 |
| plethysmograph | #475 |
| endotoxemia | #475 |
| patients heparin | #475 |
| atria | #477 |
| patients score | #479 |
| haemophiliacs | #479 |
| 08 | #479 |
| versus standard | #480 |
| thrombosis cvt | #481 |
| acutely | #481 |
| hit patients | #481 |
| 1162 | #482 |
| advisory | #482 |
| postoperative blood | #482 |
| transportability | #482 |
| thrombin inhibitors | #483 |
| events mortality | #484 |
| patients hematologic malignancies | #485 |
| diagnostic efficacy | #485 |
| awaited | #486 |
| secondary prophylaxis | #487 |
| composite scores | #487 |
| travel | #488 |
| silent | #488 |
| activity patients | #489 |
| 98 | #490 |
| blinded | #491 |
| new therapy | #493 |
| p00007 | #493 |
| treatment period | #493 |
| residual risk | #493 |
| hemophilic | #493 |
| pan troglodytes | #493 |
| vcf | #494 |
| activated protein | #495 |
| dose oral | #496 |
| favour | #496 |
| replacement hip arthroplasty | #496 |
| heterozygote | #496 |
| topic risk factors | #497 |
| 271 | #497 |
| willebrand disease | #498 |
| risk factors stroke | #498 |
| discriminative ability | #498 |
| blockages | #498 |
| hip knee | #501 |
| nri | #502 |
| ptp | #502 |
| subcategories | #503 |
| deficiencies | #503 |
| ft4 tsh | #503 |
| rapid decrease | #504 |
| nondiagnostic | #505 |
| patients referred | #505 |
| complications pulmonary | #505 |
| 1107 | #505 |
| net clinical | #506 |
| 310 | #506 |
| nonionic | #507 |
| oftentimes | #507 |
| day surgery | #507 |
| inhibitors rivaroxaban | #508 |
| guidelines diagnosis | #509 |
| 13 95 | #509 |
| coagulation tests | #509 |
| contraceptives | #509 |
| aminocaproates | #509 |
| angiography patients | #510 |
| degradation products | #510 |
| new oral anticoagulants | #510 |
| thrombosis animals | #510 |
| viii fviii | #511 |
| 019 | #512 |
| epiphenomenon | #512 |
| serial | #513 |
| interim analysis | #514 |
| 056 | #514 |
| highintensity | #514 |
| daycare | #515 |
| safety | #516 |
| crcl | #517 |
| thrombotic diseases | #518 |
| thrombophilia thrombosis | #518 |
| bleeding outcomes | #518 |
| protein antithrombin | #518 |
| sensitivity diagnosis | #518 |
| groups treatment | #519 |
| treatment cancer patients | #519 |
| study sensitivity | #520 |
| 1599 | #521 |
| 8090 | #521 |
| duration intensity | #521 |
| warfarin therapy | #524 |
| fixed doses | #525 |
| general practitioner | #525 |
| 062 | #527 |
| cindices | #528 |
| cancer age | #528 |
| 051 | #529 |
| 378 | #529 |
| convincing | #529 |
| 923 | #529 |
| health female | #530 |
| fatal | #530 |
| betaalanine | #531 |
| medically patients | #531 |
| thrombosis hemostasis | #531 |
| humans postoperative | #531 |
| thrombosis risk | #532 |
| 068 | #532 |
| intensive units icu | #532 |
| ≥50 years | #532 |
| therapy cancer | #534 |
| factor thrombin | #534 |
| 730 | #536 |
| factor pathway | #537 |
| humans neoplasms | #538 |
| patients idiopathic | #538 |
| 449 | #538 |
| concise | #539 |
| ddavp | #539 |
| cbo | #539 |
| comprehensive search | #539 |
| diagnostic accuracy studies | #540 |
| diagnosis acute | #540 |
| clinical review | #540 |
| patients eligible | #543 |
| 234 | #543 |
| vascular obstruction | #543 |
| bleeding episodes | #543 |
| conventional treatment | #543 |
| thrombotic risk | #543 |
| pad abi | #544 |
| jak2 mutation | #544 |
| coagulative | #544 |
| 00 | #544 |
| hellp syndrome | #545 |
| perc | #545 |
| v617f | #545 |
| prospective cohort study | #545 |
| association statin | #546 |
| screening strategies | #546 |
| bureau | #547 |
| prothrombin complex | #547 |
| primary | #548 |
| adequate | #549 |
| 95 difference | #549 |
| overt | #549 |
| 1103 | #550 |
| conduction anesthesia | #550 |
| percent patients | #550 |
| reviewers | #550 |
| cancer type | #550 |
| platelet inhibitors | #550 |
| amsterdam | #552 |
| management bleeding | #552 |
| 500 patients | #552 |
| studies sensitivity | #552 |
| careful | #552 |
| day patients | #552 |
| femoral arteries | #553 |
| general population patients | #554 |
| ttr | #556 |
| humans infusions | #557 |
| 66 patients | #558 |
| factor vii | #558 |
| vivo treatment | #558 |
| bleeding time | #559 |
| orthopedic surgery | #559 |
| limulus | #561 |
| female humans tests | #563 |
| risk development | #563 |
| board directors | #563 |
| patients transfusion | #563 |
| appears | #564 |
| anamnesis | #564 |
| hip replacement | #564 |
| increasing risk | #565 |
| hyperfibrinolysis | #565 |
| cardiac troponins | #566 |
| solid tumours | #566 |
| withholding | #566 |
| n46 | #568 |
| patients 2 years | #568 |
| roc curves | #568 |
| alpha1antitrypsin | #571 |
| levothyroxine | #571 |
| aggravation | #572 |
| ctnt | #573 |
| cutoff point | #574 |
| menstrual bleeding | #574 |
| revascularization procedures | #574 |
| subcutaneously | #575 |
| women proportion | #575 |
| major bleedings | #575 |
| progression cancer | #577 |
| endothelial barrier | #578 |
| patients vka | #578 |
| pharma | #579 |
| thiophenes | #579 |
| endotoxin | #579 |
| diagnostic tools | #580 |
| 99 | #580 |
| notice | #580 |
| cancer thrombosis | #581 |
| subgroups patients | #583 |
| unselected patients | #584 |
| dummy | #584 |
| coagulation disorders | #585 |
| 094 | #585 |
| chondroitin sulfates | #586 |
| feasibility safety | #588 |
| major orthopedic surgery | #588 |
| helminth proteins | #589 |
| beta alanine | #590 |
| thrombophilias | #590 |
| healthy human | #590 |
| malignancy | #590 |
| reversal agents | #590 |
| conventional management | #592 |
| doppler ultrasound | #592 |
| massive pulmonary | #592 |
| bmi30 | #594 |
| factor fv | #595 |
| ldf | #597 |
| patency rates | #597 |
| severe bleeding | #597 |
| replacement knee | #597 |
| major hemorrhage | #597 |
| infusions intravenous | #598 |
| analysis topic | #599 |
| tests sensitivity | #600 |
| loss surgical | #600 |
| 046 | #601 |
| association patients | #602 |
| vwd | #603 |
| clinical characteristics patients | #604 |
| events occurred | #604 |
| comorbid conditions | #604 |
| diagnostic studies | #606 |
| 0·3 | #607 |
| activated coagulation | #607 |
| initial increase | #607 |
| patients antibodies | #607 |
| treatment acute | #608 |
| arbitrage | #609 |
| pfizer | #609 |
| tissue factor | #609 |
| patients death | #610 |
| airline | #610 |
| benefit risk | #610 |
| 100 years | #610 |
| clinical evaluation | #611 |
| ultrasonography | #613 |
| coagulation inflammation | #614 |
| leg | #615 |
| reluctant | #615 |
| patients bariatric surgery | #615 |
| complications risk | #616 |
| arterial disease | #617 |
| treatment rivaroxaban | #617 |
| occurred | #618 |
| stroke atrial fibrillation | #618 |
| 467 | #618 |
| compared placebo | #620 |
| fh patients | #620 |
| advisory committees | #621 |
| patients elevated | #621 |
| 1002 | #622 |
| thrombocytopenia hit | #623 |
| thyrotoxic | #623 |
| sgs | #623 |
| peptide bnp | #625 |
| cochrane central register | #625 |
| stopped | #626 |
| topic practice guidelines | #626 |
| stroke warfarin | #627 |
| 66 | #628 |
| warfarin risk | #628 |
| 5000 | #628 |
| women risk factors | #628 |
| referral patients | #629 |
| physical training | #629 |
| human subjects | #629 |
| diagnostic algorithms | #629 |
| sanofi | #630 |
| absolute | #630 |
| atiii | #632 |
| risk treatment | #633 |
| screening strategy | #634 |
| outweigh | #635 |
| uneventful | #635 |
| pentoxifylline | #637 |
| travelling | #638 |
| 14 95 | #640 |
| 95 allcause mortality | #640 |
| proceedings | #641 |
| study quality | #641 |
| predictive performance | #642 |
| 3050 | #642 |
| threatening bleeding | #643 |
| neutrophilia | #643 |
| primary outcome measure | #647 |
| association mortality | #647 |
| necessitating | #648 |
| statin treatment | #648 |
| studies efficacy | #648 |
| 036 | #651 |
| thrombolysis patients | #651 |
| fixed | #651 |
| organisations | #652 |
| troglodytes | #652 |
| hemorrhagic stroke | #653 |
| fxa | #653 |
| 127 | #655 |
| patients review | #657 |
| 69 | #659 |
| coronary stent implantation | #659 |
| bleeding death | #659 |
| haematoma | #660 |
| tertiles | #661 |
| physical examination | #661 |
| coagulation proteins | #661 |
| clinical presentations | #662 |
| haemophilia | #662 |
| 95 studies | #663 |
| 1028 | #663 |
| long term treatment | #664 |
| provoked | #664 |
| sepsis shock | #665 |
| deep | #666 |
| phase iii studies | #666 |
| patients completed | #667 |
| presence patients | #667 |
| guideline adherence | #667 |
| onethird | #667 |
| male medical | #668 |
| 8 wk | #669 |
| 1110 | #671 |
| phenprocoumon | #672 |
| patients cteph | #673 |
| elevated plasma | #673 |
| hospitalization hf | #674 |
| managing | #674 |
| inhibitor 1 | #675 |
| il6 levels | #675 |
| clotting factors | #675 |
| highincome countries | #676 |
| prothrombotic | #676 |
| asymptomatic subjects | #677 |
| favourably | #678 |
| jugular | #679 |
| pulmonary endarterectomy | #681 |
| medicine humans | #681 |
| suspicion | #682 |
| conclude | #687 |
| apolipoproteina | #688 |
| efficacy safety | #690 |
| ambulatory patients | #692 |
| patients bleeding | #692 |
| myocardial infarctions | #693 |
| graduated | #693 |
| activator pa | #693 |
| precise mechanisms | #694 |
| composite outcome | #694 |
| intracranial bleeding | #694 |
| administer | #694 |
| 1718 | #695 |
| stroke prevention patients | #696 |
| moyamoya | #696 |
| combined oral contraceptives | #696 |
| participant data | #698 |
| difference 95 | #698 |
| ratio male | #698 |
| episode | #700 |
| compression devices | #700 |
| prothrombin gene | #702 |
| therapeutic management | #702 |
| diagnostic errors | #702 |
| veins venous | #703 |
| patients confirmed | #703 |
| surgery risk | #703 |
| willebrand | #704 |
| data incidence | #706 |
| subclinical hypothyroidism | #708 |
| clinical expression | #709 |
| directors | #709 |
| starters | #711 |
| 048 | #712 |
| gynaecology | #712 |
| gastrointestinal bleeding | #712 |
| medical patients | #712 |
| radionuclide imaging | #713 |
| 1098 | #714 |
| rate death | #714 |
| neurosurgical patients | #714 |
| intravenous bolus | #715 |
| rivaroxaban stroke | #716 |
| menstrual period | #716 |
| cancer groups | #717 |
| adequately | #717 |
| solid cancer | #718 |
| falsely | #718 |
| 10 30 | #718 |
| reagent kits | #719 |
| plasminogen | #719 |
| pulmonary medicine | #720 |
| pyrazoles pyridines | #721 |
| nordisk | #721 |
| clinical judgment | #721 |
| accp | #721 |
| s1p1 | #722 |
| 95 hazard ratio | #724 |
| abnormal | #726 |
| follow period | #726 |
| gentamicins | #727 |
| 59 patients | #727 |
| orthopaedic surgery | #728 |
| diagnostic therapeutic | #728 |
| diagnostic tests | #730 |
| gentamicin | #732 |
| leeches | #732 |
| tumor necrosis factor | #733 |
| oral contraception | #733 |
| relative risk 95 | #734 |
| disease pad | #735 |
| hull | #735 |
| patients levels | #735 |
| tests retrospective studies | #736 |
| atrial fibrillation risk | #736 |
| clinical prediction rule | #736 |
| 6 12 | #739 |
| post hoc analysis | #739 |
| anti tnf | #740 |
| evaluable patients | #741 |
| unclear | #742 |
| early pregnancy loss | #742 |
| 040 | #742 |
| topic predictive | #743 |
| illness time factors | #744 |
| betathromboglobulin | #744 |
| molecular weight | #744 |
| etp | #746 |
| patients 50 years | #746 |
| antithrombin activity | #746 |
| 285 | #746 |
| leukocyte activation | #748 |
| thrombolytic therapy | #749 |
| hospitalization heart failure | #750 |
| indication | #752 |
| fibrin formation | #754 |
| advisable | #754 |
| primary patients | #755 |
| pneumatic compression | #756 |
| 95 risk factors | #756 |
| hf risk | #756 |
| answer | #756 |
| 95 combination | #756 |
| venovenous | #757 |
| 1·7 | #758 |
| loe | #759 |
| 85 | #759 |
| inflammation coagulation | #760 |
| patients peripheral | #761 |
| proportion women | #763 |
| 435 | #763 |
| start treatment | #764 |
| cprs | #764 |
| hip surgery | #765 |
| 689 | #767 |
| aspirin clopidogrel | #767 |
| risk pregnancy | #767 |
| 732 | #768 |
| method drug | #769 |
| relevant | #770 |
| 566 | #770 |
| groups patients | #770 |
| baseline values | #772 |
| graft patency | #772 |
| patients criteria | #773 |
| bmi patients | #774 |
| subcutaneous injections | #774 |
| 1·5 | #776 |
| 992 | #777 |
| dose warfarin | #778 |
| study groups | #778 |
| patients 65 years | #778 |
| dose intravenous | #778 |
| miscarriage | #779 |
| 066 | #780 |
| thromboembolism prophylaxis | #780 |
| patients hyperthyroidism | #780 |
| plasmin generation | #780 |
| age ≥ | #782 |
| onefifth | #785 |
| factor ixa | #785 |
| abnormalities patients | #786 |
| polypharmacy | #787 |
| topic disease models | #787 |
| cteph | #787 |
| 100 personyears | #787 |
| general practitioners | #787 |
| preferable | #788 |
| secondary outcome | #791 |
| mechanical heart | #793 |
| recombinant tissue | #793 |
| inactivators | #795 |
| 047 | #795 |
| risk factors risk | #795 |
| patient years | #796 |
| patency | #796 |
| eligible | #797 |
| studies prevalence | #797 |
| netherlands | #797 |
| femoropopliteal | #798 |
| lupus anticoagulant | #798 |
| estrogen therapy | #799 |
| theme | #799 |
| patients lower | #799 |
| hemophilia patients | #800 |
| willebrand factor | #802 |
| subclinical | #804 |
| randomized patients | #804 |
| anticoagulant agents | #805 |
| microvesicles | #805 |
| adverse outcomes patients | #806 |
| fibrillation blood | #806 |
| stroke risk factors | #807 |
| ventricular dysfunction | #808 |
| efficacy patients | #809 |
| hypertension cteph | #809 |
| activator inhibitor1 | #810 |
| 069 | #811 |
| model patients | #813 |
| primary aim | #814 |
| factor vwf | #816 |
| flights | #816 |
| 0·4 | #818 |
| irrespective | #820 |
| health predictive | #820 |
| vehicle control | #820 |
| abruptio | #821 |
| neuroradiologist | #822 |
| prevention patients | #823 |
| reduction mortality | #823 |
| single administration | #824 |
| coc | #824 |
| risk benefit | #825 |
| study incidence | #827 |
| gp | #828 |
| cardioembolic stroke | #828 |
| patients anticoagulants | #830 |
| cava filters | #832 |
| antithrombotic treatment | #833 |
| 93 | #833 |
| myers | #833 |
| abortion habitual | #835 |
| plough | #836 |
| oral adult | #836 |
| noac | #837 |
| versus placebo | #837 |
| 87 | #838 |
| 057 | #839 |
| genetic defect | #841 |
| risk scores | #844 |
| 49 | #846 |
| antithrombotic therapy | #846 |
| multidetector row | #847 |
| 072 | #847 |
| advise | #848 |
| recurrence risk | #849 |
| caesarean | #850 |
| patients diagnosis | #850 |
| area roc curve | #852 |
| pre‐eclampsia | #853 |
| 30 patients | #853 |
| reference method | #853 |
| advanced prostate | #854 |
| fibrin | #855 |
| clopidogrel aspirin | #855 |
| patients mutation | #859 |
| ultrafiltrate | #860 |
| dutch population | #861 |
| microg | #862 |
| cardiometabolic disease | #863 |
| 090 | #865 |
| placebo study | #866 |
| diagnostic methods | #868 |
| 1046 | #869 |
| pyridones | #870 |
| 6 month | #870 |
| longterm clinical outcomes | #872 |
| individual participant | #872 |
| favoring | #873 |
| tasman | #873 |
| thromboembolic pulmonary | #874 |
| imaging reproducibility | #874 |
| targeted inhibition | #874 |
| plasminogen activation | #875 |
| titles | #875 |
| n15 | #876 |
| cha2ds2 | #877 |
| dabigatran rivaroxaban | #878 |
| risk thromboembolic | #878 |
| 57 | #879 |
| anticoagulants atrial | #879 |
| oral | #881 |
| angiograms | #882 |
| control trial | #883 |
| 92 | #884 |
| imaging tests | #885 |
| prostate turp | #888 |
| handbook | #890 |
| 084 | #894 |
| domiciliary | #894 |
| male mexico | #894 |
| loading dose | #896 |
| p011 | #896 |
| repeatedly | #897 |
| uln | #901 |
| indefinite | #902 |
| bleedings | #904 |
| vkorc1 | #905 |
| wml | #906 |
| 064 | #908 |
| factor activity | #908 |
| subcutaneous administration | #909 |
| patients clinical trials | #911 |
| documented | #911 |
| haemostatic | #912 |
| initially | #912 |
| impedance | #913 |
| specificity sensitivity | #914 |
| haemodialysis patients | #916 |
| combined approach | #916 |
| 317 | #917 |
| 022 | #918 |
| thromboembolic events | #918 |
| chronic thromboembolic | #919 |
| randomeffects model | #920 |
| standard patients | #920 |
| antagonist oral | #920 |
| loss patients | #921 |
| ultrasound examination | #921 |
| optimal dose | #921 |
| practise | #923 |
| estimate male | #923 |
| study medication | #925 |
| multifactorial disease | #925 |
| total hip | #926 |
| 902 | #928 |
| safer | #928 |
| 004 | #929 |
| recurrent events | #930 |
| fxi | #931 |
| wording | #934 |
| treatment placebo | #934 |
| 84 | #936 |
| publication clinical trials | #937 |
| subgroup patients | #938 |
| 60 patients | #938 |
| rrr | #940 |
| families patients | #941 |
| teaching hospital | #943 |
| women preeclampsia | #944 |
| stroke atrial | #944 |
| echocardiographically | #944 |
| emboli | #945 |
| predictive values | #946 |
| ssc | #946 |
| anticoagulation treatment | #947 |
| knee replacement | #948 |
| diagnostic | #948 |
| extensive disease | #948 |
| previous diagnosis | #951 |
| adjudication | #954 |
| cancer humans | #956 |
| dic | #956 |
| registro | #956 |
| network metaanalysis | #956 |
| venous insufficiency | #957 |
| reassuring | #957 |
| day1 | #958 |
| efficacy | #958 |
| combined oral | #961 |
| retropubic | #961 |
| guidelines recommend | #962 |
| 3 months | #963 |
| blood product | #964 |
| travellers | #965 |
| inhibitor1 | #966 |
| reference lists | #966 |
| peaking | #969 |
| greater risk | #970 |
| allogeneic blood | #971 |
| antiplatelet | #973 |
| prevalence characteristics | #973 |
| hoc | #973 |
| risk allcause mortality | #973 |
| segmental | #974 |
| patients anticoagulation | #975 |
| female fibrinogen | #976 |
| vascular humans | #976 |
| fvii | #978 |
| false negative | #979 |
| onset aged aged | #980 |
| 50 100 | #980 |
| 071 | #980 |
| early gestation | #984 |
| 426 | #986 |
| randomised trials | #987 |
| prophylactic treatment | #987 |
| patients safety | #988 |
| vascular patency | #989 |
| study treatment | #990 |
| missed | #991 |
| rises | #991 |
| seminar | #992 |
| academic medical center | #992 |
| counteracted | #993 |
| normal lung | #993 |
| treatment bleeding | #994 |
| aged | #999 |
| 226 | #999 |
| justification | #1000 |
| thromboembolic risk | #1000 |
| lower extremity | #1000 |
| tissue type | #1001 |
| rivaroxaban apixaban | #1002 |
| parenteral administration | #1002 |
| eclamptic | #1003 |
| extended | #1005 |
| interleukin 6 | #1005 |
| hyperprolactinaemia | #1005 |
| pyridines | #1006 |
| orthosis | #1007 |
| easier | #1007 |
| 50 patients | #1007 |
| valsalva maneuver | #1009 |
| venous catheter | #1011 |
| individual participant data | #1012 |
| weighing | #1014 |
| ticlopidine | #1018 |
| pounds | #1018 |
| clotting time | #1019 |
| prostatic carcinoma | #1020 |
| 200 patients | #1022 |
| cha2ds2 vasc | #1023 |
| years risk | #1023 |
| humans randomized | #1024 |
| international prospective | #1024 |
| 076 | #1025 |
| diagnostic challenge | #1026 |
| prothrombin time | #1027 |
| firstdegree relatives | #1030 |
| decision analysis | #1030 |
| ixa | #1031 |
| prolactin | #1032 |
| relatives | #1033 |
| risk hemorrhage | #1033 |
| cardiovascular event | #1033 |
| 052 | #1035 |
| graft occlusion | #1037 |
| male netherlands | #1037 |
| 2 hours | #1039 |
| detect | #1040 |
| 025 | #1041 |
| 3 6 months | #1046 |
| patients severe asthma | #1047 |
| vwf levels | #1047 |
| examiner | #1050 |
| patients massive | #1050 |
| continuation | #1052 |
| patients analysis | #1053 |
| mean±sd | #1054 |
| 221 | #1054 |
| free triiodothyronine | #1056 |
| diseases liver | #1057 |
| 179 | #1060 |
| coagulant | #1060 |
| birth rate | #1060 |
| 610 | #1061 |
| pad | #1061 |
| published literature | #1062 |
| primary data | #1062 |
| false | #1064 |
| 150 | #1065 |
| prekallikrein | #1065 |
| live birth | #1066 |
| 101 | #1066 |
| 00008 | #1066 |
| lysosphingolipid | #1067 |
| cut | #1067 |
| pmol | #1068 |
| 95 increased risk | #1070 |
| register controlled | #1070 |
| observer variation | #1071 |
| specialties | #1072 |
| continued | #1073 |
| laboratory diagnosis | #1074 |
| thorax | #1074 |
| systematic search | #1078 |
| 063 | #1080 |
| advocate | #1080 |
| drawbacks | #1082 |
| f1 | #1087 |
| longterm therapy | #1087 |
| bandages | #1089 |
| stopping | #1095 |
| clarifications | #1095 |
| diagnostic utility | #1096 |
| mandated | #1096 |
| idarucizumab | #1096 |
| 083 | #1099 |
| 1223 | #1099 |
| 62 | #1102 |
| 96 | #1104 |
| fourfold | #1105 |
| blueprint | #1105 |
| clinical protocols | #1107 |
| peptide brain | #1107 |
| pending | #1111 |
| incidence pulmonary | #1112 |
| assigned | #1113 |
| diagnostic approach | #1115 |
| haemodialysis | #1116 |
| bypass grafts | #1116 |
| 252 | #1117 |
| qualified | #1118 |
| sensitivity specificity | #1119 |
| critical appraisal | #1120 |
| randomized controlled trials | #1122 |
| resistance factor | #1123 |
| probands | #1123 |
| new developments | #1124 |
| advised | #1125 |
| new perspectives | #1126 |
| 445 | #1126 |
| cip | #1127 |
| heparininduced thrombocytopenia | #1127 |
| patients pad | #1128 |
| discretion | #1132 |
| judged | #1132 |
| statistic | #1133 |
| ≤10 | #1133 |
| 95 confidence interval | #1134 |
| pulse rate | #1135 |
| gram negative | #1137 |
| 1043 | #1139 |
| disseminated | #1140 |
| superior efficacy | #1141 |
| 635 | #1141 |
| 86 | #1143 |
| 734 | #1145 |
| 844 | #1147 |
| roc curve | #1150 |
| refusal | #1150 |
| medical records | #1151 |
| medline | #1151 |
| embolectomy | #1153 |
| longterm complications | #1154 |
| risk recurrence | #1155 |
| blood loss | #1156 |
| patients influenza | #1156 |
| anticoagulation therapy | #1156 |
| prophylaxis treatment | #1157 |
| 3040 | #1158 |
| patients increased | #1159 |
| extension study | #1161 |
| cvc | #1162 |
| bristol | #1163 |
| published guidelines | #1163 |
| viii | #1164 |
| hyperhomocysteinemia | #1164 |
| stable angina | #1164 |
| safety concerns | #1164 |
| intermittent | #1164 |
| age 65 years | #1165 |
| thromboembolism risk | #1165 |
| angiogram | #1167 |
| glucocorticoid treatment | #1172 |
| perioperative bleeding | #1172 |
| atherosclerotic disease | #1172 |
| crossover design | #1172 |
| practice guideline | #1173 |
| occlusive diseases | #1173 |
| 5 years patients | #1176 |
| macroglobulin | #1176 |
| findings patients | #1178 |
| analysis studies | #1178 |
| 79 | #1179 |
| concealed | #1181 |
| conceive | #1181 |
| unaware | #1182 |
| patients obesity | #1182 |
| hospitalized patients | #1182 |
| combined therapy | #1186 |
| conclusive | #1186 |
| degree relatives | #1189 |
| occult | #1189 |
| adult analysis | #1191 |
| cus | #1194 |
| administration oral | #1195 |
| 21 patients | #1197 |
| mandate | #1199 |
| cardiotonic agents | #1199 |
| international society | #1199 |
| hypercortisolism | #1200 |
| 83 | #1203 |
| categorized | #1204 |
| 015 | #1204 |
| quantitative trait locus | #1204 |
| increase plasma | #1205 |
| 31 | #1207 |
| biomarkers blood | #1210 |
| 56 patients | #1212 |
| multicenter randomized | #1214 |
| pph | #1214 |
| 103 | #1218 |
| patient treatment | #1221 |
| warranted | #1221 |
| scores patients | #1221 |
| ultrasound screening | #1222 |
| 6months | #1223 |
| 64 patients | #1224 |
| peak levels | #1224 |
| vasc | #1225 |
| 16 patients | #1226 |
| sixfold | #1227 |
| blind | #1227 |
| metabolic syndrome patients | #1228 |
| consensus guidelines | #1228 |
| peptide hydrolases | #1229 |
| radionuclide | #1229 |
| trial background | #1229 |
| 65 patients | #1230 |
| rules | #1232 |
| doubles | #1232 |
| aspirin | #1234 |
| postoperative hemorrhage | #1238 |
| coronary angiography patients | #1238 |
| milliliter | #1238 |
| humans length | #1240 |
| clinical criteria | #1241 |
| patients fh | #1242 |
| vte prophylaxis | #1244 |
| neurohormone | #1245 |
| multinational | #1246 |
| thrombolytic | #1247 |
| knee arthroplasty | #1248 |
| intermediate risk | #1250 |
| subgroups | #1252 |
| ml1 | #1252 |
| matter lesions | #1252 |
| artery pulmonary | #1254 |
| oral vitamin | #1257 |
| search strategy | #1257 |
| extensive | #1257 |
| prospective cohort | #1258 |
| symptomatic patients | #1259 |
| major surgery | #1262 |
| visiting | #1266 |
| troponins | #1266 |
| entity | #1266 |
| macroglobulins | #1267 |
| 172 | #1270 |
| amputations | #1273 |
| intensive patients | #1274 |
| equally | #1274 |
| design study | #1276 |
| antiplatelet agents | #1278 |
| proportionally | #1279 |
| routine screening | #1281 |
| statin users | #1281 |
| 75 years | #1281 |
| factors ultrasonography | #1285 |
| thyroxine | #1287 |
| 050 | #1288 |
| blockers | #1290 |
| dermatan sulfate | #1292 |
| perfusion defects | #1295 |
| janssen | #1295 |
| scan | #1295 |
| predictive | #1297 |
| hemofiltration | #1297 |
| insufficiently | #1298 |
| cardiovascular complications | #1299 |
| low prevalence | #1299 |
| dutch | #1300 |
| prolong | #1302 |
| 61 | #1303 |
| pf4 | #1303 |
| pulmonary circulation | #1304 |
| scores | #1305 |
| 95 mortality | #1307 |
| 1st | #1312 |
| apoa | #1312 |
| risk difference | #1312 |
| cyproterone | #1312 |
| adamts13 activity | #1313 |
| tests severity | #1314 |
| current strategies | #1314 |
| 0·7 | #1314 |
| claudication | #1316 |
| atrial fibrillation | #1316 |
| carotid imt | #1317 |
| international guidelines | #1318 |
| replacement hip | #1320 |
| study time | #1321 |
| coagulation factor | #1322 |
| vienna | #1323 |
| increases risk | #1324 |
| glycoprotein gpiib | #1325 |
| lipoproteina | #1325 |
| patients coronavirus disease | #1326 |
| beneficial | #1329 |
| vascular diseases | #1329 |
| antibodies monoclonal antibodies | #1329 |
| thyroid disorders | #1330 |
| low moderate | #1330 |
| plasminogen activators | #1330 |
| coagulation cascade | #1331 |
| 77 | #1331 |
| 6 months patients | #1331 |
| 126 | #1332 |
| frequent complication | #1333 |
| adjusted age | #1335 |
| transurethral resection | #1336 |
| 91 | #1342 |
| likelihood ratio | #1342 |
| venous catheters | #1342 |
| blood sample | #1343 |
| daily patients | #1344 |
| surgical trauma | #1347 |
| antitrypsin | #1347 |
| patients relatives | #1351 |
| neurosurgery | #1355 |
| arthroplasty patients | #1356 |
| patients stable angina | #1357 |
| allcause mortality 95 | #1359 |
| experimental model | #1359 |
| 15 patients | #1359 |
| vwf | #1363 |
| arsenal | #1363 |
| limb salvage | #1363 |
| vtes | #1365 |
| 95 patients | #1366 |
| operatively | #1367 |
| 12 month | #1369 |
| heart valves | #1370 |
| starting | #1372 |
| ethinyl | #1373 |
| acetylsalicylic | #1375 |
| costeffectiveness analysis | #1376 |
| utmost | #1378 |
| consented | #1382 |
| management patients | #1383 |
| gps | #1384 |
| noninferiority | #1385 |
| dl1 | #1385 |
| 224 | #1385 |
| disorders blood | #1386 |
| ivt | #1389 |
| patients cvd | #1392 |
| substitute | #1394 |
| screening tests | #1399 |
| patients control subjects | #1400 |
| record linkage | #1400 |
| equipoise | #1402 |
| antisense oligonucleotide | #1402 |
| 82 | #1402 |
| mandatory | #1403 |
| clinical challenges | #1404 |
| patients advanced cancer | #1405 |
| 1886 | #1405 |
| pregnancy loss | #1406 |
| obese patients | #1406 |
| categories | #1408 |
| 515 | #1408 |
| 994 | #1409 |
| reflected | #1410 |
| inception | #1411 |
| tranexamic | #1413 |
| adamts13 | #1417 |
| 0·1 | #1418 |
| thrombotic complications | #1419 |
| 3 6 | #1419 |
| 6 weeks | #1419 |
| 7 weeks | #1419 |
| total knee | #1420 |
| 95 0 | #1421 |
| followup data | #1422 |
| university hospitals | #1422 |
| daily | #1424 |
| ≥55 | #1424 |
| 061 | #1424 |
| eightfold | #1425 |
| 080 | #1427 |
| randomised controlled trials | #1427 |
| rgs | #1430 |
| casecontrol study | #1430 |
| outcome pregnancy | #1438 |
| 096 | #1439 |
| imaging radiopharmaceuticals | #1439 |
| principal | #1443 |
| 78 | #1443 |
| 1123 | #1445 |
| drug levels | #1446 |
| outcome studies | #1446 |
| weight bmi | #1446 |
| underreporting | #1451 |
| support systems | #1452 |
| population patients | #1454 |
| confusion | #1454 |
| aged blood | #1455 |
| platelet factor | #1455 |
| dip | #1456 |
| mbe | #1457 |
| conclusions patients | #1459 |
| prospectively | #1460 |
| multicenter studies | #1461 |
| humans | #1463 |
| inaccuracy | #1464 |
| actual | #1466 |
| funded | #1466 |
| avoided | #1468 |
| 0·9 | #1468 |
| heart failure hf | #1469 |
| 26 patients | #1469 |
| groin | #1471 |
| risk factors mortality | #1472 |
| 1215 | #1473 |
| prevalences | #1473 |
| centrally | #1474 |
| probability | #1477 |
| systemic infection | #1477 |
| lowest tertile | #1478 |
| remained | #1480 |
| atherothrombotic | #1481 |
| undetermined | #1482 |
| dysfunction patients | #1483 |
| cushing syndrome | #1485 |
| analysis randomized | #1485 |
| methodologic | #1486 |
| phase iii trials | #1486 |
| general practice | #1491 |
| procoagulant activity | #1495 |
| patients control | #1495 |
| randomly | #1496 |
| 64 | #1498 |
| aged natriuretic | #1499 |
| exposing | #1501 |
| imt | #1507 |
| fracture surgery | #1510 |
| specificity 100 | #1512 |
| odds ratio 95 | #1513 |
| adverse outcome | #1514 |
| growing body | #1514 |
| proximal | #1516 |
| ganz | #1520 |
| pregnancy postpartum | #1520 |
| patients 10 | #1520 |
| subgroup | #1521 |
| factor deficiency | #1522 |
| gsk | #1524 |
| chills | #1526 |
| contraindicated | #1527 |
| thrombotic events | #1527 |
| score | #1529 |
| time study | #1529 |
| oral contraceptive | #1534 |
| mechanical compression | #1536 |
| immobilisation | #1539 |
| comparator | #1540 |
| patients life | #1541 |
| humans neoplasm | #1542 |
| hemostatics humans | #1545 |
| 089 | #1548 |
| tsh levels | #1551 |
| patients severe sepsis | #1552 |
| live births | #1552 |
| 23 | #1554 |
| vascular thrombosis | #1555 |
| fees | #1556 |
| neonatal period | #1558 |
| patients year | #1559 |
| discriminatory | #1562 |
| hypothyroidism | #1563 |
| pfa | #1564 |
| enfermedad | #1564 |
| iii topic | #1565 |
| topic | #1566 |
| treatment prevention | #1566 |
| 95ci | #1568 |
| cushings syndrome | #1568 |
| deficient | #1568 |
| hyperlipoproteinemia type | #1568 |
| aged biomarkers | #1571 |
| 36 | #1575 |
| plasminogen activator | #1575 |
| humans platelet | #1576 |
| 012 | #1577 |
| hyperlipoproteinemia | #1580 |
| risk myocardial infarction | #1584 |
| study entry | #1586 |
| thyroid dysfunction | #1586 |
| cocs | #1586 |
| activation markers | #1586 |
| studies association | #1587 |
| adjusted hazard ratio | #1589 |
| volunteers | #1591 |
| 1·1 | #1594 |
| total mortality | #1594 |
| translates | #1597 |
| placebo | #1598 |
| noncancer | #1598 |
| exclude | #1599 |
| lmw | #1601 |
| figures | #1604 |
| paroxetine | #1606 |
| abdominal surgery | #1607 |
| complement pathway | #1609 |
| curability | #1610 |
| general surgery | #1613 |
| 162 | #1613 |
| ethinylestradiol | #1614 |
| recommending | #1615 |
| prospective cohort studies | #1616 |
| postpartum period | #1616 |
| factors tomography | #1616 |
| positive effects | #1616 |
| tests reproducibility | #1616 |
| perinatal outcome | #1618 |
| 155 | #1618 |
| female hemostasis | #1619 |
| cvd patients | #1619 |
| imaging tomography | #1619 |
| proportion | #1620 |
| 12month followup | #1621 |
| uncertain | #1621 |
| 079 | #1623 |
| competing risk | #1628 |
| isis | #1630 |
| major | #1631 |
| pa patients | #1632 |
| incidentally | #1632 |
| venous disease | #1632 |
| fresh frozen plasma | #1633 |
| clinical patients | #1633 |
| double | #1639 |
| study outcomes | #1639 |
| 029 | #1642 |
| 181 | #1643 |
| stroke prevention | #1644 |
| ctni | #1644 |
| patients hospitalized | #1647 |
| mismatched | #1648 |
| 997 | #1651 |
| dorsiflexion | #1651 |
| 35 years | #1652 |
| ≤4 | #1652 |
| thrombin activity | #1653 |
| studies data | #1653 |
| clotting | #1656 |
| remaining | #1660 |
| plasma concentration | #1661 |
| outcome data | #1663 |
| spiral | #1669 |
| homocysteine levels | #1670 |
| disease adult | #1670 |
| thrombi | #1674 |
| daily dosing | #1676 |
| inpatient treatment | #1676 |
| plasma level | #1677 |
| deficiency | #1677 |
| warfarin dose | #1680 |
| arthroscopy | #1684 |
| steroidal anti | #1686 |
| unreliable | #1686 |
| patients acs | #1687 |
| thrombin | #1690 |
| severe renal | #1694 |
| patients brain metastases | #1695 |
| prospective | #1702 |
| necrosis factor | #1705 |
| highest risk | #1707 |
| cancer screening | #1708 |
| awaiting | #1710 |
| 033 | #1712 |
| yielded | #1712 |
| intravenous | #1715 |
| hemorheology | #1715 |
| hematologic malignancies | #1720 |
| bronchospasm | #1720 |
| mb | #1721 |
| female femoral | #1721 |
| diagnostic evaluation | #1721 |
| cardioembolic | #1722 |
| cumulative incidence | #1723 |
| laser doppler | #1724 |
| conference | #1726 |
| 107 | #1726 |
| derived microparticles | #1729 |
| volunteer | #1730 |
| 021 | #1730 |
| 161 | #1733 |
| percentage patients | #1734 |
| east asian | #1735 |
| clinical scores | #1735 |
| patients icu | #1736 |
| rico | #1737 |
| 500 | #1738 |
| minor | #1739 |
| revised | #1744 |
| 691 | #1745 |
| table | #1745 |
| patients ventricular | #1745 |
| profession | #1746 |
| hyperinsulinaemia | #1747 |
| risk cardiovascular events | #1747 |
| apc | #1749 |
| turp | #1749 |
| homozygosity | #1750 |
| replacement | #1750 |
| pselectin | #1750 |
| 128 | #1752 |
| 133 | #1753 |
| intracranial hemorrhages | #1753 |
| 3 studies | #1755 |
| spontaneous | #1756 |
| arterial occlusive | #1758 |
| patients randomized | #1759 |
| audiometry | #1760 |
| treatment recommendations | #1760 |
| assessor | #1760 |
| current treatment | #1761 |
| primary setting | #1762 |
| long‐term | #1763 |
| human insulin | #1764 |
| fx | #1764 |
| duplicate | #1769 |
| arteriosclerosis | #1770 |
| hemorrhage | #1770 |
| initial management | #1770 |
| 2 6 | #1774 |
| allcause death | #1774 |
| 28 weeks | #1781 |
| hemostasis humans | #1782 |
| trough levels | #1785 |
| infusions | #1787 |
| ethinyl estradiol | #1789 |
| selfmanagement | #1790 |
| clinical consequences | #1790 |
| reid | #1793 |
| microparticle | #1793 |
| cardiac troponin | #1794 |
| vascular surgical | #1794 |
| healthy male volunteers | #1799 |
| 042 | #1800 |
| aggregation inhibitors | #1802 |
| 020 | #1802 |
| retrospective analysis | #1805 |
| hemophilia humans | #1808 |
| unpublished | #1810 |
| 95 specificity | #1812 |
| slc6a4 | #1812 |
| tumor necrosis | #1812 |
| overlapped | #1814 |
| 51 | #1815 |
| 078 | #1818 |
| economic evaluation | #1819 |
| conjoint | #1819 |
| interobserver | #1823 |
| awareness | #1824 |
| screening middle | #1825 |
| preference | #1825 |
| 303 | #1828 |
| placebo 95 | #1832 |
| undergoing coronary | #1834 |
| definite | #1837 |
| compressibility | #1837 |
| kaplanmeier estimate | #1838 |
| cushing | #1838 |
| severe sepsis | #1839 |
| 1 week | #1842 |
| central venous | #1842 |
| workup | #1848 |
| orthopaedic | #1849 |
| hydroxyethyl starch | #1852 |
| explanations | #1852 |
| 160 | #1854 |
| fibrinopeptide | #1862 |
| cancer therapies | #1865 |
| alpha 2 | #1867 |
| gramnegative | #1869 |
| serially | #1870 |
| humans pregnancy | #1874 |
| separately | #1876 |
| oral anticoagulation | #1880 |
| shrs | #1892 |
| diagnostic techniques | #1892 |
| thromboses | #1892 |
| lower incidence | #1893 |
| stable patients | #1895 |
| 067 | #1897 |
| 5 10 | #1897 |
| contraindications | #1900 |
| tnf | #1901 |
| extremity | #1901 |
| diagnostic testing | #1901 |
| clt | #1905 |
| plaster | #1906 |
| hazard ratio | #1906 |
| induced thrombocytopenia | #1906 |
| differential effects | #1907 |
| 95 year | #1909 |
| efficacy treatment | #1910 |
| referral | #1910 |
| random | #1911 |
| plato | #1913 |
| experimental mice mice | #1916 |
| 238 | #1918 |
| randomized | #1919 |
| 793 | #1920 |
| 13 patients | #1920 |
| administration | #1921 |
| pregnancy treatment | #1922 |
| stroke 95 | #1923 |
| 868 | #1923 |
| 55 years | #1924 |
| biotin | #1924 |
| trials patients | #1926 |
| venous pressure | #1926 |
| μg | #1927 |
| intracranial hemorrhage | #1927 |
| coronary syndromes | #1928 |
| 272 | #1929 |
| cardiovascular events patients | #1930 |
| chimpanzee | #1931 |
| adjusted | #1932 |
| glucocorticoid | #1934 |
| nonfatal | #1934 |
| 3months | #1935 |
| relative risks | #1935 |
| acute | #1936 |
| 17 | #1936 |
| thrombolytic treatment | #1937 |
| 27 | #1938 |
| randomized placebo | #1947 |
| femoral vein | #1950 |
| safety effectiveness | #1950 |
| 0·5 | #1952 |
| medical illness | #1954 |
| overtreatment | #1955 |
| prolongation | #1958 |
| intravascular | #1959 |
| major risk | #1960 |
| advanced age | #1961 |
| investigators | #1962 |
| observer | #1962 |
| 1050 | #1965 |
| permanent | #1966 |
| 80 female | #1967 |
| hyperglycaemia | #1970 |
| coronary angioplasty | #1971 |
| 48 hours | #1973 |
| fibrin clot | #1973 |
| surgical blood | #1973 |
| potent inhibitor | #1976 |
| renewed | #1976 |
| topic clinical trials | #1978 |
| hyperaldosteronism | #1981 |
| 771 | #1981 |
| specificity ultrasonography | #1981 |
| computerised | #1982 |
| patients pancreatic | #1985 |
| 1·0 | #1986 |
| treatment cancer | #1986 |
| randomized controlled | #1988 |
| coumarins | #1990 |
| 177 | #1991 |
| 018 | #1992 |
| prospero | #1992 |
| drug drug therapy | #1994 |
| cmax | #1994 |
| computerized | #1995 |
| cvt | #1995 |
| hemorrhage patients | #1996 |
| ors | #1998 |
| 602 | #1999 |
| clinical severity | #2000 |
| 3 months patients | #2000 |
| transient increase | #2000 |
| autopsy | #2000 |
| 53 | #2003 |
| pneumonia patients | #2006 |
| 7 patients | #2006 |
| pih | #2011 |
| mantel | #2013 |
| catheterization central | #2014 |
| angina unstable | #2017 |
| mongrel | #2017 |
| poc | #2019 |
| 225 | #2020 |
| type plasminogen | #2023 |
| pathophysiologic | #2024 |
| 35 | #2025 |
| patients statins | #2026 |
| annual | #2028 |
| 15th | #2031 |
| atheroma | #2032 |
| patients lung | #2033 |
| 097 | #2033 |
| pertechnetate | #2036 |
| costs cost | #2041 |
| medical record | #2041 |
| abstracts | #2042 |
| undergoing major | #2042 |
| questioned | #2043 |
| thrice | #2045 |
| prediction rule | #2045 |
| dichotomous | #2046 |
| normal | #2048 |
| superior vena cava | #2051 |
| quartiles | #2051 |
| inadequately | #2052 |
| 277 | #2053 |
| pregnancy trimester | #2053 |
| controversial | #2055 |
| stent implantation | #2056 |
| adherence guidelines | #2056 |
| hospitalized | #2057 |
| randomized comparison | #2060 |
| outpatient | #2061 |
| interobserver variability | #2062 |
| requested | #2063 |
| varies | #2063 |
| clinical indications | #2064 |
| biological neoplasms | #2064 |
| hemostatics | #2070 |
| national institute | #2074 |
| mcnemar | #2074 |
| 188 | #2074 |
| familial hypercholesterolemia | #2077 |
| unavailable | #2079 |
| searched | #2082 |
| disseminate | #2083 |
| ristocetin | #2086 |
| bypasses | #2087 |
| media thickness | #2087 |
| 03 | #2089 |
| versions | #2091 |
| 114 | #2092 |
| square distribution | #2092 |
| tissue plasminogen | #2093 |
| preformed | #2099 |
| reference range | #2099 |
| 038 | #2100 |
| 59 | #2101 |
| lifetime risk | #2101 |
| desmopressin | #2101 |
| placebos | #2102 |
| concealment | #2104 |
| hospital treatment | #2106 |
| fibrin deposition | #2107 |
| argatroban | #2108 |
| 031 | #2109 |
| substantial | #2109 |
| 1966 | #2109 |
| aged 80 | #2111 |
| debated | #2116 |
| jugular vein | #2117 |
| independently | #2118 |
| unnecessary | #2118 |
| exists | #2119 |
| initial | #2119 |
| development validation | #2120 |
| 11 | #2122 |
| coronary stent | #2122 |
| clinicaltrialsgov | #2122 |
| original | #2125 |
| acl reconstruction | #2125 |
| patients cardiovascular disease | #2127 |
| topic surveys | #2127 |
| controlled | #2129 |
| chose | #2129 |
| current recommendations | #2131 |
| odds ratios | #2132 |
| protamines | #2134 |
| congress | #2134 |
| 190 | #2136 |
| 788 | #2137 |
| hip arthroplasty | #2139 |
| heterozygous | #2141 |
| antagonists | #2142 |
| live | #2145 |
| clot | #2145 |
| bodyweight | #2146 |
| professionals | #2146 |
| pancreatic cancer patients | #2157 |
| committee | #2160 |
| oestrogens | #2160 |
| lowdose aspirin | #2163 |
| academic medical | #2167 |
| drains | #2170 |
| embase | #2171 |
| fibrinogen | #2175 |
| 1998 | #2178 |
| trimesters | #2179 |
| reproductive age | #2182 |
| 674 | #2183 |
| advanced cancer | #2183 |
| giant cell arteritis | #2185 |
| fifty | #2185 |
| 2 × | #2185 |
| patients diagnosed | #2187 |
| 631 | #2188 |
| controlled study | #2192 |
| superficial | #2194 |
| difference incidence | #2198 |
| adjust | #2202 |
| diagnostic performance | #2204 |
| pravastatin | #2205 |
| increased patients | #2205 |
| antagonist | #2206 |
| clinical implications | #2208 |
| lower limbs | #2209 |
| diagnosis differential | #2212 |
| neutrophil elastase | #2212 |
| doubled | #2213 |
| pao2 | #2219 |
| 364 | #2219 |
| insufficient | #2221 |
| comparing | #2222 |
| differential female | #2225 |
| 94 | #2225 |
| lung perfusion | #2226 |
| italian society | #2227 |
| 76 | #2233 |
| takeda | #2236 |
| nationwide cohort study | #2245 |
| clot formation | #2247 |
| congenital heart disease | #2252 |
| hemorrhages | #2253 |
| clots | #2257 |
| hivinfected patients | #2257 |
| kilogram | #2259 |
| aprotinin | #2261 |
| 8000 | #2264 |
| stroke aged | #2265 |
| hyperthyroidism | #2265 |
| 12 | #2266 |
| 6 months | #2267 |
| metaanalysis | #2267 |
| patients developed | #2273 |
| reverses | #2273 |
| arterial | #2274 |
| intrinsic pathway | #2275 |
| famine | #2278 |
| 656 | #2279 |
| ultrasonographic | #2281 |
| setting | #2284 |
| based case | #2284 |
| 14 patients | #2286 |
| ft3 | #2288 |
| case control | #2291 |
| patients heart failure | #2293 |
| aged molecular | #2295 |
| daily dose | #2296 |
| sole | #2298 |
| strategy | #2303 |
| 88 | #2308 |
| 0047 | #2310 |
| normalised | #2312 |
| metaanalysis studies | #2314 |
| tests | #2314 |
| initial therapy | #2316 |
| nephelometry | #2316 |
| obstetrics | #2317 |
| adjustments | #2319 |
| method female | #2324 |
| humans myocardial | #2324 |
| methodological | #2325 |
| 60 | #2327 |
| normalized | #2329 |
| brachial | #2332 |
| gradually | #2335 |
| random sample | #2336 |
| positive predictive | #2337 |
| transfusion requirements | #2340 |
| ultrasonography doppler | #2341 |
| 543 | #2343 |
| lacked | #2344 |
| inhibitor | #2344 |
| prescribe | #2347 |
| illness severity | #2350 |
| 20 weeks | #2351 |
| thr | #2353 |
| prefer | #2354 |
| cancer progression | #2364 |
| 053 | #2371 |
| 118 | #2372 |
| receiving | #2374 |
| risk bias | #2375 |
| 099 | #2375 |
| patients active | #2376 |
| hemostasis | #2377 |
| predictable | #2377 |
| enrolling | #2379 |
| acute coronary syndromes | #2379 |
| 187 | #2381 |
| anticardiolipin | #2382 |
| dosing regimen | #2382 |
| 145 | #2387 |
| scintigraphy | #2389 |
| 140 | #2391 |
| 244 | #2393 |
| complication rate | #2400 |
| 757 | #2401 |
| patients liver cirrhosis | #2401 |
| 086 | #2402 |
| letters | #2405 |
| curable | #2406 |
| protein | #2413 |
| postinjection | #2413 |
| periodicals | #2413 |
| risk estimates | #2414 |
| 22 | #2415 |
| sphingosine1 | #2415 |
| internal medicine | #2424 |
| study drug | #2424 |
| 32 | #2425 |
| guidelines | #2426 |
| sensitivity 100 | #2426 |
| legs | #2430 |
| 002 | #2430 |
| coagulants | #2430 |
| 0048 | #2430 |
| patients adult | #2431 |
| ci95 | #2432 |
| normal range | #2433 |
| prolonging | #2434 |
| ptca | #2434 |
| aminoglycoside | #2435 |
| cindex | #2437 |
| 030 | #2438 |
| cumulative | #2439 |
| 166 | #2441 |
| endogenous | #2445 |
| microplate | #2446 |
| 719 | #2448 |
| turbidimetry | #2448 |
| administration schedule | #2449 |
| transmigration | #2453 |
| homocysteine | #2454 |
| anticoagulant activity | #2455 |
| ≥75 | #2459 |
| extensively | #2463 |
| prognostic patients | #2464 |
| watchful | #2464 |
| potential benefits | #2466 |
| therapy acute | #2468 |
| nephrotoxic | #2468 |
| 477 | #2469 |
| comprised | #2469 |
| pharmacologic | #2473 |
| consisted | #2474 |
| cancer population | #2476 |
| current review | #2476 |
| 05 | #2481 |
| 50 | #2482 |
| pathway inhibitor | #2485 |
| 648 | #2485 |
| treatment efficacy | #2489 |
| 1015 | #2490 |
| 829 | #2490 |
| duration | #2493 |
| chest | #2493 |
| 25 | #2495 |
| 616 | #2503 |
| illness tomography | #2503 |
| bnp | #2504 |
| subsequent pregnancies | #2505 |
| 522 | #2507 |
| movie | #2508 |
| recurrence retrospective | #2509 |
| unstable angina | #2510 |
| presentation | #2512 |
| superinfection | #2513 |
| comprising | #2515 |
| 479 | #2516 |
| drug female humans | #2516 |
| sulfates | #2519 |
| 750 | #2520 |
| neutrophil extracellular traps | #2521 |
| 463 | #2521 |
| 152 | #2523 |
| accurate diagnosis | #2523 |
| treatment arms | #2524 |
| scientific | #2529 |
| establish | #2534 |
| 164 | #2537 |
| 874 | #2537 |
| 0046 | #2537 |
| nematode | #2540 |
| 67 | #2542 |
| pyrazoles | #2547 |
| arrive | #2549 |
| decided | #2552 |
| effectiveness analysis | #2553 |
| hours | #2560 |
| haematology | #2560 |
| hydroxyethyl | #2560 |
| 928 | #2565 |
| radiologist | #2566 |
| roc | #2568 |
| biologic | #2569 |
| clinical settings | #2570 |
| infrequent | #2572 |
| kits | #2574 |
| humans logistic | #2574 |
| 73 | #2574 |
| prevalence | #2575 |
| pill | #2575 |
| patients total | #2577 |
| translate | #2577 |
| 973 | #2578 |
| specificity | #2580 |
| cancer chemotherapy | #2581 |
| 374 | #2582 |
| 591 | #2585 |
| efficacious | #2585 |
| pivotal | #2588 |
| analysed | #2589 |
| bolus | #2595 |
| 657 | #2596 |
| multiple organ failure | #2599 |
| hypercholesterolaemia | #2600 |
| doppler duplex | #2602 |
| laboratory investigation | #2603 |
| burden disease | #2605 |
| manifest | #2605 |
| parenteral | #2606 |
| metaregression | #2606 |
| patients 2 | #2608 |
| fatal outcome | #2608 |
| 098 | #2610 |
| p0001 patients | #2613 |
| died | #2615 |
| 886 | #2618 |
| percent | #2619 |
| aviation | #2620 |
| cost analysis | #2620 |
| concentrate | #2621 |
| occlusive | #2622 |
| presenting | #2625 |
| assess | #2626 |
| prescribed | #2631 |
| agents steroidal | #2633 |
| coincided | #2635 |
| chondroitin | #2635 |
| trials rcts | #2635 |
| 10 day | #2637 |
| 345 | #2641 |
| attractive | #2641 |
| mutation patients | #2642 |
| greatest risk | #2643 |
| 23 patients | #2645 |
| decision | #2649 |
| risk cardiovascular disease | #2656 |
| 134 | #2659 |
| recurrence | #2660 |
| hamilton | #2661 |
| c677 | #2662 |
| benzimidazoles | #2662 |
| 679 | #2663 |
| shr | #2667 |
| quartile | #2674 |
| receive | #2675 |
| 439 | #2677 |
| valsalva | #2680 |
| trials | #2682 |
| 516 | #2683 |
| outcome ultrasonography | #2683 |
| initial dose | #2685 |
| iii | #2685 |
| inconclusive | #2686 |
| tmax | #2687 |
| mortality 95 | #2688 |
| tissue plasminogen activator | #2690 |
| 594 | #2691 |
| aso | #2691 |
| bleed | #2692 |
| schedule female | #2694 |
| stillbirth | #2698 |
| patients risk factors | #2702 |
| early discharge | #2703 |
| 14 | #2706 |
| previous stroke | #2720 |
| prematurely | #2725 |
| 897 | #2727 |
| txb2 | #2729 |
| dose low | #2732 |
| management strategies | #2732 |
| cart | #2736 |
| 595 | #2737 |
| classifications | #2739 |
| 427 | #2739 |
| therapeutic options | #2744 |
| risk ratio | #2745 |
| 848 | #2746 |
| predetermined | #2746 |
| patients asthma | #2747 |
| baseline characteristics | #2747 |
| direct comparison | #2752 |
| pan | #2755 |
| nephrotoxicity | #2758 |
| randomised trial | #2764 |
| contusions | #2765 |
| management acute | #2768 |
| 143 | #2768 |
| confounded | #2769 |
| alpha animals | #2772 |
| antithyroid | #2772 |
| expert consensus | #2772 |
| active control | #2775 |
| thrombomodulin | #2776 |
| inpatient | #2776 |
| 563 | #2777 |
| compression | #2778 |
| dosages | #2779 |
| leukocyte count | #2781 |
| mass screening | #2782 |
| 466 | #2783 |
| hemostatic | #2784 |
| primary outcomes | #2785 |
| percentiles | #2788 |
| 90th | #2789 |
| nadph2 | #2791 |
| consecutive series | #2802 |
| 402 | #2802 |
| reaching | #2805 |
| cirrhosis patients | #2805 |
| international | #2809 |
| standardized | #2811 |
| secondary | #2811 |
| embolic | #2812 |
| follow studies | #2813 |
| 406 | #2813 |
| prevalence risk factors | #2814 |
| httlpr | #2816 |
| discriminant analysis | #2817 |
| selectins | #2819 |
| consisting | #2823 |
| equivalency | #2825 |
| antiplatelet drugs | #2826 |
| bid | #2826 |
| genetic variations | #2830 |
| 557 | #2833 |
| male mass | #2834 |
| recurrence rate | #2835 |
| contacting | #2835 |
| ketoprostaglandin | #2836 |
| helminth | #2836 |
| kruskal | #2839 |
| crossover | #2839 |
| 554 | #2843 |
| partum | #2847 |
| anterior cruciate ligament | #2850 |
| carboxypeptidase | #2851 |
| iii trials | #2852 |
| doppler ultrasonography | #2852 |
| ≤2 | #2853 |
| postoperative patients | #2854 |
| new treatment | #2857 |
| post discharge | #2857 |
| specialised | #2858 |
| methods prospective | #2862 |
| 497 | #2870 |
| discontinuation | #2871 |
| 264 | #2876 |
| 628 | #2877 |
| 52 | #2879 |
| excessive | #2880 |
| trimester pregnancy | #2880 |
| hit | #2884 |
| mdct | #2885 |
| balloon angioplasty | #2886 |
| anterior cruciate | #2887 |
| 670 | #2895 |
| eligibility | #2896 |
| systematic review metaanalysis | #2897 |
| 21 | #2897 |
| central venous catheters | #2900 |
| statin | #2902 |
| feasible | #2903 |
| slight | #2903 |
| severe asthma | #2903 |
| 12 patients | #2908 |
| concomitantly | #2910 |
| supposed | #2911 |
| insulin receptors | #2914 |
| leading death | #2917 |
| lowrisk patients | #2917 |
| 39 | #2919 |
| routine clinical practice | #2920 |
| referrals | #2921 |
| older children | #2922 |
| proportions | #2928 |
| 993 | #2928 |
| clear | #2932 |
| 2400 | #2934 |
| risk stratification patients | #2934 |
| aggregation platelet | #2941 |
| control subjects patients | #2945 |
| meier estimate | #2946 |
| addison | #2952 |
| portal | #2954 |
| 100 | #2956 |
| returned | #2957 |
| 270 | #2960 |
| 010 | #2960 |
| 20 | #2961 |
| followup | #2962 |
| exercise therapy | #2962 |
| transabdominal | #2963 |
| 132 | #2974 |
| echocardiography patients | #2975 |
| 123 | #2978 |
| risk myocardial | #2981 |
| lecture | #2984 |
| declare | #2984 |
| eclampsia pregnancy | #2986 |
| glucose levels | #2987 |
| preoperatively | #2988 |
| adult blood | #2990 |
| point | #2991 |
| pneumatic | #2991 |
| n4 | #2992 |
| undefined | #2993 |
| treatable | #2996 |
| cvr | #2997 |
| microvessels | #2998 |
| 499 | #3004 |
| prostacyclin | #3012 |
| dipyridamole | #3013 |
| factors surveys | #3015 |
| antigen levels | #3015 |
| 2 patients | #3016 |
| 081 | #3019 |
| double‐blind | #3022 |
| 35 patients | #3023 |
| nested case | #3025 |
| early recognition | #3025 |
| comorbidity | #3026 |
| contraindication | #3028 |
| intention | #3035 |
| extremities | #3038 |
| 50 years | #3040 |
| 419 | #3040 |
| patients hf | #3041 |
| lymphopenia | #3043 |
| relevant articles | #3044 |
| 095 | #3045 |
| prenatal exposure | #3047 |
| summarize | #3050 |
| respondents | #3052 |
| respects | #3060 |
| subcutaneous injection | #3062 |
| nomogram | #3063 |
| 80 | #3063 |
| fourteen | #3065 |
| 95 p0001 | #3066 |
| patients data | #3067 |
| study prevalence | #3071 |
| 2 4 | #3076 |
| subsequently | #3076 |
| disease aged | #3077 |
| 524 | #3082 |
| 342 | #3083 |
| angioplasty | #3088 |
| chronic renal failure | #3088 |
| independent risk factors | #3089 |
| healthy | #3090 |
| clinical risk factors | #3098 |
| lancet | #3102 |
| reviewer | #3104 |
| practice guidelines | #3109 |
| trimester | #3110 |
| benchmark | #3110 |
| npv | #3115 |
| pregnant woman | #3119 |
| neutrophil activation | #3120 |
| oac | #3122 |
| lifelong | #3122 |
| wallis | #3122 |
| inadequacy | #3123 |
| intravenously | #3129 |
| claimed | #3132 |
| 136 | #3134 |
| 12 months | #3134 |
| meta‐analysis | #3137 |
| 082 | #3142 |
| levels risk | #3142 |
| placentae | #3143 |
| randomized clinical trial | #3145 |
| time interval | #3147 |
| arthroscopic | #3149 |
| 507 | #3153 |
| idiopathic | #3153 |
| marathon | #3155 |
| mega | #3156 |
| avoiding | #3158 |
| radiologists | #3165 |
| initial presentation | #3172 |
| seventh | #3173 |
| cornerstone | #3182 |
| test | #3184 |
| 494 | #3188 |
| revascularisation | #3191 |
| 409 | #3193 |
| diethylstilbestrol | #3194 |
| pregnancy women | #3194 |
| pacientes | #3197 |
| plasmin | #3198 |
| 945 | #3198 |
| tenth | #3199 |
| therapy risk | #3199 |
| gold standard | #3200 |
| vivo model | #3205 |
| res | #3207 |
| patient preference | #3211 |
| catheter | #3212 |
| cancer types | #3219 |
| suggested | #3219 |
| intravenous infusion | #3223 |
| 153 | #3223 |
| 72 hours | #3225 |
| 605 | #3227 |
| methodological quality | #3238 |
| observers | #3239 |
| recombinant | #3241 |
| meetings | #3241 |
| intravenous administration | #3242 |
| risk stroke | #3246 |
| alternative | #3249 |
| bivalirudin | #3251 |
| 198 | #3251 |
| hypothyroid | #3253 |
| 29 | #3253 |
| judgement | #3255 |
| scoring | #3255 |
| normotensive | #3256 |
| 054 | #3257 |
| patient preferences | #3261 |
| glargine | #3265 |
| validated | #3266 |
| patients evidence | #3267 |
| 116 | #3268 |
| immunoassay | #3271 |
| 414 | #3275 |
| 6 | #3277 |
| tranexamic acid | #3279 |
| gbd | #3280 |
| contraceptive | #3281 |
| inclusion | #3284 |
| arthroplasty replacement | #3288 |
| tumor markers | #3289 |
| coumarin | #3289 |
| replace | #3290 |
| 65 years | #3291 |
| swan | #3292 |
| recurrence rates | #3294 |
| efficacy outcomes | #3299 |
| 812 | #3314 |
| rtpa | #3315 |
| reversibility | #3316 |
| anticardiolipin antibodies | #3319 |
| discriminant | #3321 |
| vascular risk | #3322 |
| 104 | #3325 |
| hemophilia | #3328 |
| 972 | #3329 |
| 465 | #3330 |
| reduces | #3330 |
| cruciate ligament | #3331 |
| patients symptoms | #3334 |
| 74 | #3337 |
| meta | #3338 |
| acute coronary syndrome | #3339 |
| cerebrovascular disease | #3344 |
| inpatients | #3344 |
| evaluating | #3349 |
| 362 | #3349 |
| diagnosing | #3354 |
| spontaneous abortion | #3354 |
| 273 | #3355 |
| common complication | #3356 |
| diagnosis cancer | #3356 |
| 15 | #3357 |
| lysate | #3358 |
| 581 | #3359 |
| 092 | #3361 |
| miscarriages | #3365 |
| prevalent | #3371 |
| thrombolysis | #3376 |
| treatment modalities | #3377 |
| 363 | #3378 |
| 301 | #3379 |
| humans lower | #3379 |
| concluded | #3379 |
| intima media | #3380 |
| computed tomography | #3382 |
| hematomas | #3387 |
| calf | #3389 |
| function patients | #3389 |
| contraception | #3390 |
| repeated | #3394 |
| 413 | #3395 |
| p0002 | #3397 |
| cava | #3399 |
| 311 | #3400 |
| acute treatment | #3403 |
| 553 | #3403 |
| tunica | #3403 |
| humans kaplan | #3408 |
| saved | #3415 |
| differs | #3418 |
| randomisation | #3419 |
| preventive | #3419 |
| study risk | #3420 |
| hypothesised | #3420 |
| surgical patients | #3420 |
| thrombocythemia | #3422 |
| odds | #3424 |
| confirm | #3425 |
| testimony | #3430 |
| competing | #3434 |
| natriuretic | #3437 |
| 70 | #3439 |
| ease | #3443 |
| asian patients | #3444 |
| 124 | #3445 |
| 519 | #3447 |
| 487 | #3451 |
| prevalence incidence | #3452 |
| 168 | #3452 |
| evening | #3458 |
| covid19 infection | #3464 |
| 34 | #3470 |
| differ | #3470 |
| intensive chemotherapy | #3471 |
| patients receive | #3472 |
| pregnancy complications | #3472 |
| worsened | #3476 |
| induced platelet | #3479 |
| undiagnosed | #3482 |
| antiphospholipid | #3485 |
| cancer metastasis | #3485 |
| increased morbidity | #3486 |
| lower leg | #3487 |
| asymptomatic | #3487 |
| paradox | #3490 |
| personyears | #3490 |
| pacemaker | #3493 |
| statistical methods | #3494 |
| convergent validity | #3496 |
| failure hf | #3497 |
| 201 | #3504 |
| treat | #3506 |
| inhibitors | #3506 |
| hemorrhagic complications | #3506 |
| 938 | #3513 |
| tomography angiography | #3521 |
| discusses | #3522 |
| confirmed | #3522 |
| 291 | #3527 |
| quintiles | #3529 |
| 95 confidence intervals | #3530 |
| human cytomegalovirus | #3533 |
| lupus | #3533 |
| areas covered | #3537 |
| guidance | #3541 |
| societies | #3541 |
| 113 | #3544 |
| current practice | #3551 |
| gastro | #3551 |
| 10 | #3552 |
| stroke risk | #3559 |
| baboons | #3560 |
| 344 | #3562 |
| benefits risks | #3564 |
| neutralize | #3565 |
| nsaids | #3566 |
| bibliographic | #3567 |
| depends | #3571 |
| patients recurrence | #3573 |
| inconsistent | #3575 |
| safety profiles | #3580 |
| 508 | #3584 |
| evaluates | #3592 |
| prognosis prospective | #3596 |
| necessity | #3596 |
| patient management | #3598 |
| prognostic significance | #3604 |
| vitamin | #3605 |
| risk stratification | #3606 |
| consensus document | #3617 |
| platelet function | #3619 |
| treated | #3619 |
| platelet activation | #3622 |
| interval | #3622 |
| mutation | #3624 |
| lipid profiles | #3626 |
| q3 | #3629 |
| kappa | #3629 |
| organ damage | #3635 |
| analysis performed | #3640 |
| 75 | #3641 |
| bypass surgery | #3642 |
| homozygote | #3642 |
| undergo | #3642 |
| p006 | #3645 |
| externally | #3645 |
| occlusions | #3646 |
| 1960 | #3649 |
| 30 | #3649 |
| interindividual variability | #3651 |
| fibrillation | #3651 |
| coronary events | #3656 |
| atherogenic | #3658 |
| newer | #3662 |
| patients 95 | #3667 |
| outcome administration | #3671 |
| optimal management | #3671 |
| endovascular treatment | #3678 |
| blinding | #3679 |
| treatment complications | #3680 |
| limited data | #3683 |
| 68 | #3684 |
| clopidogrel | #3685 |
| mammography | #3693 |
| myalgia | #3703 |
| 478 | #3706 |
| rationale | #3707 |
| 813 | #3708 |
| rebound | #3720 |
| diagnostic process | #3721 |
| drug monitoring | #3721 |
| inhibitors humans | #3725 |
| pharmacodynamics | #3725 |
| 130 | #3729 |
| unknown | #3731 |
| patient population | #3733 |
| serine proteases | #3736 |
| 349 | #3738 |
| humans intracranial | #3739 |
| effective | #3739 |
| factor 4 | #3741 |
| 585 | #3743 |
| 299 | #3744 |
| network meta | #3746 |
| homozygous | #3747 |
| 495 | #3750 |
| practitioner | #3752 |
| randomised | #3754 |
| deterioration | #3754 |
| objectives | #3759 |
| 8 patients | #3762 |
| subgroup analyses | #3762 |
| 00001 | #3765 |
| host defense | #3769 |
| statin therapy | #3772 |
| scarce | #3773 |
| clinicians patients | #3774 |
| computed ultrasonography | #3774 |
| inherited | #3775 |
| 517 | #3778 |
| interpretable | #3778 |
| 483 | #3782 |
| aminoglycosides | #3789 |
| thyroid hormones | #3789 |
| total knee arthroplasty | #3789 |
| 525 | #3791 |
| 412 | #3795 |
| 441 | #3797 |
| life illness | #3801 |
| 333 | #3802 |
| versus | #3803 |
| compelling | #3804 |
| vessel wall | #3804 |
| preexisting | #3808 |
| outcome measure | #3814 |
| 330 | #3815 |
| patients lung cancer | #3815 |
| valid | #3816 |
| iu | #3818 |
| 55 patients | #3821 |
| fv | #3823 |
| stasis | #3824 |
| lost | #3825 |
| compares | #3830 |
| itching | #3831 |
| proved | #3834 |
| osmolar | #3837 |
| elective | #3838 |
| hydrolases | #3839 |
| patient education | #3843 |
| 197 | #3849 |
| meeting | #3856 |
| irs | #3856 |
| anaesthesia | #3857 |
| 4 patients | #3858 |
| congresses | #3859 |
| acquired resistance | #3860 |
| review data | #3860 |
| male neoplasms | #3862 |
| preferred | #3864 |
| occurring | #3867 |
| death | #3880 |
| optimisation | #3884 |
| cancer survival | #3884 |
| sensitivity | #3885 |
| record | #3885 |
| avoids | #3887 |
| calculated | #3888 |
| 184 | #3890 |
| difference | #3890 |
| 351 | #3890 |
| 10000 | #3902 |
| halflives | #3903 |
| methylamines | #3903 |
| methimazole | #3904 |
| patients time | #3905 |
| incidence prevalence | #3908 |
| angiography | #3915 |
| specificity tomography | #3915 |
| coronary thrombosis | #3918 |
| decide | #3927 |
| 474 | #3931 |
| ankle | #3932 |
| 955 | #3935 |
| 458 | #3938 |
| jak2 | #3939 |
| extravasation | #3945 |
| case fatality | #3946 |
| 405 | #3946 |
| preeclampsia | #3952 |
| neurology | #3953 |
| 56 | #3956 |
| dichotomy | #3961 |
| p004 | #3961 |
| randomized clinical trials | #3963 |
| women | #3964 |
| carboxypeptidases | #3965 |
| postoperatively | #3966 |
| clinical effectiveness | #3968 |
| uncontrolled | #3970 |
| risk cancer | #3970 |
| austrian | #3971 |
| behalf | #3971 |
| cardiovascular events | #3972 |
| data studies | #3975 |
| 2nd | #3975 |
| quality assurance | #3980 |
| pregnancy | #3982 |
| 986 | #3982 |
| continuous infusion | #3983 |
| unstable | #3986 |
| flying | #3986 |
| month | #3987 |
| 488 | #3990 |
| systematic analysis | #3994 |
| sequentially | #4006 |
| calculate | #4010 |
| lower risk | #4011 |
| limited evidence | #4014 |
| patients evaluated | #4016 |
| scored | #4023 |
| secondary prevention | #4026 |
| 538 | #4028 |
| equivalence | #4029 |
| gln | #4031 |
| meyer | #4032 |
| cerebral venous | #4041 |
| 296 | #4045 |
| introduction | #4045 |
| 423 | #4047 |
| 262 | #4051 |
| ended | #4052 |
| validating | #4058 |
| received | #4062 |
| recurrent disease | #4066 |
| cruciate | #4073 |
| elevated | #4074 |
| compare | #4075 |
| pcc | #4077 |
| bariatric | #4077 |
| avoid | #4080 |
| 429 | #4081 |
| 326 | #4083 |
| hour | #4088 |
| oligosaccharides | #4089 |
| natriuretic peptide | #4089 |
| angioplasty balloon | #4091 |
| maneuver | #4092 |
| 3000 | #4093 |
| 16 | #4098 |
| activation | #4099 |
| cutoff | #4099 |
| indications | #4099 |
| contact | #4102 |
| pharmacological | #4106 |
| infusion rate | #4109 |
| 392 | #4113 |
| 335 | #4117 |
| 6 months treatment | #4119 |
| ptm | #4120 |
| completing | #4125 |
| patients low risk | #4133 |
| withdrawn | #4137 |
| 008 | #4137 |
| 41 | #4138 |
| bms | #4146 |
| patients died | #4149 |
| medical students | #4152 |
| haemorrhagic | #4154 |
| continue | #4158 |
| study control | #4161 |
| nulliparous | #4167 |
| patients prostate cancer | #4171 |
| 2030 | #4171 |
| antitumour | #4177 |
| steroidal | #4178 |
| multidisciplinary approach | #4189 |
| direct | #4192 |
| therapy combination | #4198 |
| casts | #4200 |
| 411 | #4212 |
| 485 | #4212 |
| medical center | #4214 |
| 408 | #4215 |
| weighted | #4221 |
| additional | #4222 |
| 452 | #4223 |
| 289 | #4226 |
| 121 | #4226 |
| trough | #4229 |
| crosssectional analysis | #4230 |
| p0005 | #4230 |
| hormonal | #4234 |
| veins | #4235 |
| cox regression | #4242 |
| patients mortality | #4242 |
| 178 | #4246 |
| nsaid | #4261 |
| 263 | #4263 |
| abbreviated | #4267 |
| encountered | #4268 |
| atrial fibrillation patients | #4274 |
| fab | #4279 |
| late pregnancy | #4285 |
| pai1 | #4286 |
| rise | #4287 |
| oral aged | #4294 |
| q4 | #4296 |
| 228 | #4303 |
| share | #4304 |
| 10 patients | #4306 |
| 105 | #4310 |
| rehospitalization | #4314 |
| patients increased risk | #4315 |
| 185 | #4316 |
| tat | #4319 |
| separate | #4322 |
| concentrates | #4328 |
| intima | #4329 |
| devised | #4331 |
| 294 | #4339 |
| 455 | #4340 |
| 102 | #4340 |
| pronounced | #4342 |
| incidental findings | #4345 |
| managed | #4350 |
| potential risk factors | #4350 |
| detrimental | #4356 |
| 253 | #4359 |
| agreed | #4360 |
| young age | #4363 |
| specialist | #4379 |
| minutes | #4383 |
| rapid | #4383 |
| retrospective studies | #4384 |
| 447 | #4385 |
| cd11b | #4387 |
| 288 | #4391 |
| 170 | #4392 |
| concurrently | #4394 |
| slice | #4394 |
| risk cardiovascular | #4396 |
| steadily | #4402 |
| 239 | #4406 |
| general | #4407 |
| bowel diseases | #4407 |
| negative | #4407 |
| 71 | #4407 |
| guideline recommendations | #4408 |
| postoperative day | #4409 |
| ventilation | #4413 |
| lacking | #4417 |
| splanchnic | #4417 |
| immunoassays | #4419 |
| dose aspirin | #4419 |
| recombinant proteins | #4423 |
| 3 patients | #4426 |
| author | #4427 |
| 148 | #4428 |
| 281 | #4429 |
| primary myelofibrosis | #4430 |
| appropriateness | #4433 |
| profoundly | #4436 |
| completed | #4438 |
| platelet | #4440 |
| cellulitis | #4441 |
| sixteen | #4442 |
| concomitant | #4445 |
| assays | #4453 |
| 334 | #4458 |
| vascular surgery | #4459 |
| 192 | #4459 |
| proband | #4461 |
| cytomegalovirus infection | #4461 |
| total costs | #4474 |
| 377 | #4479 |
| 443 | #4482 |
| cd18 | #4486 |
| clinical manifestations | #4486 |
| inadequate | #4487 |
| pancreatic cancer | #4487 |
| coronavirus disease covid19 | #4489 |
| smr | #4492 |
| risk prediction | #4493 |
| bus | #4497 |
| current management | #4498 |
| 476 | #4499 |
| doubling | #4500 |
| infected patients | #4502 |
| activation platelet | #4503 |
| comprises | #4503 |
| 54 | #4513 |
| primary diagnosis | #4515 |
| alpha2 | #4516 |
| therapeutic | #4532 |
| septic | #4534 |
| 3 groups | #4535 |
| male pulmonary | #4541 |
| 526 | #4542 |
| elastase | #4544 |
| hitherto | #4546 |
| fairly | #4552 |
| cardiovascular death | #4559 |
| 985 | #4564 |
| 1250 | #4567 |
| calculating | #4571 |
| cerebrovascular disorders | #4571 |
| multicenter trial | #4574 |
| 2c | #4585 |
| debate | #4586 |
| disadvantage | #4588 |
| plasma concentrations | #4591 |
| 283 | #4592 |
| preserves | #4594 |
| attenuating | #4594 |
| eventually | #4595 |
| gradual | #4595 |
| simplified | #4596 |
| 204 | #4596 |
| 4 | #4601 |
| 4000 | #4601 |
| encouraged | #4603 |
| icer | #4610 |
| frequently | #4611 |
| vii | #4613 |
| acetylsalicylic acid | #4613 |
| vaginal | #4614 |
| 917 | #4619 |
| assay | #4634 |
| subclinical atherosclerosis | #4636 |
| risks benefits | #4640 |
| hospital costs | #4640 |
| 242 | #4642 |
| genetic risk factors | #4644 |
| escalating | #4648 |
| priori | #4654 |
| 003 | #4658 |
| habitual | #4658 |
| survey | #4659 |
| transurethral | #4663 |
| 171 | #4670 |
| myelofibrosis | #4670 |
| thyroid hormone | #4673 |
| 40 | #4675 |
| 407 | #4679 |
| day | #4680 |
| fh | #4680 |
| recurrent stroke | #4681 |
| wheezing | #4693 |
| ranging | #4698 |
| unchanged | #4698 |
| 5 patients | #4701 |
| complicated | #4703 |
| truncated | #4709 |
| therapeutic intervention | #4715 |
| differential humans | #4719 |
| immobilization | #4725 |
| 129 | #4727 |
| orthopedic | #4735 |
| cardiovascular morbidity | #4738 |
| current guidelines | #4739 |
| therapeutic strategies | #4744 |
| ranged | #4769 |
| 027 | #4774 |
| baseline patients | #4775 |
| chronic renal | #4775 |
| acute coronary | #4784 |
| scheduled | #4785 |
| 44 | #4785 |
| molecular | #4792 |
| knee | #4800 |
| insulin glargine | #4801 |
| prophylactic | #4802 |
| arthroplasty | #4803 |
| alternatively | #4810 |
| extracranial | #4813 |
| courses | #4819 |
| diagnostic imaging | #4825 |
| therapy humans | #4836 |
| echocardiography | #4846 |
| 174 | #4848 |
| cholesterol levels | #4853 |
| definition | #4861 |
| acl | #4861 |
| efficiency | #4869 |
| nonvalvular atrial fibrillation | #4870 |
| gpiib | #4870 |
| increased plasma | #4875 |
| unexposed | #4876 |
| gynecological | #4880 |
| antiphospholipid syndrome | #4881 |
| screening tool | #4884 |
| 322 | #4886 |
| total | #4891 |
| antiplatelet therapy | #4891 |
| treating | #4896 |
| abstracted | #4897 |
| doses | #4902 |
| ischemic heart disease | #4905 |
| preparations | #4906 |
| tests prognosis | #4906 |
| served | #4910 |
| fmd | #4913 |
| chlamydophila | #4913 |
| 560 | #4914 |
| recommendation | #4918 |
| geriatrics | #4920 |
| acute ischemic | #4923 |
| renal dysfunction | #4929 |
| 556 | #4932 |
| 154 | #4933 |
| 870 | #4934 |
| cpb | #4939 |
| 325 | #4951 |
| 26 | #4952 |
| satisfied | #4957 |
| appeared | #4959 |
| fund | #4972 |
| manufacturers | #4976 |
| dose | #4976 |
| albeit | #4982 |
| orthopedics | #4982 |
| recommended | #4987 |
| cardiology | #5000 |
| 389 | #5006 |
| references | #5006 |
| reminder | #5009 |
| epoprostenol | #5009 |
| probnp | #5014 |
| point mutation | #5018 |
| risk women | #5023 |
| syndrome patients | #5033 |
| screening test | #5040 |
| 156 | #5040 |
| proposal | #5042 |
| global burden | #5044 |
| primary health | #5045 |
| analytic | #5047 |
| obstetrical | #5048 |
| lasted | #5049 |
| patients sepsis | #5051 |
| limitations | #5055 |
| diagnosis management | #5058 |
| patients myocardial infarction | #5062 |
| spinal surgery | #5065 |
| 255 | #5068 |
| conflicting | #5070 |
| saphenous | #5075 |
| inaccessible | #5078 |
| 1a | #5079 |
| switched | #5084 |
| evaluable | #5089 |
| regarded | #5089 |
| hip fractures | #5090 |
| relation | #5090 |
| transluminal | #5093 |
| menstrual | #5094 |
| fashion | #5098 |
| amputation | #5102 |
| external validation | #5103 |
| arteritis | #5107 |
| inflammatory responses | #5109 |
| oxadiazoles | #5110 |
| dalys | #5112 |
| tailor | #5115 |
| admission patients | #5118 |
| composite | #5120 |
| discriminative | #5123 |
| bay | #5124 |
| vivo studies | #5124 |
| 108 | #5125 |
| 282 | #5129 |
| ischaemic stroke | #5130 |
| 0018 | #5130 |
| 131 | #5131 |
| female | #5131 |
| transfused | #5134 |
| balancing | #5136 |
| contrast media | #5136 |
| fetal death | #5138 |
| activator | #5139 |
| scans | #5143 |
| 341 | #5146 |
| n6 | #5150 |
| kg1 | #5151 |
| shortly | #5157 |
| disagreement | #5157 |
| preclinical studies | #5160 |
| doppler | #5165 |
| 11 patients | #5170 |
| predispose | #5170 |
| hazard | #5171 |
| readers | #5173 |
| prescriptions | #5174 |
| graft failure | #5178 |
| weaknesses | #5185 |
| renal impairment | #5186 |
| 70 patients | #5190 |
| infarctions | #5191 |
| screening | #5193 |
| threefold | #5198 |
| highest | #5202 |
| extracellular vesicles | #5204 |
| acs | #5205 |
| 144 | #5206 |
| hospital patients | #5208 |
| remains | #5209 |
| excess mortality | #5210 |
| doppler color | #5221 |
| polysaccharides | #5223 |
| heparan | #5229 |
| articles | #5233 |
| emergencies | #5233 |
| indwelling | #5241 |
| flowmetry | #5242 |
| gram | #5244 |
| 3 | #5248 |
| platelet aggregation | #5252 |
| considerably | #5253 |
| comparison | #5262 |
| testing | #5264 |
| plasma levels | #5265 |
| estimate | #5288 |
| pooling | #5289 |
| 365 | #5289 |
| aware | #5300 |
| 36 patients | #5301 |
| thrombus | #5301 |
| atherogenesis | #5302 |
| urokinase | #5302 |
| triage | #5303 |
| case reports | #5305 |
| benefit | #5308 |
| reversal | #5310 |
| stroke treatment | #5314 |
| contrasted | #5316 |
| orthomyxoviridae | #5319 |
| openlabel | #5320 |
| 70 years | #5325 |
| aged postoperative | #5330 |
| animal drug evaluation | #5332 |
| dizziness | #5334 |
| absent | #5335 |
| factor humans | #5336 |
| stratify | #5340 |
| reagent | #5341 |
| acute ischemic stroke | #5341 |
| blood vessel | #5343 |
| ultrasound imaging | #5344 |
| fatality | #5347 |
| contrast agents | #5355 |
| arose | #5361 |
| schedule drug | #5363 |
| male | #5363 |
| based guidelines | #5370 |
| hyper | #5372 |
| obstetric | #5376 |
| accepted | #5383 |
| thyrotropin | #5401 |
| informed consent | #5402 |
| blood products | #5405 |
| selected patients | #5406 |
| adult | #5407 |
| heart valve | #5409 |
| intracranial | #5411 |
| questionnaire | #5414 |
| register | #5415 |
| summarized | #5416 |
| 19 | #5417 |
| noninvasive | #5421 |
| clinical risk | #5424 |
| nonsignificant | #5429 |
| protein levels | #5430 |
| concerns | #5439 |
| charts | #5440 |
| hyperprolactinemia | #5441 |
| familiarity | #5442 |
| 37 | #5445 |
| 630 | #5448 |
| retrieved | #5450 |
| cancer growth | #5455 |
| presently | #5456 |
| congenital heart | #5465 |
| registered | #5470 |
| recombinant human | #5474 |
| intermediate | #5475 |
| 340 | #5476 |
| 395 | #5484 |
| allocation | #5488 |
| occurrences | #5490 |
| 247 | #5490 |
| moyamoya disease | #5491 |
| ntprobnp | #5493 |
| kaplan meier | #5496 |
| 260 | #5497 |
| patient risk | #5497 |
| discomfort | #5499 |
| continuing | #5499 |
| 9 patients | #5500 |
| postal | #5503 |
| ssris | #5515 |
| correctly | #5517 |
| weight | #5524 |
| 309 | #5530 |
| period | #5533 |
| limitation | #5539 |
| erythema | #5539 |
| suggestions | #5541 |
| survival benefit | #5542 |
| imputed | #5545 |
| established | #5563 |
| receptor1 | #5563 |
| 175 | #5565 |
| 545 | #5566 |
| management | #5569 |
| 46 | #5573 |
| reduce risk | #5573 |
| 324 | #5595 |
| excludes | #5597 |
| equivalent | #5598 |
| circulating levels | #5598 |
| categorical | #5600 |
| stm | #5607 |
| grounds | #5617 |
| expert | #5620 |
| 02 | #5624 |
| microgram | #5626 |
| minus | #5627 |
| premenopausal women | #5629 |
| retrieve | #5633 |
| food preferences | #5637 |
| drug administration | #5641 |
| platelet count | #5643 |
| reclassification | #5644 |
| 80 years | #5644 |
| 65 | #5651 |
| trial | #5653 |
| 087 | #5667 |
| published data | #5671 |
| 48 | #5676 |
| seventy | #5684 |
| 214 | #5689 |
| latex | #5690 |
| platelet glycoprotein | #5692 |
| reproducible | #5696 |
| 1997 | #5698 |
| meier | #5714 |
| 370 | #5718 |
| return | #5721 |
| 40 years | #5729 |
| atherosclerotic | #5730 |
| 89 | #5732 |
| perform | #5734 |
| 995 | #5748 |
| 091 | #5755 |
| stand | #5756 |
| 0014 | #5761 |
| metabolic effects | #5764 |
| semiquantitative | #5771 |
| milder | #5771 |
| 241 | #5777 |
| recurrence patients | #5781 |
| varied | #5784 |
| creatinine clearance | #5788 |
| 3rd | #5791 |
| incidence rates | #5804 |
| mpo | #5804 |
| 95 women | #5809 |
| orthopedic procedures | #5810 |
| male middle aged | #5811 |
| url | #5812 |
| aircraft | #5819 |
| 1000 | #5819 |
| income countries | #5828 |
| diagnosed | #5840 |
| undergoing surgery | #5843 |
| true | #5852 |
| atrial | #5852 |
| 088 | #5854 |
| attending | #5856 |
| 290 | #5857 |
| women pregnancy | #5857 |
| hip | #5866 |
| advantageous | #5875 |
| complete resolution | #5878 |
| occurrence | #5894 |
| reliable | #5894 |
| excluded | #5899 |
| aged models | #5919 |
| adding | #5923 |
| safety patients | #5927 |
| 22 patients | #5928 |
| aged platelet | #5928 |
| graded | #5934 |
| premenopause | #5938 |
| revision | #5938 |
| 353 | #5945 |
| prodrugs | #5946 |
| rrs | #5949 |
| 141 | #5952 |
| gastrointestinal hemorrhage | #5954 |
| janus kinase | #5959 |
| rcts | #5962 |
| 43 | #5962 |
| families | #5967 |
| 328 | #5971 |
| deemed | #5977 |
| savings | #5980 |
| counseling | #5985 |
| blood platelets | #5987 |
| blood | #5990 |
| receiver operating | #5996 |
| guideline | #5998 |
| cancer incidence | #6006 |
| current standard | #6013 |
| therapeutic interventions | #6028 |
| nadir | #6034 |
| registries risk | #6039 |
| patients experience | #6042 |
| allocated | #6044 |
| ≥3 | #6052 |
| wash | #6059 |
| advance | #6062 |
| quarter | #6065 |
| spect | #6068 |
| glycosaminoglycans | #6069 |
| decompensated | #6074 |
| 24 | #6076 |
| bacteremia | #6090 |
| topics | #6101 |
| type iii | #6101 |
| suggestive | #6105 |
| emerging evidence | #6113 |
| prevent | #6117 |
| safety data | #6120 |
| directly | #6133 |
| 72 | #6135 |
| 267 | #6136 |
| lipid profile | #6140 |
| ≥2 | #6144 |
| normalization | #6151 |
| centuries | #6153 |
| 47 | #6157 |
| ffa | #6160 |
| generation | #6160 |
| lobar | #6161 |
| agents blood | #6164 |
| 292 | #6165 |
| informed | #6173 |
| pharmacodynamic | #6188 |
| lung male | #6190 |
| updating | #6192 |
| advantages disadvantages | #6194 |
| lower | #6195 |
| bilateral | #6198 |
| cyclosporine | #6208 |
| tumour growth | #6212 |
| pathogenetic | #6221 |
| femoral artery | #6224 |
| terminated | #6228 |
| mortality morbidity | #6228 |
| new drugs | #6229 |
| 312 | #6230 |
| evidence base | #6232 |
| vitro studies | #6234 |
| crp | #6235 |
| discontinued | #6236 |
| 111 | #6240 |
| abdomen | #6248 |
| denmark | #6254 |
| proportional | #6268 |
| colleagues | #6273 |
| practitioners | #6273 |
| administered | #6277 |
| 1978 | #6283 |
| screened | #6293 |
| infused | #6297 |
| 840 | #6318 |
| prostatectomy | #6330 |
| 017 | #6334 |
| saphenous vein | #6339 |
| 63 | #6340 |
| 135 | #6340 |
| percentile | #6344 |
| higher doses | #6345 |
| adequacy | #6347 |
| divided | #6348 |
| apache | #6351 |
| screen | #6357 |
| opinions | #6360 |
| opposed | #6362 |
| percentage | #6370 |
| longterm followup | #6372 |
| risk mortality | #6386 |
| dyslipidemias | #6390 |
| kaplan | #6391 |
| consensus | #6392 |
| 208 | #6397 |
| potential mechanisms | #6404 |
| factor gene | #6405 |
| roche | #6405 |
| initiated | #6408 |
| compensated | #6411 |
| investigating | #6427 |
| ultrasound | #6441 |
| restenosis | #6442 |
| bootstrap | #6452 |
| collection | #6457 |
| post operative | #6464 |
| enzyme linked | #6467 |
| bariatric surgery | #6468 |
| coronary syndrome | #6469 |
| decreased risk | #6471 |
| 218 | #6472 |
| perfusion | #6475 |
| imbalance | #6484 |
| angina pectoris | #6493 |
| calendar | #6498 |
| accuracy | #6501 |
| peripheral artery disease | #6501 |
| incidence risk | #6502 |
| cancer cell | #6502 |
| complement activation | #6505 |
| pregnancies | #6519 |
| surgical procedure | #6520 |
| supervised | #6521 |
| models male | #6522 |
| 138 | #6523 |
| washout | #6524 |
| 318 | #6524 |
| triiodothyronine | #6524 |
| peripheral | #6525 |
| vena | #6527 |
| increased incidence | #6532 |
| highrisk patients | #6532 |
| cochrane | #6532 |
| placebo patients | #6536 |
| replaced | #6537 |
| exogenous | #6538 |
| bowel | #6538 |
| thirteen | #6540 |
| aspirin patients | #6540 |
| year | #6546 |
| superior | #6549 |
| clinical assessment | #6550 |
| cohorts | #6555 |
| dilemma | #6560 |
| crt | #6561 |
| dosing | #6576 |
| tertile | #6581 |
| 231 | #6586 |
| limited | #6589 |
| md | #6592 |
| prediction | #6596 |
| treatment choice | #6600 |
| pooled | #6601 |
| occurs | #6610 |
| 510 | #6611 |
| belgium | #6620 |
| crude | #6621 |
| injections | #6638 |
| pancreatic neoplasms | #6641 |
| genetic testing | #6641 |
| complications | #6650 |
| individual | #6650 |
| complaints | #6652 |
| degranulation | #6663 |
| methylenetetrahydrofolate | #6665 |
| liver diseases | #6674 |
| patents | #6680 |
| smoking cessation | #6696 |
| 17 patients | #6704 |
| routinely | #6706 |
| tumour progression | #6708 |
| saline | #6709 |
| 194 | #6713 |
| approval | #6727 |
| recognised | #6729 |
| hazard ratios | #6729 |
| thromboxane | #6734 |
| allcause mortality | #6744 |
| multicenter | #6747 |
| appropriately | #6748 |
| increasing age | #6751 |
| body temperature | #6766 |
| 385 | #6766 |
| q1 | #6768 |
| clinical signs | #6771 |
| age patients | #6774 |
| defined | #6780 |
| 2 groups | #6780 |
| expense | #6781 |
| 42 patients | #6791 |
| train | #6796 |
| hyperglycemia | #6801 |
| premedication | #6803 |
| reached | #6803 |
| response relationship | #6807 |
| plasma proteins | #6807 |
| benefits | #6810 |
| cardiovascular risk | #6821 |
| 256 | #6831 |
| 280 | #6838 |
| iqr | #6839 |
| glucocorticoids | #6840 |
| summary | #6850 |
| 279 | #6854 |
| cancer diagnosis | #6856 |
| systematic | #6870 |
| points | #6877 |
| ambulatory | #6883 |
| weekly | #6884 |
| reviews | #6891 |
| physicians | #6893 |
| fibrillation patients | #6898 |
| adverse event | #6912 |
| disturbances | #6912 |
| sought | #6918 |
| 112 | #6923 |
| 251 | #6940 |
| complications patients | #6948 |
| vasopressin | #6957 |
| failure | #6965 |
| subsequent | #6971 |
| hematologic | #6974 |
| 246 | #6976 |
| intensity | #6976 |
| humans hydroxymethylglutaryl | #6982 |
| papers | #6983 |
| tpa | #6986 |
| intervals | #6987 |
| addressed | #6989 |
| 259 | #6992 |
| shock septic | #6995 |
| 222 | #6995 |
| adapted | #6998 |
| disclosed | #7001 |
| incidence risk factors | #7008 |
| hazards models | #7015 |
| cardiovascular disease | #7019 |
| myeloperoxidase | #7020 |
| lung cancer patients | #7023 |
| stenting | #7024 |
| responded | #7026 |
| cohort | #7037 |
| 1 patient | #7038 |
| unacceptable | #7039 |
| interleukin8 | #7042 |
| reductases | #7045 |
| preventing | #7056 |
| curve | #7058 |
| patients baseline | #7065 |
| animal doseresponse relationship | #7071 |
| reduced risk | #7075 |
| written | #7080 |
| applicability | #7084 |
| asymptomatic patients | #7086 |
| monoclonal antibody | #7098 |
| hospitalization humans | #7101 |
| betacoronavirus covid19 | #7104 |
| computed | #7104 |
| novartis | #7108 |
| complications pregnancy | #7111 |
| infarction stroke | #7114 |
| superiority | #7116 |
| interquartile range | #7120 |
| select | #7122 |
| carotid intima | #7141 |
| internationality | #7146 |
| surveys questionnaires | #7160 |
| 163 | #7166 |
| pharmacy | #7167 |
| patients renal | #7171 |
| physicians patients | #7177 |
| randomization | #7184 |
| liver cirrhosis | #7187 |
| 211 | #7188 |
| brain metastases | #7190 |
| oral animals | #7192 |
| walking | #7195 |
| drawn | #7196 |
| combination | #7197 |
| withdrawal | #7204 |
| 5year | #7204 |
| acting | #7210 |
| cardiovascular disease cvd | #7210 |
| disposition | #7212 |
| paucity | #7218 |
| humans lung | #7221 |
| 20 patients | #7225 |
| sulfate | #7240 |
| operating characteristic | #7244 |
| treatment children | #7250 |
| vldl | #7250 |
| hematocrit | #7255 |
| retrospective cohort study | #7257 |
| 199 | #7257 |
| alongside | #7258 |
| clinical benefit | #7265 |
| controls | #7267 |
| diagnostics | #7270 |
| option | #7273 |
| grouped | #7275 |
| young women | #7278 |
| products | #7282 |
| likelihood | #7284 |
| modest | #7290 |
| sensitivity analysis | #7290 |
| atrium | #7291 |
| 360 | #7303 |
| types | #7304 |
| factors stroke | #7305 |
| undergoing | #7327 |
| partial | #7330 |
| patients isolated | #7332 |
| ischemic stroke | #7338 |
| pectoris | #7338 |
| 1c | #7352 |
| interleukin6 | #7352 |
| standardised | #7356 |
| myocardial infarction | #7356 |
| p0001 | #7356 |
| betacoronavirus | #7357 |
| simple | #7360 |
| radiology | #7379 |
| pap | #7392 |
| patients aspirin | #7400 |
| angiopathies | #7401 |
| regimens | #7405 |
| 109 | #7409 |
| bias | #7411 |
| peptide fragments | #7413 |
| iiia | #7424 |
| intravenous injection | #7429 |
| 420 | #7431 |
| propranolol | #7438 |
| favourable | #7440 |
| hypercholesterolemia | #7441 |
| respective | #7444 |
| dose dependent | #7447 |
| infusion | #7448 |
| clinical setting | #7454 |
| ways | #7465 |
| risk adverse | #7497 |
| il6 | #7510 |
| mortality rates | #7515 |
| 209 | #7516 |
| considerations | #7517 |
| exclusions | #7518 |
| patient safety | #7520 |
| urgently | #7522 |
| angina | #7522 |
| cmv infection | #7541 |
| phase iii | #7555 |
| 257 | #7558 |
| € | #7559 |
| interim | #7561 |
| injection | #7564 |
| 191 | #7578 |
| cinahl | #7578 |
| comorbid | #7578 |
| pheochromocytoma | #7585 |
| ischaemic | #7598 |
| antibodies monoclonal | #7601 |
| reasons | #7602 |
| tended | #7608 |
| pooled analysis | #7609 |
| azathioprine | #7615 |
| 13 | #7616 |
| predictor | #7620 |
| femoral | #7640 |
| random allocation | #7646 |
| 29 patients | #7647 |
| epidemiological studies | #7647 |
| abrupt | #7655 |
| derivation | #7662 |
| interquartile | #7675 |
| manifestation | #7676 |
| temporary | #7679 |
| positive patients | #7687 |
| 18 | #7705 |
| medical conditions | #7705 |
| seventeen | #7710 |
| 304 | #7719 |
| ligament | #7732 |
| consent | #7733 |
| study association | #7735 |
| cytomegalovirus | #7736 |
| severe | #7742 |
| adverse outcomes | #7745 |
| costs | #7753 |
| cardiac surgical | #7760 |
| 189 | #7770 |
| cochrane library | #7771 |
| pregnancy outcome | #7787 |
| 110 | #7802 |
| manufacturer | #7802 |
| ≤ | #7803 |
| 9 | #7811 |
| oxygenases | #7813 |
| male gender | #7815 |
| interleukin | #7816 |
| pts | #7819 |
| 31 patients | #7828 |
| label | #7828 |
| hormone replacement | #7828 |
| cpr | #7829 |
| 5 | #7833 |
| abortion | #7838 |
| influenza | #7845 |
| radiation exposure | #7850 |
| regular | #7877 |
| tramadol | #7878 |
| academic | #7878 |
| septic patients | #7880 |
| 95 confidence | #7884 |
| replacing | #7886 |
| patients chemotherapy | #7888 |
| iib | #7908 |
| journals | #7922 |
| strict | #7927 |
| expertise | #7928 |
| bioavailability | #7930 |
| adoption | #7934 |
| urogenital | #7939 |
| highrisk | #7939 |
| diseased | #7944 |
| increasing evidence | #7947 |
| disadvantages | #7949 |
| 243 | #7965 |
| patients 1 | #7972 |
| human blood | #7973 |
| fragment | #7975 |
| new class | #7976 |
| 28 | #7989 |
| individualized | #7990 |
| aim | #7992 |
| premenopausal | #7995 |
| advice | #8016 |
| qol | #8022 |
| malignant disease | #8026 |
| pulmonary disease | #8031 |
| 99mtc | #8034 |
| oligonucleotides | #8040 |
| vascular disease | #8049 |
| medical | #8051 |
| preventable | #8051 |
| 600 | #8051 |
| list | #8059 |
| selective | #8062 |
| routine clinical | #8068 |
| fact | #8078 |
| lasting | #8080 |
| helpful | #8084 |
| 36 months | #8086 |
| outcome acute | #8092 |
| extracorporeal | #8095 |
| 248 | #8113 |
| 90 | #8114 |
| training | #8120 |
| patients heart | #8120 |
| 2004 | #8122 |
| initiating | #8123 |
| tsh | #8125 |
| cholesterol ldl | #8138 |
| sensorineural | #8140 |
| investigational | #8141 |
| imaging studies | #8141 |
| mild | #8156 |
| nosocomial | #8164 |
| multiple organ | #8175 |
| stroke | #8176 |
| 237 | #8183 |
| 158 | #8184 |
| arteries | #8190 |
| confidence | #8204 |
| parenteral nutrition | #8204 |
| renal dialysis | #8209 |
| 33 | #8223 |
| impairment | #8228 |
| renal function | #8228 |
| 81 | #8233 |
| therapy | #8235 |
| quantitative | #8240 |
| smoking | #8243 |
| lowest | #8250 |
| lists | #8250 |
| version | #8260 |
| 125i | #8264 |
| activated | #8264 |
| minimum | #8270 |
| mortality | #8280 |
| leukopenia | #8281 |
| 0008 | #8284 |
| agents | #8286 |
| 119 | #8290 |
| utilisation | #8298 |
| practice | #8310 |
| suffered | #8316 |
| schedule | #8320 |
| thrombectomy | #8322 |
| endothelium vascular | #8338 |
| postulated | #8338 |
| immunosorbent assay | #8339 |
| elimination | #8341 |
| linked immunosorbent | #8345 |
| hematology | #8351 |
| 2 years | #8382 |
| absence presence | #8382 |
| cell derived | #8384 |
| 229 | #8394 |
| draw | #8405 |
| occur | #8415 |
| 28 patients | #8415 |
| ≥50 | #8416 |
| reports | #8427 |
| 137 | #8433 |
| mentioned | #8436 |
| covid19 coronavirus | #8447 |
| 265 | #8452 |
| glucuronidase | #8458 |
| patient characteristics | #8459 |
| procedures operative | #8463 |
| transient ischemic | #8463 |
| 295 | #8466 |
| exceed | #8486 |
| knowledge | #8493 |
| 27 patients | #8496 |
| evaluate | #8501 |
| covariate | #8501 |
| criterion | #8504 |
| inborn | #8519 |
| validate | #8528 |
| rabbits | #8537 |
| atherosclerosis | #8557 |
| large cohort | #8558 |
| menstrual cycle | #8563 |
| 193 | #8565 |
| 250 | #8568 |
| adjusted life | #8574 |
| leukocytes | #8581 |
| 146 | #8582 |
| adolescent | #8582 |
| row | #8590 |
| thirty | #8596 |
| carotid arteries | #8596 |
| safety profile | #8602 |
| cox | #8604 |
| intensities | #8605 |
| risks | #8606 |
| 15 years | #8624 |
| fish oil | #8624 |
| attenuates | #8625 |
| entry | #8639 |
| thresholds | #8646 |
| presumed | #8652 |
| emissioncomputed | #8654 |
| 223 | #8655 |
| hydroxymethylglutaryl coa | #8656 |
| valves | #8658 |
| syndrome | #8664 |
| factors patients | #8666 |
| evaluations | #8679 |
| certainty | #8687 |
| markers | #8689 |
| renal failure | #8690 |
| biomarkers | #8693 |
| polytetrafluoroethylene | #8698 |
| publication aged aged | #8706 |
| portal vein | #8708 |
| hold | #8723 |
| 1 2 | #8723 |
| additional studies | #8726 |
| cardiotonic | #8729 |
| definitions | #8731 |
| address | #8733 |
| judgment | #8744 |
| platelet counts | #8754 |
| requiring | #8755 |
| endovascular | #8756 |
| practical | #8756 |
| cardiovascular | #8756 |
| vasoactive | #8762 |
| 236 | #8763 |
| interpret | #8766 |
| undetected | #8778 |
| subpopulation | #8789 |
| medical treatment | #8792 |
| illnesses | #8798 |
| cardiovascular mortality | #8802 |
| 249 | #8834 |
| internship | #8836 |
| convenient | #8837 |
| hydroxymethylglutaryl | #8837 |
| resolving | #8863 |
| representative | #8864 |
| 2 | #8872 |
| cesarean | #8876 |
| merits | #8887 |
| endarterectomy | #8896 |
| chronic liver disease | #8902 |
| mimics | #8903 |
| early treatment | #8910 |
| surgical intervention | #8911 |
| planned | #8914 |
| micrograms | #8914 |
| epoxide | #8916 |
| aged myocardial | #8919 |
| influenced | #8934 |
| normal subjects | #8936 |
| proportional hazards | #8945 |
| signs symptoms | #8945 |
| clinicians | #8956 |
| cessation | #8958 |
| experienced | #8960 |
| heparan sulfate | #8962 |
| leads | #8973 |
| 24 hours | #8977 |
| rct | #8980 |
| options | #9002 |
| patients placebo | #9002 |
| comprise | #9005 |
| chemoprevention | #9005 |
| societies medical | #9007 |
| clinical events | #9007 |
| reply | #9017 |
| receiver | #9026 |
| rank | #9043 |
| 7 | #9061 |
| databases factual | #9064 |
| early mortality | #9075 |
| diagnose | #9080 |
| mps | #9080 |
| frequency | #9083 |
| jan | #9088 |
| statins | #9090 |
| alpha1 | #9115 |
| blood proteins | #9116 |
| prone | #9142 |
| valve prosthesis | #9147 |
| time points | #9147 |
| patient patients | #9150 |
| pelvis | #9158 |
| square | #9165 |
| life threatening | #9170 |
| molecular mechanisms | #9179 |
| 75 patients | #9183 |
| advanced stage | #9184 |
| lysis | #9190 |
| editor | #9193 |
| consensus statement | #9209 |
| 361 | #9213 |
| considerable | #9225 |
| platelets | #9226 |
| 1 month | #9227 |
| pci | #9230 |
| dyspnea | #9230 |
| performs | #9233 |
| contrast | #9238 |
| 4 hours | #9259 |
| extrinsic | #9263 |
| illness surveys | #9264 |
| hazards | #9264 |
| experts | #9266 |
| uncomplicated | #9267 |
| mumol | #9278 |
| attenuation | #9283 |
| rabbit | #9286 |
| positive | #9286 |
| trial registration | #9297 |
| corresponded | #9298 |
| dialysis | #9319 |
| feasibility | #9320 |
| earlier | #9339 |
| suboptimal | #9342 |
| patients negative | #9355 |
| p0004 | #9355 |
| preceded | #9376 |
| loss | #9378 |
| 014 | #9380 |
| higher incidence | #9380 |
| purposes | #9383 |
| invited | #9384 |
| single center | #9385 |
| death patients | #9391 |
| radioactivity | #9394 |
| bacterial infections | #9401 |
| fourth | #9402 |
| 2b | #9412 |
| ascending | #9415 |
| haemorrhage | #9425 |
| 167 | #9436 |
| properly | #9442 |
| rheumatic | #9446 |
| hospitalised | #9448 |
| dysfunction | #9460 |
| belonged | #9480 |
| secondary analysis | #9483 |
| respiratory tract | #9486 |
| 169 | #9490 |
| 240 | #9493 |
| ipd | #9502 |
| factual | #9503 |
| valvular | #9505 |
| thyroid function | #9507 |
| selectin | #9509 |
| hrs | #9524 |
| inflammatory agents | #9529 |
| confirms | #9530 |
| designed | #9535 |
| cardiopulmonary bypass | #9540 |
| swelling | #9542 |
| 3 4 | #9544 |
| insight | #9557 |
| cooperation | #9561 |
| requirements | #9566 |
| hemoglobins | #9573 |
| rose | #9592 |
| il10 | #9597 |
| observational cohort | #9598 |
| lpa | #9600 |
| rates | #9617 |
| comparative effectiveness | #9630 |
| primary point | #9638 |
| kidney failure | #9638 |
| successful treatment | #9639 |
| laboratories | #9644 |
| cardiogenic | #9645 |
| optimal treatment | #9650 |
| 2008 | #9656 |
| hf | #9670 |
| published | #9674 |
| congestive | #9695 |
| pathophysiological | #9704 |
| patients hospital | #9713 |
| spontaneously | #9720 |
| modalities | #9721 |
| inappropriate | #9724 |
| reuptake | #9727 |
| acts | #9729 |
| identifier | #9730 |
| 2007 | #9732 |
| lactoferrin | #9734 |
| 42 | #9744 |
| substitutes | #9747 |
| hypothetical | #9754 |
| nested | #9764 |
| nonesterified | #9768 |
| 90 patients | #9777 |
| reproducibility | #9778 |
| sepsis | #9802 |
| 210 | #9803 |
| absence | #9813 |
| straightforward | #9814 |
| precise | #9817 |
| easily | #9817 |
| coa reductase | #9828 |
| nmol | #9828 |
| classification | #9836 |
| 212 | #9839 |
| craniotomy | #9839 |
| 0006 | #9849 |
| utility | #9855 |
| danish | #9857 |
| labile | #9865 |
| heterozygotes | #9871 |
| nonhuman primates | #9871 |
| discordant | #9908 |
| moderately | #9919 |
| cmv | #9930 |
| 60 years | #9933 |
| lower limb | #9936 |
| promise | #9937 |
| 2003 | #9941 |
| degradation | #9941 |
| tomography | #9944 |
| treatment strategy | #9951 |
| 216 | #9958 |
| low dose | #9971 |
| investigator | #9983 |
| detecting | #9992 |
| regimen | #9995 |
| casecontrol studies | #9997 |
| pancreatic | #9997 |
| 12 hours | #9997 |
| 213 | #10000 |
| neoplasm metastasis | #10001 |
| chance | #10008 |
| physician | #10015 |
| extending | #10027 |
| informative | #10028 |
| hereditary | #10041 |
| obstacles | #10045 |
| protective | #10045 |
| addressing | #10051 |
| medication adherence | #10052 |
| mthfr | #10079 |
| presentations | #10082 |
| familial | #10087 |
| higher prevalence | #10089 |
| chart | #10108 |
| recipients | #10113 |
| qualitative | #10117 |
| 1980 | #10134 |
| completely | #10145 |
| tested | #10150 |
| aged obesity | #10170 |
| 182 | #10176 |
| invasive | #10181 |
| abnormalities | #10186 |
| regularly | #10189 |
| cast | #10193 |
| multicentre | #10198 |
| cell activation | #10199 |
| investigations | #10199 |
| cardiovascular risk factors | #10209 |
| medical therapy | #10213 |
| clinical data | #10213 |
| tumor necrosis factoralpha | #10215 |
| replacement therapy | #10225 |
| routine | #10234 |
| syndrome humans | #10253 |
| heart failure | #10265 |
| 183 | #10280 |
| gaps | #10291 |
| hospitalization | #10293 |
| blood transfusion | #10293 |
| postpartum | #10305 |
| measuring | #10314 |
| aetiology | #10315 |
| 8 | #10318 |
| photon emission | #10329 |
| 032 | #10336 |
| dilution | #10336 |
| worldwide | #10337 |
| 667 | #10337 |
| aorta | #10352 |
| greatly | #10352 |
| indirectly | #10377 |
| restoration | #10378 |
| creatinine | #10381 |
| cardiopulmonary | #10385 |
| pneumonia viral | #10397 |
| medical management | #10404 |
| outcome measures | #10408 |
| p0003 | #10408 |
| tissue injury | #10411 |
| bidirectional | #10419 |
| reductase inhibitors | #10432 |
| circulation | #10432 |
| transfusion | #10435 |
| enrolment | #10446 |
| reflux | #10457 |
| patients age | #10461 |
| priority | #10461 |
| quality life | #10471 |
| phase 3 | #10481 |
| activity levels | #10489 |
| increased prevalence | #10489 |
| style | #10491 |
| 1991 | #10491 |
| 147 | #10501 |
| predictive factors | #10514 |
| sex age | #10526 |
| assessing | #10529 |
| necrosis | #10534 |
| matched | #10556 |
| lower rate | #10558 |
| portable | #10563 |
| patients moderate | #10570 |
| ray | #10570 |
| 125 | #10574 |
| p002 | #10576 |
| pulmonary artery | #10578 |
| inform | #10580 |
| recurrences | #10583 |
| antisense | #10583 |
| 293 | #10584 |
| 180 | #10598 |
| manifestations | #10601 |
| closer | #10602 |
| microvascular | #10605 |
| 159 | #10605 |
| vasoconstrictor | #10607 |
| hospitals | #10612 |
| medical oncology | #10615 |
| november | #10628 |
| percutaneous coronary | #10633 |
| persist | #10635 |
| fragments | #10637 |
| ascertained | #10641 |
| 1b | #10647 |
| publication administration | #10653 |
| postoperative | #10659 |
| held | #10674 |
| concerned | #10674 |
| pulmonary vascular | #10690 |
| discriminate | #10697 |
| term | #10697 |
| risk developing | #10704 |
| synergism | #10709 |
| multivariable analysis | #10713 |
| neutrophil | #10729 |
| consultation | #10735 |
| centres | #10751 |
| median duration | #10755 |
| decisions | #10759 |
| entire | #10774 |
| haemoglobin | #10797 |
| perioperative | #10798 |
| patients cirrhosis | #10804 |
| term mortality | #10829 |
| 300 | #10832 |
| 38 | #10849 |
| prospective observational | #10855 |
| sustained | #10865 |
| randomised controlled | #10867 |
| anatomical | #10873 |
| diagnoses | #10903 |
| airways | #10903 |
| neurosurgical | #10905 |
| monoclonal antibodies monoclonal | #10909 |
| coronavirus infections | #10921 |
| maximal | #10924 |
| threatening | #10963 |
| amniotic | #10987 |
| coronary intervention | #10989 |
| relative | #10990 |
| blocker | #10996 |
| needed | #11009 |
| obese | #11037 |
| neutropenia | #11057 |
| ischemic | #11057 |
| ethical | #11062 |
| summarizes | #11062 |
| attained | #11062 |
| treatment option | #11070 |
| balloon | #11071 |
| 12 weeks | #11074 |
| originally | #11083 |
| location | #11108 |
| inability | #11108 |
| catheters | #11143 |
| beta2 | #11159 |
| ischemic attack | #11165 |
| hematoma | #11189 |
| confirmation | #11199 |
| neoplasms risk | #11201 |
| metabolic syndrome | #11202 |
| iia | #11204 |
| strokes | #11217 |
| choice | #11228 |
| eligible patients | #11247 |
| risk groups | #11263 |
| 1992 | #11272 |
| cerebrovascular | #11281 |
| humans kidney | #11281 |
| waiting | #11282 |
| ≥1 | #11291 |
| endothelial function | #11297 |
| troponin | #11304 |
| determine | #11306 |
| 202 | #11308 |
| aged prevalence | #11331 |
| post | #11332 |
| adherent | #11338 |
| acute respiratory | #11345 |
| acute myocardial infarction | #11361 |
| event | #11363 |
| combination therapy | #11380 |
| glycoprotein | #11391 |
| factors smoking | #11395 |
| reconstructive | #11397 |
| apply | #11399 |
| developed | #11405 |
| 2005 | #11415 |
| competent | #11416 |
| medically | #11426 |
| treatment decisions | #11427 |
| prostaglandins | #11434 |
| diuretics | #11439 |
| hematological malignancies | #11443 |
| morbidity | #11445 |
| media | #11464 |
| protocol | #11487 |
| satisfying | #11502 |
| performances | #11525 |
| hospital admission | #11526 |
| placebo treatment | #11533 |
| occlusion | #11533 |
| multicenter study | #11542 |
| outflow | #11542 |
| enrolled | #11545 |
| humans intensive | #11570 |
| 55 | #11577 |
| chronic inflammation | #11600 |
| definitive | #11621 |
| baseline | #11624 |
| younger patients | #11624 |
| sct | #11638 |
| investigate | #11670 |
| normal controls | #11684 |
| contribution | #11687 |
| reference | #11694 |
| life qol | #11697 |
| lipopolysaccharides | #11699 |
| hypotension | #11715 |
| ascites | #11717 |
| myoglobin | #11741 |
| independent risk | #11745 |
| acute myocardial | #11753 |
| radiopharmaceuticals | #11783 |
| extent | #11786 |
| orally | #11790 |
| involving | #11792 |
| 2010 | #11802 |
| nonspecific | #11809 |
| vena cava | #11829 |
| distinction | #11841 |
| episodes | #11865 |
| eclampsia | #11872 |
| release | #11874 |
| woman | #11885 |
| 151 | #11891 |
| 006 | #11906 |
| elicited | #11912 |
| icu patients | #11915 |
| vasculitis | #11937 |
| activating | #11948 |
| age | #11953 |
| sulphate | #11955 |
| began | #11957 |
| lethality | #11967 |
| collectively | #11970 |
| inferior | #11978 |
| serum creatinine | #11979 |
| myocardial injury | #11980 |
| adp | #11981 |
| immunosorbent | #12006 |
| cardiovascular diseases | #12015 |
| mortality rate | #12041 |
| reduced | #12043 |
| thirds | #12057 |
| dietary intake | #12057 |
| minority | #12058 |
| monitored | #12061 |
| differently | #12066 |
| early pregnancy | #12076 |
| humanized | #12077 |
| wounds injuries | #12079 |
| fair | #12096 |
| thoracotomy | #12111 |
| evidenced | #12130 |
| 1995 | #12135 |
| elevated risk | #12140 |
| 085 | #12141 |
| profile | #12143 |
| prostate | #12153 |
| 149 | #12157 |
| 120 | #12170 |
| digoxin | #12177 |
| offset | #12179 |
| uncommon | #12187 |
| healthcare | #12202 |
| causality | #12208 |
| lung | #12208 |
| spent | #12219 |
| takes | #12233 |
| tendency | #12271 |
| pregnancy risk | #12276 |
| expectancy | #12281 |
| resolve | #12300 |
| flaps | #12302 |
| micromol | #12326 |
| mismatch | #12335 |
| favored | #12342 |
| births | #12351 |
| obstructive pulmonary | #12358 |
| epinephrine | #12365 |
| dependently | #12372 |
| prescription | #12394 |
| registration | #12398 |
| incremental | #12399 |
| inflammatory response | #12409 |
| switzerland | #12409 |
| consistent | #12418 |
| potential confounders | #12425 |
| echocardiographic | #12450 |
| fifty patients | #12451 |
| arginine | #12475 |
| patient discharge | #12480 |
| apparent | #12483 |
| prospective randomized | #12486 |
| sensitivity analyses | #12490 |
| 117 | #12494 |
| switch | #12513 |
| 10 years | #12521 |
| standards | #12524 |
| requires | #12540 |
| guide | #12540 |
| statistically | #12548 |
| prognostic | #12579 |
| chronic obstructive | #12584 |
| monoclonal | #12589 |
| rapidly | #12597 |
| tomography ray | #12611 |
| lipoprotein | #12619 |
| literature | #12637 |
| repeat | #12653 |
| single dose | #12673 |
| drug interactions | #12680 |
| hypertension pulmonary | #12684 |
| physiological | #12687 |
| pharmacogenetics | #12706 |
| 45 | #12708 |
| prostatic | #12708 |
| endocrine | #12709 |
| ifngamma | #12722 |
| minute | #12733 |
| dosage | #12736 |
| congestive heart failure | #12747 |
| cardiac surgery | #12756 |
| personal | #12770 |
| estrogens | #12778 |
| animal model | #12796 |
| thyroid | #12808 |
| settings | #12820 |
| malignancies | #12823 |
| infections | #12836 |
| burden | #12849 |
| intraoperative complications | #12862 |
| cancer patient | #12864 |
| reporting | #12866 |
| 196 | #12881 |
| 1999 | #12904 |
| cvd | #12906 |
| raised | #12910 |
| endpoints | #12912 |
| extracted | #12940 |
| confirming | #12947 |
| 18 years | #12976 |
| ray computed | #12983 |
| postoperative complications | #12990 |
| filters | #13009 |
| monotherapy | #13017 |
| transiently | #13024 |
| oral administration | #13041 |
| instance | #13041 |
| located | #13049 |
| tumor angiogenesis | #13067 |
| based cohort | #13094 |
| fold | #13100 |
| severity | #13106 |
| cancer risk | #13107 |
| escalation | #13107 |
| vomiting | #13112 |
| physical | #13112 |
| latin | #13125 |
| sexes | #13143 |
| drug therapy | #13144 |
| 0 | #13145 |
| ratio | #13159 |
| focused | #13189 |
| appearance | #13195 |
| compliance | #13199 |
| pregnant women | #13202 |
| optimal | #13213 |
| expensive | #13226 |
| support | #13231 |
| exist | #13235 |
| 142 | #13236 |
| lack | #13240 |
| narcotic | #13261 |
| formal | #13262 |
| commercially | #13265 |
| participant | #13273 |
| median follow | #13286 |
| indirect | #13288 |
| emission computed | #13352 |
| mediator | #13366 |
| maintain | #13391 |
| electronic databases | #13394 |
| hypothesized | #13395 |
| advantage | #13432 |
| admitted | #13437 |
| p00001 | #13442 |
| anti | #13455 |
| reliably | #13459 |
| surveys | #13463 |
| endothelial dysfunction | #13466 |
| transient | #13478 |
| patients experienced | #13481 |
| provided | #13489 |
| crosssectional study | #13491 |
| patients patient | #13494 |
| surrogate | #13537 |
| vivo | #13545 |
| retrospectively | #13548 |
| maintained | #13555 |
| 195 | #13556 |
| accurate | #13563 |
| pulmonary hypertension | #13563 |
| longterm outcomes | #13585 |
| monitoring | #13620 |
| laboratory | #13629 |
| elucidated | #13643 |
| abdominal | #13652 |
| whilst | #13665 |
| mitral | #13682 |
| north america | #13705 |
| marker | #13707 |
| competence | #13708 |
| vascular | #13708 |
| 45 years | #13716 |
| 2009 | #13734 |
| icu | #13748 |
| drug effects | #13753 |
| medicine | #13755 |
| healthy individuals | #13758 |
| inhibitory effects | #13763 |
| establishing | #13766 |
| explanation | #13773 |
| pelvic | #13773 |
| participating | #13774 |
| phospholipid | #13776 |
| heart diseases | #13789 |
| women risk | #13816 |
| conservative | #13820 |
| circulating | #13824 |
| condition | #13859 |
| kidney diseases | #13860 |
| systematically | #13868 |
| tissue | #13876 |
| coronary angiography | #13889 |
| internal | #13916 |
| techniques | #13923 |
| microparticles | #13927 |
| dissemination | #13928 |
| 1993 | #13939 |
| 176 | #13979 |
| require | #13986 |
| castration | #13998 |
| radioisotopes | #14011 |
| 48 patients | #14013 |
| insufficiency | #14022 |
| algorithms | #14029 |
| risk death | #14033 |
| members | #14033 |
| requirement | #14046 |
| independent predictors | #14058 |
| continuous | #14060 |
| organ failure | #14072 |
| focus | #14084 |
| situations | #14084 |
| vasoconstriction | #14119 |
| offer | #14137 |
| supporting | #14164 |
| activates | #14188 |
| cardiac output | #14194 |
| leukocyte | #14204 |
| mitral valve | #14205 |
| sensitivities | #14216 |
| document | #14242 |
| primary prevention | #14248 |
| newborns | #14256 |
| nausea | #14276 |
| making | #14285 |
| effectiveness | #14304 |
| independent | #14342 |
| inhibition | #14357 |
| 4 years | #14367 |
| meaningful | #14371 |
| pathologic | #14372 |
| female fetal | #14377 |
| acquired | #14378 |
| 6 patients | #14391 |
| min1 | #14391 |
| amniotic fluid | #14403 |
| substances | #14409 |
| pregnant | #14423 |
| disease chronic | #14460 |
| interleukin1 | #14489 |
| infarction | #14491 |
| influence | #14509 |
| interventions | #14510 |
| costeffectiveness | #14535 |
| locations | #14586 |
| participated | #14592 |
| similarities | #14608 |
| 205 | #14632 |
| statistics | #14637 |
| renal insufficiency | #14637 |
| reasonable | #14646 |
| comparative | #14648 |
| natural | #14667 |
| blood samples | #14672 |
| surgery patients | #14696 |
| entered | #14698 |
| pandemics | #14707 |
| classify | #14715 |
| institutes | #14736 |
| surveyed | #14741 |
| 39 patients | #14742 |
| sampled | #14749 |
| 2017 | #14783 |
| arms | #14785 |
| independent predictor | #14787 |
| validity | #14787 |
| databases | #14808 |
| heart association | #14814 |
| white matter | #14816 |
| complete | #14819 |
| stable | #14828 |
| cox proportional | #14835 |
| pge2 | #14844 |
| duplex | #14845 |
| population | #14872 |
| contribute | #14928 |
| retest | #14931 |
| criteria | #14938 |
| premature | #14952 |
| critical illness | #15004 |
| phospholipids | #15030 |
| european society | #15041 |
| cardiac catheterization | #15042 |
| prostheses | #15059 |
| questionnaires | #15082 |
| treatment failure | #15087 |
| sf36 | #15089 |
| elective surgical | #15107 |
| controlled clinical | #15109 |
| flight | #15110 |
| ldl | #15120 |
| relate | #15127 |
| health costs | #15128 |
| initiation | #15140 |
| obstruction | #15142 |
| obstructive | #15146 |
| stratification | #15164 |
| proper | #15177 |
| selection | #15187 |
| registries | #15197 |
| decrease | #15201 |
| copd | #15201 |
| randomized controlled trial | #15210 |
| unilateral | #15223 |
| ongoing | #15230 |
| induces | #15231 |
| individuals | #15239 |
| young patients | #15247 |
| previous | #15250 |
| methods retrospective | #15255 |
| disorders | #15278 |
| drug | #15278 |
| myocardial | #15279 |
| 4 weeks | #15296 |
| quantitation | #15298 |
| fewer | #15300 |
| hospital discharge | #15328 |
| quantify | #15340 |
| activators | #15356 |
| neonates | #15370 |
| consequence | #15405 |
| locally | #15441 |
| impaired | #15446 |
| pedigree | #15471 |
| women age | #15474 |
| randomised controlled trial | #15474 |
| grafts | #15484 |
| zealand | #15509 |
| asthma | #15511 |
| undetectable | #15512 |
| current literature | #15513 |
| records | #15520 |
| 1994 | #15522 |
| aggregation | #15535 |
| thrombocytopenia | #15537 |
| implementation | #15538 |
| pa | #15540 |
| intended | #15567 |
| reviewed | #15577 |
| surgery | #15590 |
| updated | #15592 |
| discharged | #15616 |
| immunoenzyme | #15617 |
| purpose | #15634 |
| heterozygosity | #15660 |
| centre | #15666 |
| standard | #15679 |
| patients admitted | #15702 |
| perinatal | #15711 |
| explain | #15726 |
| view | #15729 |
| unexpected | #15737 |
| detection | #15766 |
| start | #15808 |
| examination | #15813 |
| effectively | #15813 |
| prescribing | #15823 |
| vary | #15829 |
| febrile | #15847 |
| confer | #15849 |
| serologic | #15853 |
| reach | #15876 |
| interpretation | #15881 |
| janus | #15892 |
| numerous | #15899 |
| inter | #15907 |
| quality adjusted | #15919 |
| dyslipidemia | #15942 |
| prominent | #15961 |
| blocked | #15985 |
| severely | #15997 |
| discuss | #15997 |
| alanine | #15998 |
| external | #16007 |
| causal | #16021 |
| hepatectomy | #16025 |
| complication | #16054 |
| compared controls | #16057 |
| rarely | #16076 |
| systemic inflammation | #16077 |
| fever | #16082 |
| metabolic | #16112 |
| demonstrates | #16117 |
| insensitive | #16125 |
| affect | #16135 |
| conditional | #16136 |
| basis | #16144 |
| carotid | #16168 |
| bypass | #16221 |
| early | #16262 |
| antiretroviral | #16271 |
| neoplasms | #16294 |
| hospital | #16314 |
| special | #16336 |
| signs | #16384 |
| cost | #16418 |
| recommendations | #16420 |
| aimed | #16432 |
| area | #16442 |
| syndromes | #16485 |
| unable | #16508 |
| develop | #16513 |
| prevented | #16513 |
| cancer treatment | #16516 |
| 106 | #16543 |
| radiography | #16545 |
| calibrated | #16568 |
| multivariable | #16576 |
| 2021 | #16583 |
| descriptive | #16618 |
| alternatives | #16629 |
| integrins | #16641 |
| creactive protein | #16645 |
| gained | #16652 |
| consists | #16666 |
| weeks | #16674 |
| downregulation | #16681 |
| residual | #16708 |
| prior | #16725 |
| explained | #16763 |
| fat | #16775 |
| electrocardiography | #16807 |
| epidemiology | #16821 |
| potent | #16848 |
| thought | #16868 |
| genetic risk | #16876 |
| survival | #16892 |
| 093 | #16911 |
| humans liver | #16932 |
| constitute | #16939 |
| gestational age | #16946 |
| vasodilator | #16950 |
| driven | #16958 |
| critically patients | #16965 |
| enable | #16976 |
| verify | #16984 |
| smokers | #16998 |
| inherent | #17023 |
| carotid artery | #17040 |
| apolipoproteins | #17063 |
| individual patients | #17078 |
| markedly | #17097 |
| units | #17139 |
| estimates | #17144 |
| assayed | #17145 |
| elderly patients | #17150 |
| regard | #17197 |
| critically | #17220 |
| adjustment | #17237 |
| lung neoplasms | #17262 |
| cooperative | #17262 |
| estimated | #17274 |
| largest | #17288 |
| acute phase | #17288 |
| 400 | #17295 |
| clinician | #17339 |
| desirable | #17347 |
| 2019 | #17393 |
| limb | #17439 |
| dilated | #17443 |
| disease cvd | #17451 |
| synthetic | #17459 |
| increasingly | #17488 |
| kinds | #17510 |
| antibodies | #17538 |
| prompt | #17565 |
| demographics | #17584 |
| cirrhosis | #17586 |
| 0002 | #17604 |
| finding | #17620 |
| applicable | #17636 |
| obtaining | #17637 |
| coronary | #17653 |
| sex factors | #17688 |
| prosthesis | #17710 |
| independent risk factor | #17712 |
| distal | #17714 |
| multivariate analysis | #17792 |
| gastrointestinal | #17804 |
| selecting | #17815 |
| 3 years | #17833 |
| 2006 | #17840 |
| illustrated | #17852 |
| 1 | #17853 |
| hemorrhagic | #17855 |
| drugs | #17878 |
| current evidence | #17881 |
| undergone | #17883 |
| marked | #17903 |
| epidemiologic | #17920 |
| hospitalizations | #17922 |
| nationwide | #17924 |
| global | #17933 |
| percutaneous | #17942 |
| essential | #17964 |
| corticosteroids | #17975 |
| distant | #18007 |
| intensive | #18031 |
| reductase | #18047 |
| verified | #18052 |
| peptide | #18060 |
| defects | #18070 |
| 000 | #18092 |
| operated | #18111 |
| trend | #18115 |
| centers | #18134 |
| protein crp | #18152 |
| clinical significance | #18164 |
| consistently | #18169 |
| quality | #18175 |
| chemotherapy | #18203 |
| prenatal | #18250 |
| participate | #18252 |
| deaths | #18263 |
| year follow | #18286 |
| metastases | #18296 |
| ventricular function | #18296 |
| inflammatory bowel | #18314 |
| gestation | #18344 |
| tolerated | #18425 |
| attributable | #18434 |
| and or | #18480 |
| coa | #18497 |
| larger | #18513 |
| mutations | #18533 |
| humans hypertension | #18543 |
| stratified | #18569 |
| heart disease | #18579 |
| commercial | #18589 |
| bayes | #18675 |
| ≥ | #18700 |
| extra | #18726 |
| mechanisms | #18742 |
| questions | #18760 |
| plasma | #18797 |
| conventional | #18799 |
| monoclonal antibodies | #18844 |
| increases | #18850 |
| life | #18851 |
| vessel | #18855 |
| oligopeptides | #18887 |
| clearance | #18903 |
| validation | #18907 |
| classical | #18919 |
| hormone | #18938 |
| molecular basis | #19034 |
| single | #19069 |
| worse | #19094 |
| statistical | #19103 |
| soluble | #19124 |
| simultaneously | #19131 |
| tailored | #19134 |
| real | #19158 |
| 5 years | #19189 |
| variable | #19205 |
| moderate | #19239 |
| contributes | #19241 |
| decade | #19291 |
| infarct | #19308 |
| ages | #19312 |
| pubmed | #19345 |
| 0005 | #19412 |
| essentially | #19469 |
| ventricular | #19481 |
| investigates | #19493 |
| 2 3 | #19507 |
| therapies | #19511 |
| called | #19515 |
| partially | #19535 |
| explore | #19544 |
| endothelium | #19553 |
| systemic | #19561 |
| january | #19567 |
| uterine | #19582 |
| reversed | #19601 |
| procedures | #19611 |
| tka | #19675 |
| etiology | #19677 |
| operating | #19692 |
| guided | #19709 |
| histology | #19727 |
| characterised | #19753 |
| inflammation | #19779 |
| median followup | #19863 |
| exclusively | #19881 |
| autologous | #19886 |
| graft | #19904 |
| endothelial cell | #19986 |
| controlled trial | #20019 |
| comorbidities | #20045 |
| gestational | #20050 |
| 2002 | #20050 |
| additionally | #20057 |
| cytokines | #20058 |
| salvage | #20102 |
| inversely | #20149 |
| concentration | #20153 |
| predisposition disease | #20162 |
| diastolic | #20170 |
| small | #20201 |
| alterations | #20228 |
| body | #20230 |
| alpha | #20261 |
| polymorphism genetic | #20264 |
| variables | #20277 |
| subjects | #20283 |
| combine | #20369 |
| adjusting | #20377 |
| catheterization | #20391 |
| introduced | #20458 |
| 1 3 | #20492 |
| younger | #20499 |
| hormones | #20508 |
| length | #20512 |
| theoretically | #20515 |
| ability | #20536 |
| analyses | #20553 |
| clarify | #20561 |
| elisa | #20562 |
| persistent | #20562 |
| improves | #20570 |
| september | #20598 |
| persons | #20696 |
| humans models | #20753 |
| active | #20756 |
| observational | #20823 |
| incorporated | #20843 |
| prognosis | #20934 |
| fetal | #20955 |
| reduce | #21005 |
| measure | #21033 |
| auc | #21046 |
| report | #21048 |
| intrinsic | #21055 |
| responsible | #21081 |
| constructed | #21098 |
| innate | #21135 |
| attenuated | #21137 |
| operative | #21137 |
| 1 year | #21144 |
| designated | #21167 |
| october | #21177 |
| performing | #21185 |
| × | #21191 |
| upper | #21226 |
| reflecting | #21230 |
| selected | #21264 |
| depending | #21267 |
| preschool female | #21270 |
| 005 | #21324 |
| hemodynamics humans | #21403 |
| symptoms | #21425 |
| center | #21469 |
| differed | #21501 |
| 1990 | #21507 |
| 0004 | #21546 |
| logistic | #21639 |
| explored | #21757 |
| animals antibodies | #21767 |
| young | #21860 |
| 139 | #21894 |
| majority | #21894 |
| observe | #21969 |
| facilitate | #21994 |
| decreased | #22047 |
| progression | #22078 |
| genotype | #22116 |
| imaging | #22125 |
| coronary disease | #22178 |
| tract | #22180 |
| neoadjuvant | #22207 |
| generally | #22291 |
| regression | #22321 |
| surgical procedures | #22327 |
| authors | #22330 |
| demonstrated | #22352 |
| inhibiting | #22426 |
| newborn male | #22473 |
| varying | #22556 |
| significance | #22586 |
| represented | #22593 |
| slower | #22607 |
| allogeneic | #22614 |
| grade | #22615 |
| phase | #22698 |
| older | #22831 |
| differential | #22835 |
| july | #22843 |
| modified | #22851 |
| march | #22907 |
| application | #22920 |
| combining | #22961 |
| ratios | #22986 |
| 2012 | #23037 |
| anti inflammatory | #23123 |
| offered | #23214 |
| protocols | #23283 |
| 2016 | #23284 |
| challenging | #23285 |
| yielding | #23334 |
| prevents | #23432 |
| resting | #23488 |
| includes | #23496 |
| renal | #23566 |
| median | #23599 |
| inhibits | #23686 |
| inbred c57bl mice | #23705 |
| increasing | #23723 |
| endopeptidases | #23727 |
| advanced | #23745 |
| adverse | #23767 |
| naive | #23767 |
| reactive protein | #23807 |
| minimal | #23827 |
| interestingly | #23831 |
| showing | #23885 |
| longer | #23967 |
| surgical | #24020 |
| vascular endothelial | #24085 |
| prolonged | #24478 |
| generate | #24487 |
| count | #24514 |
| december | #24569 |
| unrelated | #24572 |
| determining | #24577 |
| activity | #24581 |
| changed | #24651 |
| implies | #24682 |
| underlying | #24749 |
| suggests | #24813 |
| august | #24821 |
| linearly | #24940 |
| february | #24945 |
| frequent | #25109 |
| june | #25175 |
| representing | #25214 |
| acceptable | #25300 |
| carried | #25310 |
| illness | #25373 |
| suitable | #25501 |
| enhance | #25503 |
| 0003 | #25598 |
| linked | #25616 |
| local | #25663 |
| mm | #25732 |
| fully | #25888 |
| reducing | #25912 |
| describes | #25923 |
| difficult | #26054 |
| supported | #26091 |
| scanning | #26181 |
| differentiate | #26212 |
| respect | #26378 |
| promising | #26384 |
| asked | #26410 |
| define | #26421 |
| defective | #26510 |
| female heart | #26685 |
| dependent | #26722 |
| leading | #26774 |
| improving | #27057 |
| contained | #27059 |
| national | #27215 |
| strongest | #27229 |
| quantitatively | #27333 |
| recognized | #27386 |
| mass bmi | #27411 |
| commonly | #27411 |
| implicated | #27484 |
| caused | #27495 |
| remain | #27689 |
| correlate | #27710 |
| artery | #27999 |
| cross | #28142 |
| recorded | #28182 |
| detected | #28405 |
| inflammatory | #28439 |
| multivariate | #28454 |
| examine | #28475 |
| beta | #28655 |
| allowed | #28793 |
| hypothesis | #28801 |
| improved | #28920 |
| required | #29047 |
| large | #29116 |
| chemically | #29137 |
| short | #29272 |
| patients chronic | #29316 |
| genetic predisposition | #29434 |
| bmi | #29470 |
| female health | #29531 |
| achieved | #29589 |
| 001 | #29634 |
| underwent | #29797 |
| 2011 | #30149 |
| indicating | #30233 |
| approved | #30511 |
| declined | #30756 |
| participants | #30828 |
| predisposition | #30981 |
| genotype humans | #31051 |
| aims | #31216 |
| measured | #31265 |
| antineoplastic agents | #31706 |
| expected | #31791 |
| specific | #31901 |
| endothelial | #32294 |
| modality | #32386 |
| inhibit | #32629 |
| conducted | #32675 |
| predicted | #32889 |
| inhibited | #33631 |
| agreement | #33673 |
| sensitive | #34362 |
| antineoplastic | #34560 |
| correlated | #34744 |
| greater | #34856 |
| poor | #35078 |
| neoplasms male | #35230 |
| humans magnetic | #35433 |
| 0001 | #35646 |
| free | #35793 |
| sectional | #35852 |
| include | #39773 |
| collected | #40746 |
| examined | #41010 |
| mediated | #41310 |
| neoplasm | #47468 |
运行报告 | |
关键人物 Pulmonary Embolism
世界顶级科尔斯
Harry Roger Büller:专家影响
哪个概念Harry Roger Büller具有直接影响:Pulmonary embolism, Venous thromboembolism, Venous thrombosis, Major bleeding, Deep vein thrombosis, Atrial fibrillation, Vein thrombosis.
Harry Roger Büller:KOL的影响
与其他作者的工作有关的概念for which Harry Roger Büller 有影响力:Venous thromboembolism, Pulmonary embolism, Atrial fibrillation, Deep vein thrombosis, Oral anticoagulants, Major bleeding, Vte patients.
Tools
这是您的个人资料吗？ 要求您的个人资料 复制URL 嵌入到您的个人资料的链接 |